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SUMMARY 	  
In eukaryotic cells, more than a third of all newly synthesized proteins do not fold 
properly. This is attributed to the imperfect process of protein folding, which 
involves a random sampling of contact points between amino acid residues of the 
polypeptide until a lowest energy state is reached.  In this state, most proteins’ 
hydrophobic regions are found buried in the inner core of the final structure. 
Environmental stress, along with genetic mutations and errors that occur in 
replication, transcription, and translation steps, increases the difficulty of the 
folding process. Therefore, many proteins inevitably become terminally 
misfolded.  The study of mechanisms that target misfolded proteins for 
degradation is critical for understanding the underlying causes of protein 
misfolding-related diseases such as Parkinson’s and Alzheimer’s. 
 
The degradation of misfolded proteins in the ER and cytosol is predominantly 
mediated by E3 ligases, which are able to recognize and ubiquitinate misfolded 
proteins. Subsequent polyubiquitination of the offending proteins targets them for 
degradation by the 26S proteasome.  The recognition steps and substrate 
specificity of the Hrd1 and Doa10 E3 quality control complexes in the ER have 
been well characterized, with substrates being recognized based on specific sites 
of misfoldededness: substrates with lesions in luminal domain are recognized by 
Hrd1p, while those with lesions in transmembrane or cytosolic domains are 
recognized by Doa10p. In addition, misfolded glycosylated proteins are targeted 
	  viii 	  
based on a timer-based signaling mechanism involving glycan modifications that 
occur only when folding does not proceed at a normal pace. 
 
The San1 and Ubr1 E3 ligases are both factors required for efficient cytosolic 
protein quality control in S. cerevisiae. Historically, San1p has also been also 
been implicated in quality control in the nucleus, while Ubr1p was first 
characterized as the sole mediator of the N-end rule in yeast, which relates the 
half-life of any protein to its N-terminal residue.  
 
In Chapter 3, I perform a mutational and biochemical analyses of two previously 
characterized CytoQC substrates, leading to the discovery of a novel set of N-
terminal based degradation signals recognized by Ubr1p, part of a pathway which 
I term the “misfolded protein/N-end rule”.  In Chapter 4, the importance of 
substrate misfoldedness is assessed for the misfolded protein/N-end rule. Within 
the context of a bi-partite signal involving a destabilizing N-terminal sequence of 
the misfolded protein/N-end rule, I demonstrate that structural abnormality is 
significant for efficient degradation by the misfolded/protein N-end rule. This bi-
partite degradation signal serves as a minimum requirement for efficient 
recognition and degradation of at least one subset of cytosolic misfolded proteins 
by Ubr1p.  In the Chapter 5, I perform a bioinformatic analysis of the yeast 
proteome to uncover the scope of specificity of the misfolded protein/N-end rule 
as mediated by Ubr1p.  The results indicate that a substantial portion of 
mitochondrial and secretory pathway proteins would be substrates of Ubr1-
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mediated quality control in the event of mistranslocation and subsequent 
misfolding. Biochemical analysis of several mistranslocated forms of endogenous 
mitochondrial and secretory pathway proteins corroborates the validity of this 
model. 
 
While Ubr1p has long been known to function as the primary mediator for the N-
end rule pathway, its recently discovered function as an E3 for cytosolic quality 
control was presumed to be unrelated to the N-end rule.  This thesis work 
characterizes a novel branch of the N-end rule pathway, termed the misfolded 
protein/N-end rule, and demonstrates that Ubr1p cytosolic quality control is 
indeed highly dependent on N-end rule pathways.  The identification of mis-
translocated proteins as Ubr1 misfolded protein/N-end rule substrates reveals that 
Ubr1p’s role in cytosolic quality control is highly specialized for the clearance of 
aberrantly localized misfolded proteins.  These findings contribute to our 
understanding of how misfolded proteins of different types are managed and may 
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CHAPTER 1 
Introduction 	  
Proteins are an essential component of all living organisms, allowing them to 
grow, thrive, and propagate. Diverse types of proteins are involved in the 
multitude of cellular functions required for survival, which range from replication 
of genetic material to provision of structural integrity.  As such, proteins exist in a 
variety of forms. For example, hydrophobic integral plasma membrane proteins 
form channels that facilitate the uptake of nutrients from the environment, while 
soluble cytosolic proteins carry out glycolysis to produce energy for the cell in the 
form of ATP.  The large variety of specific cellular roles among proteins is a 
byproduct of a cell’s ability to synthesize proteins with unique amino acid 
sequences and lengths as encoded by its DNA.  However, with this versatility 
comes the complexity of properly folding all types of proteins, which for the most 
part possess distinct three-dimensional conformations. 
 
Nascent proteins emerge from ribosomes as linear polypeptides that are not 
functional until folded into stable conformations. A stochastic process, protein 
folding is highly error prone, with 30% of all proteins failing to fold completely 
(Schubert et al., 2000). Furthermore, error rates found in the processes of 
replication, transcription, and translation, as well as environmental stress factors, 
increase the probability of misfolding occurring. This poses a major obstacle 
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toward achieving cellular homeostasis, as misfolded proteins have the tendency to 
form aggregates that can interfere with normal cellular function, resulting in 
toxicity or even cell death. 
 
In mammalian cells, the accumulation of misfolded protein that cannot be 
immediately eliminated by degradation machinery leads to the formation of 
structures called aggresomes near the centrosome/microtubule organizing center 
(MTOC).  This formation requires the action of microtubules and a reorganization 
of interfilaments which encapsulate ubiquitinated and misfolded proteins 
(Johnston et al., 1998).  In yeast, two types of analogous structures also form due 
to misfolded protein accumulation: insoluble protein deposits (IPODS), 
containing proteins that are permanently insolubilized, and a juxtanuclear quality 
control (JUNQ) compartment, in which a fraction of protein is soluble and can 
readily diffuse back into the cytosol (Kaganovich et al., 2008).  The creation of 
aggresomes, IPODS, and JUNCs, appears to occur as cellular defense 
mechanisms to prevent potentially toxic effects of aberrant proteins. 
 
Aberrant protein buildup is often associated with human disease.  The formation 
of inclusion bodies, large concentrations of protein aggregates, is common to 
many protein misfolding-related diseases (Kopito, 2000; Tran and Miller, 1999; 
Frydman, 2001). A widely studied occurrence is the formation of amyloid fibrils 
seen in conditions such as Alzheimer’s (Stefani, 2004). The constituents of 
amyloid fibrils are varied depending on the disease type, and may include small 
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peptides, intrinsically disordered proteins, or natively folded proteins whose 
structures have been destabilized. These serious maladies highlight the significant 
detrimental effects that can occur when cells are unable to eliminate misfolded 
proteins efficiently. Fortunately, both prokaryotes and eukaryotes have evolved 
elaborate mechanisms of protein surveillance, together known as protein quality 
control (PQC), which enable them to detect, sequester, and degrade improperly 
folded proteins. 
 
1.1 Protein misfolding 
Protein folding is a dynamic process that involves an unfolded polypeptide 
stochastically assuming intermediate states that lead it closer to its intended native 
conformation. This view suggests that fluctuations of unfolded or partially folded 
polypeptide states result in the random formation of intramolecular contacts, some 
of which are native, and others non-native. Intermediate conformations resulting 
from native contacts are more stable than those with non-native ones, and thus 
increase the likelihood of the polypeptide continuing the path toward its native 
structure (Figure 1.1) (Jahn, 2005). During this process, intermediate 
conformations with non-native contacts may get trapped, unable to reorganize to 
conformations amenable to proper folding, thus becoming terminally misfolded.  
Proteins typically fold into structures of lowest energy state, and in the case of 
soluble proteins, hydrophobic residues are buried into the core once native 
conformation is achieved (Jahn, 2005; Wolynes, 2005).  On the other hand, 
protein-folding intermediates are likely to have hydrophobic residues exposed. If 
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off-pathway partially folded states persist, they have a high tendency to form 
aggregates due to a high propensity for interaction between exposed patches of 
hydrophobic residues with replicates of itself or other molecules, driven by the 
same forces that promote interaction between hydrophobic regions within a single 
polypeptide during normal folding (Fink, 1998). Protein aggregates in turn, are 
associated with numerous pathologies such as Alzheimer’s, Parkinson’s, 
Creutzfeldt-Jacob and Huntington’s diseases, and type II diabetes (Stefani, 2004).  




Figure 1.1 Representation of energy landscape of protein folding and 
aggregation states.  Nascent proteins proceed through a series of higher energy 
folding intermediate states before finally achieving native conformations. 
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However, due to errors in protein synthesis, stress, or chance, some proteins 
inevitably fail to progress through the correct intermediate structures to reach a 
fully folded structures. If terminally misfolded, these proteins form aggregates 
with other proteins to reach lower energy states. Figure taken from Jahn, et al. 
(2005).  
 
1.1.1   Molecular folding chaperones 
A network of folding chaperones is present in cells to facilitate protein folding.  
While it has been shown that a protein’s amino acid sequence is sufficient to 
specify its final conformation, interactions with chaperones help to ensure that it 
folds correctly and efficiently within its native cellular environment (Anfinsen 
1973; Dobson et al., 1998; Hartl, 1996). Furthermore, these chaperones serve as a 
buffer for random mutations that would otherwise inhibit a protein from folding 
normally, helping to promote the genetic evolutionary development of an 
organism (Tokuriki & Tawfik, 2009; Rutherford and Lindquist, 1998). Folding 
chaperones are in the heat shock protein (HSP) family of proteins, which are so 
named by virtue of being upregulated during a cell’s exposure to high 
temperatures in addition to other conditions of stress. These states inhibit folding 
processes and increase the number of aggregation prone folding intermediates that 
require stabilization by chaperones (Vabulas et al., 2010). Hsp70s and Hsp90s, 
and Hsp60 chaperonins are examples of chaperones that participate in folding 
duties. In addition to facilitating de novo folding of newly synthesized 
polypeptides, certain chaperones have the additional task of refolding natively 
structured proteins that have denatured due to stress (Hartl et al., 2011). 
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1.1.2  Hsp70/Hsp40 folding chaperone system 
Chaperones involved in the folding and refolding of proteins operate in multi-
component machinery through an ATP-dependent process regulated by co-factors 
that promote cycles of binding and release of substrates that are not in native 
conformations. The 70kDa heat-shock protein (Hsp70)-family chaperones work in 
conjunction with cognate Hsp40s to carry out such a process (Qiu et al., 2006). 
 
Hsp70 chaperones harbor an ATPase domain and a substrate-binding domain, and 
exist in ATP or ADP bound forms. The substrate-binding domain preferentially 
binds to segments of polypeptides with hydrophobic properties and inhibits 
aggregation (Flynn et al., 1991). In the ATP-bound form, an Hsp70 has a low 
affinity for substrates.  Hsp70s have one or several cognate Hsp40s containing a 
J-domain, named after a highly conserved motif of E.coli Hsp40 protein DnaJ. 
Hsp40 J-domains stimulate Hsp70 ATPase activity and facilitate ATP hydrolysis, 
converting ATP to the adenosine diphosphate form (Walsh et al., 2004; Qiu et al., 
2006; Fan et al, 2004).  Hydrolysis of ATP induces a conformational change in 
Hsp70 that helps stabilize its interaction with substrates (Montgomery et al., 
1999). The result is an ADP-bound form of Hsp70, which has a high affinity and 
low release rate for substrates. Nucleotide exchange factors (NEFs) cause the 
exchange of ADP for ATP, thus returning Hsp70 to a low substrate affinity state, 
promoting substrate release which allows the substrate to continue folding 
(Dragovic et al., Kabani et al., 2002). This cycle repeats until the protein reaches 
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one of two fates: either native conformation is reached, or the cell determines that 
the protein is terminally misfolded and targets it for degradation (Figure 1.2). 
 
 
Figure 1.2 Hsp70/Hsp40 cycle of substrate binding and release. In a low 
affinity ATP-bound state, Hsp70 engagement with substrates through its substrate 
binding domain (SBD) is inhibited. Hsp40 stimulates the ATPase domain of 
Hsp70 which results in hydrolysis of ATP to ADP form. This reaction structurally 
stabilizes Hsp70 interaction with the target substrate.  Cognate nucleotide 
exchange factors (NEFs) facilitate the exchange of bound-ADP with ATP, 
allowing release of the substrate for the continuation of folding. Figure taken from 
Vembar and Brodsky (2009). 
 
1.1.3  The role of folding chaperones in protein quality control 
Due to the intimacy with which folding chaperones are associated with non-fully 
folded proteins, it is logical that they would also play a primary role in linking 
recognition with degradation for proteins that are unable to fold. Hsp70 and its 
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cofactors are one such system of chaperones that has been implicated in mediating 
protein quality control. Fully functional ER-localized Hsp70 Kar2p/BiP and its 
cognate Hsp40s and were shown to be required for the efficient degradation of ER 
quality control (ERQC) substrates (Kabani et al., 2003; Nishikawa et al., 2001; 
Kanehara et al., 2010).  Mice carrying mutant BiP alleles exhibit abnormal brain 
development and characteristics associated with ERQC defects (Mimura et al., 
2008).  Furthermore, degradation of cytosolic quality control substrates is also 
dependent on cytosolic Hsp70/Hsp40 chaperones (McClellan et al., 2005; Park et 
al., 2007; Prasad et al., 2010; Hampton et al., 2010).  Substrates form aggregates 
in Hsp70 deficient conditions, which suggests that Hsp70s maintain the solubility 
of quality control substrates so that they are degradation-competent. Studies have 
also demonstrated that specific chaperones are able to directly interact with E3 
ubiquitin ligases that mark substrates for degradation, suggesting an active role 
for chaperones in the identification and targeting of misfolded proteins to 
downstream quality control factors (McClellan et al., 2005; Esser et al., 2004; 
Summers et al., 2013). 
 
1.2  Ubiquitin Proteasome System (UPS) 
Ubiquitin-dependent proteasomal degradation is one of the major proteolytic 
pathways in eukaryotic cells.  Its key factor, ubiquitin, is a highly conserved 76 
amino acid residue protein residing in all eukaryotic cells (Ozkaynak 1987).  First 
known as a component required for resistance to cell stress, it was later 
discovered that cells use ubiquitin to specifically mark proteins for degradation 
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through its conjugation to lysine residues in target substrates, a process also 
known as ubiquitination (Glickman and Ciechanover, 2001). In some cases, 
conjugation with specific lysine residues is necessary to induce generation of a 
polyubiquitin chain, a prerequisite for targeting a protein for degradation (Baldi et 
al. 1995; Weissman, 2001). Polyubiquitin chains are recognized by the 26S 
proteasome complex, a molecular recycling machine that breaks down whole 
proteins into smaller constituent peptides that are then further reduced to amino 
acids, enabling them for use in the synthesis of new proteins or other cellular 
molecules (Wolf and Hilt, 2004). A polyubiquitin chain is created through a 
process in which the initial ubiquitin molecule attached to a protein is extended 
with successive additions of free ubiquitin to the most recently conjugated 
ubiquitin molecule; the carboxy-terminal Gly76 of a free ubiquitin is linked to 
Lys48 of the previous (Chau et al., 1998). While polyubiquitin chain formation 
may occur at other lysine residues present in ubiquitin, they serve other functions 
such as triggering endocytosis of proteins from the plasma membrane for 
vacuolar-based degradation (Hicke and Dunn, 2003). Polyubiquitin chains formed 
through ubiquitin Lys48 linkages are specifically used for recognition and 
degradation by the 26S proteasome (Spence, 1995). 
1.2.1  The ubiquitination cascade: E1, E2, and E3 Ubiquitin Enzymes 
The ubiquitination of a protein involves a three-step cascade requiring three key 
enzymes: an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme 
(UBCs), and in the last step, an E3 ubiquitin-ligase (Figure 1.3) (Glickman and 
Ciechanover, 2001).  In the first step, an E1 activates ubiquitin through an ATP-
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dependent reaction that generates E1-S~ubiquitin, a high-energy thiol ester 
intermediate. Next, an E2 ubiquitin conjugating enzyme (UBC) initiates the 
transfer of the activated ubiquitin molecule from the E1 to an E3-bound substrate 
through another high-energy thiol ester intermediate, E2-S-ubiquitin.  E3 enzymes 
contain either a catalytic RING (Really Interesting New Gene) finger domain or 
HECT (homologous to the E6-AP COOH terminus) domain that carries out the 
final step of covalent attachment of ubiquitin to the target substrate. E3s with 
HECT domains catalyze transfer of the ubiquitin molecule to itself before transfer 
to the substrate.  In contrast, RING domain-containing E3s catalyze direct 
ubiquitin transfer from the E2 to the substrate.  E3s also carry out 
polyubiquitination.  In some cases, efficient polyubiquitination requires the 
addition of an E4 enzyme, defined as factor that aids in chain elongation, and is 
often times an E3 itself. Such is the case for polyubiquitination of Mgt1p in yeast 
by Ubr1p E3 ligase and Ufd4p, the acting E4 factor (Hwang et al, 2010; Metzger, 
2010). 
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Figure 1.3 The E1, E2, and E3 ubiquitin conjugation cascade and 26S 
proteasome-mediated degradation. An E1 enzyme activates a ubiquitin 
molecule through an ATP-dependent reaction forming an E1-S-ubiquitin thioester 
intermediate. An E2 faciliates the transfer of the ubiquitin molecule from the E1 
to an E3 ligase through a E2-S-ubiqutin intermediate. E3s of the HECT-type or 
RING-type then transfer the ubiquitin molecule from the E2 to the target 
substrate. The leads to subsequent polyubiquitination and targeting of the 
substrate for degradation by the 26S proteasome. Figure taken from Donohue 
(2002). 	  
1.2.2   26S Proteasome 
The 26S proteasome is a large multi-unit proteolytic particle that specializes in the 
degradation of diverse proteins, including those tagged with Lys48 polyubiquitin 
chains consisting of 4 or more ubiquitin molecules (Coux et al, 1996). It 
comprises two sub-complexes: the 20S catalytic core and 19S regulatory cap 
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(Lupas et al., 1993; Peters, 1994). Its importance to cellular health is obvious, as 
an intact and functional proteasome is essential for survival; in yeast, 13 of the 14 
known subunits of the 20S particle are required for viability (Hilt and Wolf, 
1996).  Evidence suggests that the 19S cap acts as a gateway into the proteasome, 
unfolding substrates to enable entry into the chamber of the 20S complex where 
they undergo proteolysis (Dubiel et al., 1995; Voges et al., 1999). 
In humans, GFP fusion studies with proteasome subunit LMP2 showed that 
proteasomes are concentrated in the cytosol and the nucleus (Palmer et al., 1994, 
1996), while a subset bound to the ER membrane (Yang et al., 1995). In yeast, 
they are strongly localized to the nuclear periphery, which suggests that the 
nucleus is a major site of protein degradation (Wilkinson et al., 1998).  
1.2.3  The role of the UPS in protein quality control  
The ubiquitin-proteasome system has been implicated in a wide range of protein 
quality control systems (Kriegenburg et al., 2011; Goldberg, 2003). Pioneering 
studies in yeast suggested an increase in abnormal proteins that were 
ubiquitinated upon exposure to heat and chemical stress, and which were 
stabilized in 20S proteasome mutants (Heinemeyer et al., 1991; Heinemeyer et al., 
1993; Hilt et al., 1993). Sommer and Jentsch (1993) then linked ER quality 
control degradation to the UPS by showing that mutant alleles of Ubc6p, an ER-
localized E2 enzyme, suppressed defects seen in sec61 ER translocation mutants, 
presumably by stabilizing components of the SEC61 translocation complex. This 
paved the way for the discovery and detailed characterization of E3 complexes 
and cofactors dedicated to ER quality control (Kawaguchi and Ng, 2007). More 
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recently, the identities of some E3 ligases involved in quality control for the 
cytosol and plasma membrane have been discovered in both mammalian and 
yeast models (McClellan and Frydman, 2001; Murata et al., 2001; Prasad et al., 
2010; Fang et al., 2011; Okiyoneda et al., 2010; Zhao et al., 2013;). 
1.2.4 Recognition of misfolded substrates by E3 ligases 
While chaperones are often required for the recognition of misfolded proteins, E3 
ubiquitin ligases generally have the ability to independently and directly 
recognize substrates harboring specific determinants, conferring upon themselves 
substrate specificity (Deshaeies and Jaozeiro, 2009). The E3s of quality control 
pathways are not excluded. For example, in yeast, nuclear-localized San1p E3 
recognizes damaged nuclear proteins based on the level of exposed 
hydrophobicity, a general characteristic of protein misfoldedness (Rosenbaum et 
al., 2011). The exposure of as few as five consecutive hydrophobic residues of the 
substrate is sufficient to facilitate recognition by San1p (Fredrickson et al., 2011).  
Hrd1p, involved in ER quality control, can detect proteins with incorrectly 
structured membrane domains, sensing them through its own transmembrane 
segments (Sato et al., 2009).  Substrate recognition by E3 ligases such as San1p 
seems to provide an additional screening stage downstream of substrate-
chaperone interaction, ensuring that the quality control machinery does not 
promiscuously target healthy proteins. This may be less the case for secretory 
proteins with compromised membrane domains, which as a result of being 
embedded within lipid bilayers may be less exposed for scrutiny by multiple 
factors. Recognition in such situations may rely solely on an E3, as observed with 
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Hrd1p and quality control substrates of the ERAD-M pathway (refer to Section 
1.4.3; Recognition and targeting of ERAD substrates). 
 
1.3   Eukaryotic protein quality control 
Due to the complex physiology and highly compartmentalized structure of 
eukaryotic cells, they have, out of necessity, developed unique mechanisms of 
protein quality control specific for different subcellular compartments.  Thus far, 
distinct protein quality control systems have been identified in the endoplasmic 
reticulum, golgi, mitochondria, nucleus, cytosol, as well as at the plasma 
membrane. Most of these systems have been found to depend on E3 ubiquitin 
ligases for ubiquitination of misfolded proteins, a process that targets them to the 
ubiquitin-proteasome system (UPS) for degradation. Other systems rely on a 
combination of proteases for the destruction of such proteins.  For instance, 
secretory proteins that fail to fold in the ER are dealt with by a process known as 
ER-associated degradation (ERAD), which in budding yeast is mediated by the 
ER-membrane bound Hrd1p and Doa10p E3 ligase complexes (Hampton et al., 
2002). Cytosolic protein quality control (CytoQC) has also been found to involve 
a combination of E3 ligases and the UPS system (Prasad et al. 2010; Eisele and 
Wolf, 2009; Trombetta and Parodi, 2003; McDonough and Patterson, 2003; 
Metzger et al., 2008). In contrast, misfolded proteins found in the mitochondria 
are primarily degraded by proteases (Arnold and Langer, 2002). 
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The majority of proteins fold in the ER or the cytosol, making quality control 
mechanism at these sites of particular interest. While ER quality control (ERQC) 
has been extensively studied and characterized, cytosolic quality control 
(CytoQC) is a burgeoning field that is only beginning to be unraveled. 
 
1.4   ER Quality Control 
Secretory proteins account for roughly one-third of the proteome in eukaryotes (1-
5).  First synthesized in the cytosol, they must be transported into the ER where 
folding and maturation occur.  Within the oxidizing environment of the ER lumen 
reside enzymes that catalyze modifications such as glycosylation and disulfide 
bond formation either post or co-translationally.  These steps enable secretory 
proteins to fold and mature completely so that they may be directed to their final 
destinations.  However, issues often arise that prevent proper maturation in the 
ER, either due to intracellular stresses that disrupt folding, or because of errors 
intrinsic to the polypeptide sequence.  While some misfolded ER proteins are 
degraded through lysosomal pathways, the majority is eliminated by ERAD 
(Hong, 1996; Tsai, 2002; Trombetta and Parodi, 2003). In some cases, molecular 
chaperones that facilitate folding also serve as front-line detectors that initiate and 
target aberrant proteins for degradation. 
1.4.1  ER-associated degradation (ERAD) 
Three ERAD pathways exist for different categories of misfolded proteins: 
ERAD-L, specific for proteins with luminal lesions, ERAD-C for cytosolic 
lesions, and ERAD-M, which is able to detect proteins with defective intra-
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membrane domains (Huyer et al., 200; Vashist and Ng, 2004). Despite handling 
diverse sets of clients, the pathways share in common five key steps: recognition, 
targeting to ERAD machinery, retrotranslocation to the cytosol, ubiquitination, 
and proteasomal degradation (Vembar and Brodsky, 2008). While mammalian 
cells have evolved more numerous and overlapping pathways for ERAD 
involving a larger number of factors, ERAD in yeast is mediated solely through 
the Doa10 and Hrd1 E3 ligase protein complexes. 
1.4.2   Doa10 and Hrd1 complexes 
The Doa10 complex provides the machinery required for the degradation of 
ERAD-C substrates.  It consists of the Doa10p E3 ligase, an E2 complex 
comprised of the Ubc7 E2 anchored to the membrane by Cue1p, and also the 
Cdc48p complex, which comprises AAA-ATPase Cdc48p with cofactors Ufd1p 
and Npl4p, and its membrane anchorage protein Ubx2p. The Hrd1 complex 
handles both ERAD-L and ERAD-M pathway proteins. It contains the core 
membrane proteins Hrd1p E3 ligase, Hrd3p, Usa1p, and Der1p.  In addition, 
soluble lectin Yos9p and Hsp70 chaperone Kar2p interact with the large luminal 
domain of Hrd3p, and along with Usa1p and Der1p, are specifically needed for 
ERAD-L substrates. For ERAD-M, only Hrd1p and Hrd3p are essential. Similar 
to the Doa10 complex, Ubc7 E2 and Cdc48 complexes are also associated with 
the Hrd1 complex, and are required for the ubiquitination and retrotranslocation 
of substrates, respectively (Figure 1.4) (Ismail and Ng, 2006). 
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Figure 1.4 The Doa10p and Hrd1p E3 ligase complexes.  The Doa10 complex 
mediates recognition and degradation of ERAD-C substrates, which have 
cytosolically localized lesions, while the Hrd1 complex engages and degrades 
ERAD-L and ERAD-M substrates, which possess luminal and cytosolic lesions, 
respectively. The Hrd3p, Yos9p, and Kar2p complex screens proteins for luminal 
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misfolding and facilitates their transfer to Hrd1p. Derp1 and Usa1p, while 
required for ERAD-L substrates, is not necessary for ERAD-M substrates. The 
Cdc48/Ubx2/Npl4/Ufd1 is required for the retrotranslocation of the proteins from 
the ER for degradation in the cytosol by the 26S proteasome. Figure taken from 
Ismail and Ng (2004). 
 
1.4.3   Substrate recognition and targeting of ERAD substrates 
Depending on the locations of the lesions, recognition of some ERAD substrates 
initiates upon interactions with molecular chaperones and cofactors either in the 
lumen or the cytosol via a sequential checkpoint mechanism, with surveillance of 
cytosolic domains taking precedence (Vashist and Ng, 2004; Meusser, 2005).  In 
mammalian cells, the Hsp70-Hsp90 family of chaperones are involved in 
targeting transmembrane proteins with compromised cytosolic domains to the 
cytosolic CHIP E3 ligase for ubiquitination. An analogous process occurs in 
budding yeast, but instead, proteins are targeted to the Doa10p membrane-bound 
E3 ligase complex (Vashist and Ng, 2004). If cytoplasmic domains are 
determined to be native, luminal and membrane domains undergo evaluation next. 
Identification of luminal substrates requires a surveillance complex consisting of 
Kar2p (yeast homolog of mammalian BIP), multi-spanning membrane protein 
Hrd3p, and the lectin Yos9p, which is only required in the case of glycoproteins 
(Carvalho et al., 2006; Denic et al., 2006; Xie et al., 2009). Failure at this 
checkpoint results in targeting to the Hrd1/HRD1 E3 ligase, mediator of the 
ERAD-L and ERAD-M pathways. Hrd1p has the ability to recognize proteins 
with membrane domain defects independently (Sato et al., 2009). 
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Aside from a few known cases, only after these checkpoints are passed can a 
protein proceed through the secretory pathway. Those that escape detection in the 
ER may still be eliminated through recognition mechanisms at the Golgi or the 
plasma membrane, culminating with vacuolar degradation (Arvan et al., 2002 
Ferreira et al., 2002; Fayadat and Kopito, 2003). 
 
Interestingly, misfolded glycoproteins are recognized by an additional signal 
found on N-linked glycans. Upon entry into the ER, nascent polypeptides are 
glycosylated by oligosaccharyltransferase, which attaches Glc3Man9GlcNAc2 
glycans to asparagines on Asn-X-Ser/Thr consensus motifs.  The N-linked glycan 
is then remodeled by glucosidase I, glucosidase II, and ER mannosidase I. If the 
protein does not fold in a timely manner, the action of an additional ER 
mannosidase, Htm1p/ER degradation-enhancing α-mannosidase-like protein 
(EDEM) is able to further perform a further modification in the form of mannose 
trimming that results in a Man7GlcNAc2. This results in the exposure of a   
terminal α1,6-linked mannose that serves as an ERAD targeting signal recognized 
by an ER-localized lectin, Yos9p (OS-9/XTP3-B in mammals) (Figure 1.5) (Clerc 
et al, 2009).  Thus, Yos9p, in conjunction with other components of the Hrd1p E3 
ligase complex, is critical for targeting misfolded glycoproteins for degradation. 
The discovery of the N-glycan ERAD signal led to the determination that 
recognition of misfolded glycoproteins is dependent on the target substrate 
harboring a bi-partite signal comprising a disordered misfolded region as well as 
an Htm1p processed N-linked glycan at a specific location along the body of the 
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substrate (Xie et al, 2009).  There exists an additional pathway of ERAD-L for the 
handling of nonglycosylated substrates, for which there is evidence of a separate 
degradation signal (Kanehara et al, 2010). The nature of this signal and its mode 
of recognition are still to be deciphered. 
 
Figur 1.5 N-glycan processing in the ER produces a signal required for 
degradation of glycosylated ERAD-L substrates. Asn-X-Ser/Thr motif linked 
N-glycans of the form Glc3Man9GlcNAc2 are processed to Man7GlcNAc2 by 
Gls1p, Gls2p, Mns1p, and Htm1p when folding takes an excessive period of time, 
a symptom of the inability to fold. This sequence of mannose-trimming exposes a 
terminal α1,6-linked mannose recognized by ERAD surveillance factor Yos9p, 
thereby targeting the misfolded protein for degradation. Figure taken from Hirsch 
et al. (2009). 
 
1.4.4  Ubiquitination, retrotranslocation, and degradation 
Substrates must undergo retrotranslocation into the cytosol where degradation 
occurs.  In addition to Hrd1p’s existing role as the cognate E3 ligase in ERAD-L 
and ERAD-M, recent crosslinking studies implicate the multi-spanning membrane 
protein as the primary membrane component through which ERAD substrates exit 
the ER, thus physically linking recognition of a substrate with its subsequent 
degradation in the cytosol (Carvalho et al, 2010; Nakatsukasa et al 2013).  Once 
contact with the cytoplasm is made, the substrate is ubiquitinated by the RING 
domain of Hrd1p with the help of either Ubc7p or Ubc1p E2 conjugating 
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enzymes. This process leads to polyubiquitination of the substrate (Bays et al., 
2001a; Bordallo et al., 1998). The Cdc48p/Ufd1p/Npl4p ATPase complex then 
facilitates the complete extraction of the substrate from the ER and delivery to the 
26S proteasome for degradation. 
 
1.5   Cytosolic Quality Control 
Based on a large-scale localization study of nearly half of the yeast proteome 
using a GFP-fusion method, Kumar et al. (2002) predicted that 47% of all yeast 
proteins are localized to the cytoplasm. Cytoplasmic inclusion bodies are a 
hallmark of many neurological diseases (Tran and Miller, 1999). This highlights 
the catastrophic effects that may result when there is inability to eliminate 
cytosolic protein aggregates, and suggests a need for effective quality control 
mechanisms in this cellular compartment, together known as CytoQC (Metzger et 
al, 2008). The autophagy-lysosome pathway of protein degradation in the cytosol 
is involved in the clearance of cytotoxic proteins (Rubinzstein, 2006). In fly and 
mouse models of Huntington’s disease, autophagy functions to eliminate and 
reduce the toxicitiy of aggregation-prone mutants of HD protein containing 
expanded polyglutamine tracts (Ravikumar et al., 2002, Ravikumar et al., 2004). 
A growing number of cytosolic chaperones and ubiquitin-related enzymes 
involved in misfolded protein degradation have been identified in recent years, 
linking components involved in protein folding and the UPS system to critical 
cytosolic protein quality control pathways. How cytosolic misfolded proteins are 
recognized by these factors, and the sequence of steps involved in their 
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degradation, is currently a topic of wide interest and focus. Interestingly, 
accumulating evidence also suggests that in one major pathway misfolded 
proteins in the cytosol are first trafficked to the nucleus, where they are 
ubiquitinated and degraded (Prasad et al., 2010). 
1.5.1  The role of cytosolic chaperones 
Cytosolic Hsp70 sand Hsp40s were the some of the first chaperones shown to be 
required for degrading abnormal and short-lived proteins (Lee et al., 1996; 
Bercovich et al., 1997). Initial models proposed that these chaperones played a 
passive role in quality control by merely maintaining the solubility of proteins so 
that they remain accessible and therefore degradation-competent, while the actual 
recognition of substrates was performed by other factors such as the 
ubiquitination machinery (Wickner et al., 1999). Alternative models were later 
presented with the discovery that some chaperones had direct interactions with the 
ubiquitin-proteasome system (Verma et al., 2000), suggesting that specific 
chaperones have the role and ability of targeting folding-incompetent proteins for 
degradation.  This latter view has been corroborated by studies of model 
substrates showing unique chaperone dependencies for folding and degradation, 
as in the case of von Hippel-Lindau (VHL) tumor-supressor protein, which 
requires both Hsp70 and Hsp90 to remain degradation competent, but only Hsp70 
to remain soluble (McClellan  et al., 2005).  
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1.5.2 Degradation of cytosolic quality control substrates has unique 
chaperone dependencies 
Ssa1p was the first Hsp70 determined to be required for cytosolic protein quality 
control in yeast (Park et al., 2007). Park and colleagues demonstrated that the 
degradation of ΔssCPY*, a misfolded, import-incompetent mutant of ER protein 
carboxypeptidase yscY which remains in the cytosol, is Ssa1-dependent, but 
independent of Ssb1/Ssb2, members of another class of Hsp70s.  They also show 
that Ydj1p, an Hsp40, is required for efficient degradation of ΔssCPY*, a result in 
line with the known role of Hsp40 as activator of Hsp70 chaperone function in 
addition to modulator of its substrate specificity (Fan et al., 2003; Rudiger et al., 
2001; Johnson and Craig, 2001). Though Hsp90 was shown to be required for 
degradation of VHL tumor-suppressor protein, it was not required for ΔssCPY*.  
This is also the case with Hsp26 and Hsp42, small heat shock proteins known to 
relieve cellular stress through binding of unfolded proteins (Haslbeck et al., 2004; 
Cashikar et al., 2005).  The data together show that chaperone dependencies for 
degradation of misfolded proteins is substrate specific, requiring unique sets of 
chaperones and cofactors for different proteins, as can be seen when comparing 
the degradation of VHL tumor-suppressor with that ΔssCPY* (McClellan et al., 
2005; Park et al., 2007).  Furthermore, the lack of known dependency on 
chaperones such as Hsp26 and Hsp42 for the degradation of misfolded substrates, 
despite both having known roles in sequestering unfolded proteins, indicates that 
roles in the maintenance of unfolded protein solubility and degradation-
competency are not necessarily linked. 
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1.5.3 Select chaperones: Ssa1p/Ssa2p, Ydj1p, Sse1p, Fes1p 
Recent studies revealed that yeast Hsp70 chaperones Ssa1 and Ssa2p are both 
involved in the cytosolic quality control pathway and serve partially redundant 
functions, as deletion of both factors results in a synergistic stabilization of 
various misfolded substrates: tGnd1, a truncated form of Gnd1p; ΔssPrA, a signal 
sequence deletion mutant of vacuolar proteinase A (PrA); and Δ2GFP, containing 
a deletion near the N-terminus of green fluorescent protein (GFP) that induces 
misfolding (Heck et al., 2010; Prasad et al., 2010). In addition to the Type-1 
Hsp40 Ydj1p, degradation of these substrates is also reliant on Sse1p, an Hsp110.  
The Hsp110-family of cochaperones acts as nucleotide exchange factors (NEFs) 
for Hsp70/Hsp40 folding cycles (Dragovic et al., 2006; Raviol et al., 2006).  Sse1 
harbors an ATPase domain essential for its NEF activity, and forms a stable 
complex with Ssa1 (Schaner et al., 2005). Thus, a complete chaperone system 
consisting of an Hsp70, cognate ATPase-activating Hsp40, and a functional NEF 
(Hsp110), is required for effective degradation of misfolded proteins in the 
cytosol. Ydj1p and Sse1p also have a demonstrated capacity to interact with some 
substrates directly, which may further contribute to the recognition and 
degradation processes (Cyr, 1995; Polier et al., 2008). More recently, the Hsp70 
NEF Fes1p was characterized as a factor that facilitates triaging of misfolded 
proteins, catalyzing their releasing them from Hsp70 chaperones to enable 
degradation by the UPS, while Sis1p, a Type-2 Hsp40, promotes the 
disaggregation of misfolded proteins (Gowda et al., 2013; Summers et al., 2013).  
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1.5.4  Trafficking of misfolded proteins to the nucleus for degradation 
Recent work performed by Prasad and colleagues indicates that misfolded 
cytosolic proteins are trafficked to the nucleus for degradation. There, they are 
recognized and ubiquitinated by San1p and Ubr1p E3 ligases (Prasad et al., 2010). 
Over 80% of proteasomes localize to the nucleus, making it a logical destination 
for proteins to be transported to and degraded (Laporte et al., 2008; Russel et al., 
1999). Deletion of Ssa1p and Ssa2p inhibits the nuclear localization of misfolded 
substrates and causes the appearance of cytosolic inclusions, suggesting that 
Hsp70s are required to maintain the solubility of substrates so that they remain 
competent for nuclear import. Furthermore, this nuclear transport is directly 
dependent on Hsp40 activity, as the deletion of Ydj1, or the use of the 
temperature sensitive strain ydj1-151ts, results in an accumulation of substrate 
along the outside of the nuclear periphery.  In contrast, Sse1p and two Hsp90s 
(Hsc82p, Hsp82p) appeared to play a minimal role for nuclear import (Prasad et 
al., PhD Thesis). This model also suggests that the partitioning of misfolded 
protein degradation from the site of protein synthesis and folding in the cytosol 
provides a barrier that prevents the inadvertent degradation of actively folding 
proteins that are on track to native conformations. 
1.5.5 E3 ligases 
Several E3 ligases involved in cytosolic protein quality control have been 
identified in mammalian and yeast models.  In higher eukaryotes, CHIP 
ubiquitinates misfolded cytosolic proteins in addition to membrane proteins with 
aberrant cytosolic domains in mechanisms that are dependent on interactions with 
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Hsc70/Hsp40 or Hsp90 chaperone systems (Murata et al., 2001; Meacham et al., 
2001).  Interaction is mediated through the binding of CHIP’s tetratricopeptide 
repeat to the tetratri-copeptide (TPR) acceptor sites of Hsc70 and Hsp90 (Connell 
et al., 2001; Ballinger et al., 1999). In yeast, Doa10p, primarily known for its role 
in ER quality control, also participates in the degradation of some CytoQC 
substrates and utilizes cytosolic chaperones Ssa1p and Ydj1p chaperones to do so 
(Metzger et al., 2008). Hul5p, a HECT-type ligase, is uniquely involved in the 
ubiquitination of proteins in the cytosol during and after exposure to heat shock, 
as well as low-solubility proteins under normal conditions (Fang et al., 2011). 
Some cytosolic E3s are specialized in co-translational quality control, such as 
Ltn1/Rkr1, which is linked to the ribosome and targets non-stop polypeptides 
(Bengtson et al., 2010).  
 
The yeast San1p and Ubr1p E3 ligases constitute one system of CytoQC and have 
partially overlapping specificity for misfolded substrates (Prasad et al., 2010; 
Hampton et al., 2010). They exhibit the capacity to synergistically degrade 
multiple misfolded substrates, including: Ste6*C, a truncated variant of plasma 
membrane ATP-binding cassette (ABC) transporter consisting of only its 
cytosolic tail with a deletion near the C-terminus; Δ2GFP, green fluorescent 
protein (GFP) with a deletion near the N-terminus; ΔssPrA, vacuolar proteinase A 
(PrA) devoid of its signal sequence. Deletion of either San1p or Ubr1p results in a 
decrease of degradation efficiency for each substrate, while the deletion of both 
fully stabilizes them. However, the individual contributions of San1p and Ubr1p 
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to total substrate degradation efficiency differ from substrate to substrate (Prasad 
et al., 2010, Prasad et al., 2012). For instance, degradation of Δ2GFP by San1p 
alone is much more efficient than by Ubr1p alone. The differences in substrate 
degradation efficiencies observed between San1p and Ubr1p for different 
substrates is of particular interest and are explored in this study. 
 
1.6 The N-End Rule Pathway 
The N-end rule pathway relates the in vivo half-life of a protein to the identity of 
its N-terminal residue. It is conserved from bacteria and fungi into higher 
mammalian cells. There are two subdivisions of the N-end rule, the Ac/N-end 
Rule, which targets acetylated N-terminal residues, and the Arg/N-end rule, which 
targets specific unacetylated residues. Targeting by the N-end rule pathways 
results in the degradation of the proteins by the ubiquitin proteasome system. This 
process involves the recognition of destabilizing N-terminal residues, or N- 
degrons, by cognate E3 ligases, termed N-recognins, that carryout 
polyubiquitination of target substrates and directs them for degradation by the 26S 
proteasome. In yeast, Doa10p is the N-recognin for the Ac/N-end rule pathway, 
and Ubr1p is the sole N-recognin for the Arg/N-end rule pathway (Figure 1.6). 
 
	  28 	  
 
Figure 1.6 Two branches of the N-end rule pathway.  The N-end rule relates 
the half-life of a protein to the identity of its N-terminal residue. The Arg/N-end 
rule pathway involves the recognition of specific, unacetylated, destabilizing N-
terminal residues by Ubr1p E3 ligase, while the Ac/N-end rule pathway 
destabilizing residues are acetylated and recognized by Doa10p E3 ligase.  
Recognition of substrates by Ubr1p or Doa10p results in protein instability via 
degradation through the ubiquitin-proteasome system. 
 
Destabilizing residues of the Arg/N-end rule pathway are divided into three 
categories: tertiary, secondary, and primary.  Tertiary residues Asn and Gln are 
deamidated by N-terminal amidase Nta1, which become the secondary residues 
Asp and Glu, which can be arginylated to become Arg, a primary residue.  The 
primary residues are classified into Type-1 basic residues (Arg, Lys, His) or 
Type-2 bulky hydrophobic residues (Phe, Trp, Tyr, Leu, Ile).   
 
A small number of endogenous N-end rule pathway substrates have been 
confirmed in yeast and mammalian models.  In yeast, these include the C-terminal 
fragment of Scc1p, for which degradation is required by Ubr1p to ensure proper 
sister chromatid separation during meiosis; Mgt1p, which facilitates DNA repair; 
and Cup9p, a transcriptional repressor involved in down-regulating uptake of 
extracellular di- and tri-peptides.  In mammalian cells, previously identified N-
end rule substrates were found to be generated either by non-processive 
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proteolytic cleavage by factors such as caspases, or N-terminal arginylation of N-
terminal cysteine bearing proteins, generated as a result of initiating methionine 
cleavage, which represents a distinct mechanism absent from yeast.  
 
 Interestingly, the majority of Arg/N-end rule substrates that have been identified 
are ultimately degraded through an Arg N-degron, leaving a gaping hole in the 
purpose for why the N-end rule targets the remaining primary residues which are 
significantly underrepresented in the set of successfully identified endogenous 
substrates.  One proposed explanation for this mystery is that other destabilizing 
residues primarily act as components of small peptides that modulate Ubr1p 
function, and not full proteins that require degradation.  Another theory is that 
since the majority of N-end rule substrates would be generated through a 
transiently occurring mechanism, the concentrations of these substrates are too 
low, or their presence being too transient, for effective isolation and identification. 
Thus, still remaining to be discovered are greater numbers of substrates which 
may help to understand the true scope of Ubr1p specificity. 
 
1.7 Ubr1p 
Ubr1p is a 225kDa RING-type E3 ubiquitin ligase first characterized in yeast as a 
recognition factor that mediates the N-end rule pathway, which relates the in vivo 
half-life of a protein to the identity of its N-terminal residue (Bartel et al., 1990). 
It harbors three substrate binding sites, including a UBR box domain and ClpS-
homology domain. The cysteine-rich UBR box domain is a ~70-residue zinc 
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finger-like motif that recognizes and binds type-1 N-end rule pathway substrates 
via their N-termini, while the ClpS-homology domain recognizes type-2 
substrates (Tasaki et al., 2009; Tasaki et al., 2005; Lupas et al., 2003).  The third 
substrate-binding domain is allosterically activated upon binding of peptides to 
the UBR box and ClpS-homology domains and causes the dissociation of its 
autoinhibitory (AI) domain from its N-terminal region, where the third substrate-
binding domain resides. This allows the targeting of CUP9 protein for degradation 
through a C-terminally localized internal degradation signal yet to be identified. 
CUP9 is a transcriptional repressor of di- and tri-peptide transporter protein 
PTR2. As a result of CUP9 degradation, PTR2 is upregulated, increasing the 
uptake of peptides into the cell (Turner et al., 2000; Du et al., 2002). 
 
In addition to the original characterization of Ubr1p as an N-recognin of the N-
end rule pathway, studies in recent years also implicate Ubr1p in cytosolic quality 
control (refer to Section 1.5) (Heck et al., 2010; Prasad et al., 2010; Nillegoda et 
al., 2010; Eisele and Wolf, 2008). Most of these studies have concluded that the 
N-end rule pathway of protein degradation is unrelated to Ubr1p’s involvement in 
protein quality control on the basis of the observations discussed below. 
 
Eisele and Wolf identified the first Ubr1 cytoplasmic quality control substrate, 
ΔssCL*myc (2008).   ΔssCL*myc is a misfolded, signal sequence-deleted form of 
carboxypeptidase yscY fused to a myc tag, and localizes to the cytoplasm (Park et 
al., 2007). ΔssCL*myc harbors a novel amino terminus of the sequence Met-Ile-
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Ser. The “Sherman-rule” states that the initiating methionine of a protein is 
removed only when the second encoded residue of the protein (P2 residue) has a 
radius of gyration of 1.29Å or less (Moerschell et al, 1990). Thus, based on the 
Sherman Rule, the N-terminal residue of ΔssCL*myc is a methionine.  The 
authors of this study state that since methionine is not a destabilizing residue of 
the N-end rule pathway, ΔssCL*myc is not recognized via the N-end rule. 
 
Ubr1p degrades Tpk2 (cAMP-dependent protein kinase catalytic subunit) upon 
cell treatment with Geldanamycin (GA), an Hsp90 inhibitor drug that disrupts 
proper folding of Tpk2 and other protein kinases (Caplan et al., 2010). The 
addition of dipeptides that block Ubr1 Type-1 and Type-2 N-end rule binding 
domains did not significantly alter GA-induced Ubr1-mediated degradation of 
HA-Tpk2, suggesting that the N-end rule pathway is not involved. 
 
In a screening for substrates of San1p and Ubr1p quality control pathways, Heck 
et al. identified 3HA-stGnd1 and 3HA-tGnd1-GFP as endogenous substrates, both 
being truncated forms of full length Gnd1p (Heck et al, 2010). stGnd1 is encoded 
by residues 1-150, whereas tGnd1 consists of residues 1-368. Both forms are 
degraded by a combination of San1p and Ubr1p pathways. Interestingly, 3HA-
stGnd1 is degraded mostly through Ubr1p, while 3HA-tGnd1-GFP is primarily 
degraded through San1p.  This result indicates that the determinants for each 
pathway are distinct yet partially overlapping. 
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1.8 Objectives of the thesis 
The recent identification of San1p, Ubr1p, and Hul5 as the major E3 ligases 
mediating protein quality control in the cytosol is an important advancement in 
understanding the pathways by which aberrant proteins in the cytosol are dealt 
with. E3 ligases are generally endowed with an intrinsic ability to independently 
recognize their own client substrates as opposed to solely relying on other factors 
for proper substrate engagement, though the latter also facilitates substrate 
recognition and targeting, thus serving to enhance the efficiency and accuracy of 
substrate triaging stages (Deshaeies and Jaozeiro, 2009; McClellan et al., 2005; 
Esser et al., 2004; Summers et al., 2013). Of importance to uncovering the 
specialized roles of individual E3 ligases in any given cellular function is to 
determine their scope of specificity for substrates. For example, Hul5p is thought 
to act as an E4 in cytosolic quality control, as deletion of the HUL5 gene results 
in a decrease of polyubiquitinated misfolded substrates, while having a relatively 
small effect on monoubiquitinated substrates  (Fang et al., 2011). Another 
cytosolic E3, Ltn1/Rkr1, specializes in the detection and degradation of aberrant 
proteins co-translationally. Still unknown then, is how and why the scope of client 
substrates for San1p and Ubr1p differ. Several substrates that require the activity 
of both pathways for efficient degradation have been characterized. Interestingly, 
most do not share an equivalent dependency for the two pathways.  For instance, 
3HA-stGnd1 and Ste6*C are primarily dependent on on the Ubr1 pathway, while 
ΔssCPY* and Δ2GFP have a greater requirement for the San1 pathway for 
efficient elimination.  
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One method for successfully identifying the set of possible substrates of an E3 
ligase is to first determine what are the recognition determinants the E3 uses to 
select substrates. Once the recognition determinants are characterized, a 
subsequent of proteomic analysis screening for those proteins that possess, or may 
have a good chance of possessing, the necessary determinants can be performed.  
The candidates derived from such a screen can then be viewed with a higher 
confidence that they are actual substrates of the E3. Biochemical analysis of 
candidates substrates’ degradation dependency on, or physical interaction with, a 
particular E3 can then be used to verify the screen’s accuracy.  
 
Following the methodology just described, in Chapter 3 of this thesis, I present 
evidence that Ubr1p recognizes a set substrates through novel N-terminal 
sequenced based degradation signals, also known as N-degrons. This was 
achieved through a systematic analysis of N-terminal mutants of an existing 
misfolded Ubr1 substrate, Ste6*C.  I term the degradation of a substrate through 
recognition of these novel N-degrons the “misfolded protein/N-end rule”, 
following a previously defined naming convention in which any determinant 
recognized by the Ubr1 E3 ligase leading to shorter protein longevity is referred 
to as an “N-end rule” based mechanism. In Chapter 4, I demonstrate that 
misfolded N-end rule N-degrons are recognized by Ubr1p as part of a bi-partite 
signal consisting of an N-degron and misfolded or aberrant structural 
conformation.  The presence of both is necessary for degradation through the 
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misfolded N-end rule pathway.  Finally, in Chapter 5, I capitalize on the 
knowledge acquired involving misfolded protein bi-partite signals, applying it as 
search criteria for a bioinformatic screening of the entire yeast proteome.  This 
analysis led to the identification of 2085 nuclear encoded proteins as possible 
Ubr1 substrates. I have verified multiple mistranslocated proteins as Ubr1 
substrates through biochemical experiments, helping to a confirm a model of 
protein quality control in which a large proportion of secretory or mitochondrial 
proteins that misfold in the cytosol are subject to Ubr1p quality control by virtue 









	  35 	  
CHAPTER 2 
Materials and Methods 
2.1 S. cerevisiae strains, growth media, and genetic techniques 
2.1.1 S. cerevisiae strains used in this study (Table 2.1) 
Table 2.1 List of yeast strains 
Strain Genotype Source 
W303 MATa, leu2-3,112, his3-11, trp1-1, ura3-1, can1-




ATY39 MATa, pRP22, W303 background 
 
This study 
ATY40 MATa, ubr1::KANMX, pRP22, W303 background 
 
This study 
ATY55 MATa, san1::KANMX, pRP22, W303 background 
 
This study 




ATY54 MATa, pRP44, W303 background 
 
This study 
ATY66 MATa, ubr1::KANMX, pRP44, W303 background 
 
This study 
ATY57 MATa, san1::KANMX, pRP44, W303 background 
 
This study 




ATY53 MATa, pRP42, W303 background 
 
This study 
ATY65 MATa, ubr1::KANMX, pRP42, W303 background 
 
This study 
ATY56 MATa, san1::KANMX, pRP42, W303 background 
 
This study 




ATY256 MATa, pAT51, W303 background This study 
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ATY257 MATa, ubr1::KANMX, pAT51, W303 background 
 
This study 
ATY258 MATa, san1::KANMX, pAT51, W303 background 
 
This study 




ATY252 MATa, pAT55, W303 background 
 
This study 
ATY253 MATa, ubr1::KANMX, pAT55, W303 background 
 
This study 
ATY254 MATa, san1::KANMX, pAT55, W303 background 
 
This study 




ATY146 MATa, ubr1::KANMX, pAT33, W303 background 
 
This study 
ATY261 MATa, ubr1::KANMX, pAT34, W303 background 
 
This study 
ATY38 MATa, ubr1::KANMX, pAT35, W303 background 
 
This study 
ATY307 MATa, ubr1::KANMX, pAT36, W303 background 
 
This study 
ATY341 MATa, ubr1::KANMX, pAT37, W303 background 
 
This study 
ATY344 MATa, ubr1::KANMX, pAT38, W303 background 
 
This study 
ATY350 MATa, ubr1::KANMX, pAT39, W303 background 
 
This study 
ATY386 MATa, ubr1::KANMX, pAT40, W303 background 
 
This study 
ATY377 MATa, ubr1::KANMX, pAT41, W303 background 
 
This study 
ATY380 MATa, ubr1::KANMX, pAT42, W303 background 
 
This study 
ATY383 MATa, ubr1::KANMX, pAT43, W303 background 
 
This study 
ATY395 MATa, ubr1::KANMX, pAT44, W303 background 
 
This study 
ATY389 MATa, ubr1::KANMX, pAT45, W303 background 
 
This study 
ATY392 MATa, ubr1::KANMX, pAT46, W303 background 
 
This study 
ATY410 MATa, ubr1::KANMX, pAT47, W303 background This study 
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ATY407 MATa, ubr1::KANMX, pAT48, W303 background 
 
This study 
ATY404 MATa, ubr1::KANMX, pAT49, W303 background 
 
This study 
ATY347 MATa, ubr1::KANMX, pAT50, W303 background 
 
This study 
ATY147 MATa, san1::KANMX, pAT33, W303 background 
 
This study 
ATY262 MATa, san1::KANMX, pAT34, W303 background 
 
This study 
ATY64 MATa, san1::KANMX, pAT35, W303 background 
 
This study 
ATY225 MATa, san1::KANMX, pAT36, W303 background 
 
This study 
ATY342 MATa, san1::KANMX, pAT37, W303 background 
 
This study 
ATY345 MATa, san1::KANMX, pAT38, W303 background 
 
This study 
ATY351 MATa, san1::KANMX, pAT39, W303 background 
 
This study 
ATY387 MATa, san1::KANMX, pAT40, W303 background 
 
This study 
ATY378 MATa, san1::KANMX, pAT41, W303 background 
 
This study 
ATY381 MATa, san1::KANMX, pAT42, W303 background 
 
This study 
ATY384 MATa, san1::KANMX, pAT43, W303 background 
 
This study 
ATY396 MATa, san1::KANMX, pAT44, W303 background 
 
This study 
ATY390 MATa, san1::KANMX, pAT45, W303 background 
 
This study 
ATY393 MATa, san1::KANMX, pAT46, W303 background 
 
This study 
ATY411 MATa, san1::KANMX, pAT47, W303 background 
 
This study 
ATY408 MATa, san1::KANMX, pAT48, W303 background 
 
This study 
ATY405 MATa, san1::KANMX, pAT49, W303 background 
 
This study 
ATY348 MATa, san1::KANMX, pAT50, W303 background 
 
This study 
ATY148 MATa, san1::KANMX, ubr1::KANMX, pAT33, 
W303 background 
This study 
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ATY364 MATa, san1::KANMX, pAT61, W303 background 
 
This study 




ATY457 MATa, pAT66, W303 background 
 
This study 
ATY458 MATa, ubr1::KANMX, pAT66, W303 background 
 
This study 
ATY489 MATa, san1::KANMX, pAT66, W303 background 
 
This study 




ATY526 MATa, pAT68, W303 background 
 
This study 
ATY527 MATa, ubr1::KANMX, pAT68, W303 background 
 
This study 
ATY528 MATa, san1::KANMX, pAT68, W303 background 
 
This study 




ATY370 MATa, ydj1::KANMX, W303 background 
 
This study 
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ATY371 MATa, sse1::KANMX, W303 background 
 
This study 




ATY548 MATa, ydj1::KANMX, pAT, W303 background 
 
This study 
ATY492 MATa, sse1::KANMX, pAT, W303 background 
 
This study 




ATY555 MATa, prc1::KANMX, W303 background 
 
This study 
WXY331 MATa, pep4::KANMX, pXW92, W303 background 
 
This study 
WXY194 MATa, prc1::KANMX, pXW92, W303 background 
 
This study 
ATY542 MATa, san1::KANMX, pXW92, W303 background 
 
This study 




ATY544 MATa, san1::KANMX, pAT72, W303 background 
 
This study 






MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 








MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 






ATY439 MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 




ATY440 MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 




ATY443 MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 
trp1- Δ 901 ura3-52 tom40::HIS3 
This study 
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(pRS314-tom40-2), ubr1::LEU2, tom40 plasmid, 
pAT65 
 
ATY478 MATa his3-Δ200 leu2-3,112 ade2-101 suc2- Δ 9 




















ATY151 MATa, pAT11, W303 background 
 
This study 
ATY152 MATa, ubr1::KANMX, pAT11, W303 background 
 
This study 
ATY153 MATa, san1::KANMX, pAT11, W303 background 
 
This study 




ATY155 MATa, pAT12, W303 background 
 
This study 
ATY156 MATa, ubr1::KANMX, pAT12, W303 background 
 
This study 
ATY157 MATa, san1::KANMX, pAT12, W303 background 
 
This study 




ATY314 MATa, pAT79, W303 background 
 
This study 
ATY315 MATa, ubr1::KANMX, pAT79, W303 background 
 
This study 
ATY316 MATa, san1::KANMX, pAT79, W303 background 
 
This study 
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ATY401 MATa, pAT52, W303 background 
 
This study 
ATY402 MATa, ubr1::KANMX, pAT52, W303 background 
 
This study 
ATY403 MATa, san1::KANMX, pAT52, W303 background 
 
This study 




ATY518 MATa, pAT100, W303 background This study 
ATY519 MATa, ubr1::KANMX, pAT100, W303 background 
 
This study 
ATY520 MATa, san1::KANMX, pAT100, W303 background 
 
This study 




2.1.2 Media for culturing yeast 
Unless otherwise specified, all yeast strains were grown in in either YPD (10 gm/l 
yeast extract, 20 gm/l peptone, 2% dextrose/glucose), or synthetic complete (SC) 
media (7 gm/l yeast nitrogen base and 2% dextrose/glucose) lacking methionine 
and cysteine but containing amino acid supplements applicable for the selection 
of single or multiple protein expression plasmids: strains expressing Ste6*C-HA, 
Δ2GFP-HA, GFP-HA, ATP2Δ1,2,3-HA, and their derivatives, were grown in SC 
media lacking histidine (SC-His); strains expressing TOM40 and tom40-2 alleles 
were grown in SC media lacking tryptophan (SC-Trp); strains expressing stGnd1, 
tGnd1, Gnd1p, wild-type Ubr1p or mutants of Ubr1p (D176E-1, P406S-2), were 
grown SC media lacking leucine (SC-Leu); strains expressing Atp2p and 
carboxypeptidase Y (CPY) and their derivatives were grown in SC media lacking 
uracil (SC-Ura). All solid media was identically formulated as described with the 
addition of 2% bacto-agar. 
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2.1.3 Generation of double knockout strains 
Generation of the Δtom40Δubr1 strain from the Δtom40 strains expressing 
TOM40 (TK8) or tom40-2 (TK3) alleles was performed using the yeast high 
efficiency transformation protocol (see Section 2.1.5.2). A LEU2 deletion cassette 
carrying Ubr1p ORF flanking sequences was transformed into the TK8 or TK3 
strain and plated onto SC-Trp-Leu dropout media agar plates. Several resultant 
colonies (double mutant candidates) were streaked for purification on solid media 
and purified colonies inoculated and grown to log phase in liquid media.  
Genomic DNA of the candidates was extracted using the yeast genomic DNA 
extraction kit (see Section 2.1.8 Yeast Genomic). Successful deletion of the 
UBR1 ORF from candidates was verified by amplifying the fragment between the 
UBR1 ORF flanking regions using primers X and X. 
2.1.4 Low efficiency quick yeast transformation for plasmids 
Sonicated salmon sperm DNA was boiled for 5 minutes at 100°C and cooled on 
ice for 2 minutes to produce of single stranded DNA used to facilitate 
transformation. A 100 µl aliquot of plate mix transformation solution (40 % PEG, 
10 mM Tris pH 7.5, 1 mM EDTA, 0.1 M lithium acetate pH 7.5) was prepared for 
each sample in 1.5ml eppendorf tubes. 3µls of the single stranded salmon sperm 
DNA (ssDNA) was added to the solution, followed by 200-800ng of plasmid 
DNA, depending on plasmid size. A small patch of yeast cells grown on solid 
media was isolated using a toothpick and resuspended into the transformation 
solution, and vortexed for 10 seconds.  After 3-6 hrs at room temperature, yeast 
cells were pelleted by microcentrifugation at 14000rpm for 30 seconds.  
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Supernatant was then removed, then the pellet resuspended in 30ul of ddH2O and 
plated on appropriate solid selective media for isolation for growth of 
transformants.  
 
2.1.5 High efficiency yeast transformation for deletion cassettes 
2.1.5.1 Conditioning yeast cells for competence 
Yeast cells were grown overnight to stationary phase, diluted to 0.2 OD600, and 
incubated at 30°C for 3-4 hrs. Cells were pelleted at 1000xg for 4 minutes and the 
supernatant was removed. Cells were resuspended in 0.1M LiOAc and the 
supernatant was removed. Cell were again pelleted at 1000xg for 30 seconds and 
the supernatant was removed. Finally , cells were resuspended in 150ul of LiOAc 
Mix (0.1 M LiOAc, 10 mM Tris-HCl, 1 mM EDTA, pH 7.4) 
2.1.5.2 Transformation of deletion cassette into competent yeast cells 
Sonicated salmon sperm DNA was boiled for 10 minutes at 100°C and cooled on 
ice for 2 minutes to produce of single stranded DNA used to facilitate 
transformation. 75ul of competent yeast cells (see Section 2.1.5.1) was prepared 
in a 1.5ml eppendorf tube for one transformation. 5ul of the deletion cassette 
(amplified by PCR) was added to the cells, followed by 5ul of single stranded 
salmon sperm DNA. 350ul of plate mix transformation solution (40 % PEG, 10 
mM Tris pH 7.5, 1 mM EDTA, 0.1 M lithium acetate pH 7.5) was added, and the 
sample vortexed for 10 seconds. Sample was incubated at room temperature for 
60 min. 50ul of dimethyl sulfoxide  (DMSO) was added and the sample mixed by 
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vortexing for 10 seconds.  The cells were then heat shocked at 37°C for 20 
minutes, and pelleted at 14000rpm for 30 seconds.  Supernatant was removed and 
the cells resuspended in 1mL of YPD.  Cells were incubated at 30°C for 1 hr and 
pelleted at 14000rpm for 30 seconds.  Cells were resuspended in 50ul of  SC 
media and plated and solid selective media followed by a 2-3 day incubation at 
30°C for growth of colonies. 
 
2.2 Molecular biology techniques 
2.2.1 List of plasmids used in this study (Table 2.2) 
Table 2.2 List of plasmids 
Plasmid Protein Promoter Vector Source 
pRP22 Ste6*C-HA TDH3 pRS313 D. Ng (NUS) 
PRP44 Δ2GFP-HA TDH3 pRS313 D. Ng (NUS) 
pRP42 ΔssPrA-HA TDH3 pRS313 D. Ng (NUS) 
pAT33 Ste6*C-HA-I2K TDH3 pRS313 This study 
pAT34 Ste6*C-HA-I2Y TDH3 pRS313 This study 
pAT35 Ste6*C-HA-I2F TDH3 pRS313 This study 
pAT36 Ste6*C-HA-I2A TDH3 pRS313 This study 
pAT37 Ste6*C-HA-I2L TDH3 pRS313 This study 
pAT38 Ste6*C-HA-I2E TDH3 pRS313 This study 
pAT39 Ste6*C-HA-I2V TDH3 pRS313 This study 
pAT40 Ste6*C-HA-I2G TDH3 pRS313 This study 
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pAT41 Ste6*C-HA-I2R TDH3 pRS313 This study 
pAT42 Ste6*C-HA-I2M TDH3 pRS313 This study 
pAT43 Ste6*C-HA-I2P TDH3 pRS313 This study 
pAT44 Ste6*C-HA-I2W TDH3 pRS313 This study 
pAT45 Ste6*C-HA-I2N TDH3 pRS313 This study 
pAT46 Ste6*C-HA-I2D TDH3 pRS313 This study 
pAT47 Ste6*C-HA-I2H TDH3 pRS313 This study 
pAT48 Ste6*C-HA-I2Q TDH3 pRS313 This study 
pAT49 Ste6*C-HA-I2C TDH3 pRS313 This study 
pAT50 Ste6*C-HA-I2T TDH3 pRS313 This study 
pAT51 Ste6*C-HA-I2S TDH3 pRS313 This study 
pAT55 Δ2GFP-HA-S2I TDH3 pRS313 This study 
pAT56 Δ2GFP-HA-S2F TDH3 pRS313 This study 
pAT57 Δ2GFP-HA-S2K TDH3 pRS313 This study 
pAT58 ΔssPrA-HA-K2S TDH3 pRS313 This study 
pAT59 ΔssPrA-HA-K2I TDH3 pRS313 This study 
pAT60 ΔssPrA-HA-K2F TDH3 pRS313 This study 
pAT61 GFP-HA-S2I TDH3 pRS313 This study 
pAT66 ATP2Δ1,2,3-HA TDH3 pRS313 This study 
pAT68 
ATP2Δ1,2,3-HA-
V2S, L3P TDH3 pRS313 This study 
pAT65 ATP2-HA TDH3 pRS316 This study 
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pXW92 CPY-HA PRC1 pRS316 D. Ng (NUS) 











pAT24 D176E-1 UBR1 ADH1 pRS315 
A. 
Varshavsky(MIT) 
pAT25 P406S-2 UBR1 ADH1 pRS315 
A. 
Varshavsky(MIT) 
pAT77 FLAB-UBR1 empty ADH1 pRS315 This study 
pAT11 stGnd1-HA GND1 pRS315 This study 
pAT12 tGnd1-HA GND1 pRS315 This study 
pAT79 
stGnd1-HA-HA-
S2I,A3P GND1 pRS315 This study 
pAT84 Gnd1-HA GND1 pRS315 This study 
pAT85 Gnd1-HA-S2I,A3P GND1 pRS315 This study 
pAT52 Ste6C-HA TDH3 pRS313 This study 
pAT97 HSP60-HA TDH3 pRS313 This study 
pAT100 Δss7-26-HSP60-HA TDH3 pRS313 This study 
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2.2.2 List of oligonucleotide primers used in this study (Table 2.3) 
 
Table 2.3 List of olignonucleotide primers 
 
Primer Construct Sequence (5' => 3') 
AT21 pAT33 TTCGACGGATCCATGAAGCCCGATATAAGTAGA 
AT22 pAT34 TTCGACGGATCCATGTACCCCGATATAAGTAGA 
AT23 pAT35 TTCGACGGATCCATGTTCCCCGATATAAGTAGA 
AT24 pAT36 TTCGACGGATCCATGGCTCCCGATATAAGTAGA 
AT25 pAT37 TTCGACGGATCCATGCTACCCGATATAAGTAGA 
AT26 pAT38 TTCGACGGATCCATGGAACCCGATATAAGTAGA 
AT27 pAT39 TTCGACGGATCCATGGTTCCCGATATAAGTAGA 
AT28 pAT40 TTCGACGGATCCATGGGTCCCGATATAAGTAGA 
AT29 pAT41 TTCGACGGATCCATGAGACCCGATATAAGTAGA 
AT30 pAT42 TTCGACGGATCCATGATGCCCGATATAAGTAGA 
AT31 pAT43 TTCGACGGATCCATGCCACCCGATATAAGTAGA 
AT32 pAT44 TTCGACGGATCCATGTGGCCCGATATAAGTAGA 
AT33 pAT45 TTCGACGGATCCATGAATCCCGATATAAGTAGA 
AT34 pAT46 TTCGACGGATCCATGGATCCCGATATAAGTAGA 
AT35 pAT47 TTCGACGGATCCATGCATCCCGATATAAGTAGA 
AT36 pAT48 TTCGACGGATCCATGCAACCCGATATAAGTAGA 
AT37 pAT49 TTCGACGGATCCATGTGTCCCGATATAAGTAGA 
AT38 pAT50 TTCGACGGATCCATGACTCCCGATATAAGTAGA 
AT39 pAT51 TTCGACGGATCCATGTCCCCCGATATAAGTAGA 
AT40, pAT52 CGCGGATCCCGATGATACCCGATATAAGTAGAG















































2.2.3 Construction of plasmids 
Standard cloning procedures were utilized for the construction of plasmids 
(Sambrook, et al., 1989). Unless otherwise stated, exogenously expressed 
substrates possess an engineered single hemagglutinin (HA) epitope tag attached 
to the C-terminus.  Ste6*C, Δ2GFP, ATP2Δ1,2,3, and their derivatives, were 
expressed under control of a high expression, constitutive TDH3 (glyceraldehyde-
3-phosphate dehydrogenase) promoter in yeast centromeric plasmids. Prc1p 
(carboxypeptidase Y) and its derivatives were placed under control of its native 
constitutive endogenous promoter in yeast centromeric plasmids. Site-directed 
mutagenesis of the original constructs expressing Ste6*C, Δ2GFP, and 
ATP2Δ1,2,3 was performed to generate mutant substrates. 
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pAT1: A fragment carrying the PRC1 promoter was PCR amplified from 
pSW119 with BamHI and NotI restriction ends.  The amplified fragment and 
pSW119 were digested with NotI and BamHI and ligated to generate pAT1. 
 
pAT32: A fragment encoding the TDH3 promoter, followed by Ste6*C-HA, 
followed by the ACT1 terminator sequence, was PCR amplified from pRP22 with 
primers AT270 and AT273 and digested with NotI and XhoI.  The fragment was 
then ligated into an empty pRS316 vector to generate pAT32.  
 
pAT33-pAT51: pAT33 through pAT51 (expressing Ste6*C-I2K, Ste6*C-I2Y, 
Ste6*C-I2F, Ste6*C-I2A, Ste6*C-I2L, Ste6*C-I2E, Ste6*C-I2V, Ste6*C-I2G, 
Ste6*C-I2R, Ste6*C-I2M, Ste6*C-I2P, Ste6*C-I2W, Ste6*C-I2N, Ste6*C-I2D, 
Ste6*C-I2H, Ste6*C-I2Q, Ste6*C-I2C, Ste6*C-I2T, Ste6*C-I2S) were 
constructed by mutation of the base-pairs encoding the 2nd residue of Ste6*C 
through site-directed mutagenesis using primers AT21-39 and pRP22 as a 
template. 
 
pAT52: A fragment encoding residues 1201-1290 of the STE6 ORF followed by a 
hemagglutinin epitope (HA-tag) sequence was PCR amplified from yeast 
genomic DNA using primers AT40 and AT41.  The fragment was digested with 
BamHI and XbaI and ligated to pRP22 digested with BamHI and XbaI generating 
pAT52.  
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pAT55-pAT57: pAT55 through pAT57 (expressing Δ2GFP-S2I, Δ2GFP-S2F, 
Δ2GFP-S2K) were constructed by mutation of the base-pairs encoding the 2nd 
residue of Δ2GFP through site-directed mutagenesis using primers AT18-AT20 
and pRP44 as a template. 
 
pAT61: A 741bp fragment of the GFP ORF followed by the hemagglutinin  (HA) 
tag sequence was PCR amplified using mutational primers AT189 and AT190 and 
pAT7 as a template. The resultant PCR product carrying the GFP ORF with the 
2nd residue mutated to an isoleucine was digested with BamHI and XbaI and 
ligated to pAT7 digested with BamHI and XbaI generating pAT61. 
 
pAT64: A 1563-bp fragment carrying the ATP2 ORF followed by the  
hemagglutinin epitope (HA-tag) sequence was PCR amplified from yeast 
genomic DNA using primers AT244 and AT226.  The fragment was digested 
with BglII and XbaI and ligated to pAT7 digested with BamHI and XbaI 
generating pAT64. 
 
pAT65: pAT66 was digested with ClaI and XhoI to release a 2671-bp fragment 
encoding the TDH3 promoter, ATP2Δ1,2,3-HA, and ACT1 terminator sequences.  
This fragment was ligated into an empty pRS316 vector digested with ClaI and 
XhoI to generate pAT65. 
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pAT66: A 1506-bp fragment carrying the ATP2 ORF with deletions of residues 5-
12, 16-19, and 28-34, followed by the  hemagglutinin  epitope (HA-tag) sequence 
was PCR amplified from yeast genomic DNA using primers AT246 and AT226.  
The fragment was digested with BglII and XbaI and ligated to pAT7 digested 
with BamHI and XbaI generating pAT66. 
 
pAT68: pAT68 (expressing ATP2Δ1,2,3-V2S,L3P-HA) was constructed by 
mutation of the sequences encoding the 2nd and 3rd residues of ATP2Δ1,2,3-HA, 
from valine to serine at the P2 position,  and leucine to proline at the 3rd position, 
through site-directed mutagenesis using primer AT275 and pAT66 as a template. 
 
pAT72: pAT72 (expressing PRC1-12iE) was constructed by the insertion of a 
three base-pair sequence encoding a glutamic acid residue at the 12th codon 
position of the PRC1 ORF through site-directed mutagenesis using primer AT280 
and pXW92 as a template. 
 
pAT77: pFlagUBR1SBX (PWO-0400, Varshavksy), expressing FLAG-tagged 
Ubr1p under control of a ADH1 promoter, was digested with SalI and XhoI to 
release the UBR1 ORF.  The linearized backbone of the vector was then re-ligated 
to generate pAT77, an empty vector control for pFlagUBR1SBX. 
 
pAT78: A fragment containing the GND1 promoter and encoding residues 1-149 
of the GND1 ORF was PCR amplified from yeast genomic DNA using primers 
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AT60 and AT61.  The fragment was digested with NcoI and NotI and ligated to 
pAT1 digested with NcoI and NotI, generating pAT11. 
 
pAT79: pAT79 (expressing stGnd1-HA-S2I,A3P) was constructed by mutation of 
the base-pairs encoding the 2nd and 3rd residue of stGnd1 through site-directed 
mutagenesis using primers AT158 and pAT78 as a template. 
 
pAT82: pAT82 (expressing stGnd1-HA-S2L,A3P) was constructed by mutation 
of the base-pairs encoding the 2nd and 3rd residue of stGnd1 through site-directed 
mutagenesis using primers AT158 and pAT78 as a template. 
 
pAT84: A fragment containing the GND1 promoter and full GND1 ORF followed 
by a hemagglutinin epitope (HA-tag) sequence was PCR amplified from yeast 
genomic DNA using primers AT59 and AT61.  The fragment was digested with 
NcoI and NotI and ligated to pAT1 digested with NcoI and NotI, generating 
pAT84. 
 
pAT85: pAT85 (expressing Gnd1-HA-S2I,A3P) was constructed by mutation of 
the base-pairs encoding the 2nd and 3rd residue of Gnd1 through site-directed 
mutagenesis using primers AT158 and pAT84 as a template. 
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pAT87: pAT87 (expressing stGnd1-HA-S2Y,A3P) was constructed by mutation 
of the base-pairs encoding the 2nd and 3rd residue of stGnd1 through site-directed 
mutagenesis using primers AT158 and pAT78 as a template. 
 
2.2.4 Yeast genomic DNA extraction 
Yeast genomic DNA was isolated from strains of interest using the Yeast DNA 
Extraction Kit (Thermoscientific, Rockford, IL) as follows: 10ml of cells were 
grown overnight and pelleted at 2700rpm for 10 minutes, resuspended in 1mL of 
media, and transferred to a fresh 1.5ml eppendorf tube. Cells were again pelleted 
at 3000-5000xg for 5 minutes at room temperature.  The supernatant was 
discarded and resuspended in Y-PER Reagent at a ratio of 8ul/1mg of pellet by 
gentle vortexing and pipetting until a homogenous mixture was achieved. The 
sample was then incubated at 65°C for 10 minutes and pelleted at 13,000xg for 5 
minutes.  Supernatant was discarded and 400 ul of DNA Releasing Agent A and 
400ul of DNA Releasing Agent B was added to the pellet. The pellet was 
resuspended and incubated at 65°C for 10 minutes.  200ul of Protein Removal 
Reagent was added, and the sample inverted ten times for thorough mixing, then 
centrifuged at 13000xg for 5 minutes.  Supernatant was transferred to a new 1.5ml 
tube.  600ul of isopropyl alcohol was added and mixed by gentle inversion. 
Genomic DNA was precipitated from the sample by centrifugation at 13,000xg 
for 10 minutes. Supernatant was carefully removed, and the pellet washed with 
1.5 ml of 70% ethanol by gentle inversion and centrifugation at 13,000xg for 1 
minute.  The ethanol was removed and the pellet was air-dried until all ethanol 
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residue was evaporated.  The pellet was resuspended in 50ul of TE buffer or 
sterile water by pipetting. 
2.2.5 Site-directed mutagenesis 
A single primer encoding the mutation sequence flanked by 15 residues upstream 
and downstream of the mutation region was 5’-phosphorylated as follows: a 50ul 
mixture containing 5ul 10x T4 PNK buffer, 5ul 10mM ATP, 1ul T4 PNK, 5ul 
100uM mutagenic primer, and ddH2O was incubated for 30 minutes at 37°C. A 
thermal cycle reaction for generating mutated anti-sense strands of the template 
plasmid DNA (65°C, 5 minutes => 95°C, 2 minutes => 25 x [95°C, 10 seconds 
=> 55°C, 30 seconds => 65°C, 1 minute/kb] => 75°C, 7 minutes) was carried out 
on the following: 50ul mixture containing 1ul template plasmid (150ng/ul), 1.5ul 
5’-phosphorylated primer, 2.5ul 10x Pfu buffer, 2.5ul 10x Taq DNA ligase buffer, 
1ul dNTP Mix(10mM total, 2.5mM each), 1ul Turbo Pfu polymerase, 0.5ul Taq 
(Thermus aquaticus) DNA ligase, and ddH2O. Sample was digested with DpnI for 
15-18 hours at 37°C to eliminate methylated template plasmid DNA, and 
subsequently run in a thermal cycle reaction for sense-strand polymerization 
(95°C, 30 seconds => 2 x [95°C, 30 seconds => 55°C, 1 minute => 65°C, 1 
minute/kb] => 75°C, 7 minutes). 1-5ul of the reaction was transformed into 100ul 
of XL-1 Blue competent cells. Plasmid from 5 to 10 XL-1 Blue transformants 
were extracted and screened for successful mutagenesis by DNA sequencing. T4 
PNK (polynucleotide kinase), Taq (Thermus aquaticus) DNA ligase, and DpnI 
restriction enzyme kits were obtained from New England Biolabs; Turbo Pfu was 
obtained from Stratagene. 
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2.2.6 Sequencing of plasmids 
The following mixture was prepared for sequencing of plasmids: 8ul Big Dye 
Terminator (Applied Biosystems), 200ng plasmid DNA, 0.32ul 10uM primer, up 
to a final volume of 20ul with ddH2O. A primer approximately 200 bp upstream 
of the region of interest was used for the sequencing reaction. 
 
2.3 Biochemical and immunological techniques 
2.3.1 Antibodies used in this study Anti-­‐HA	  monoclonal	  antibody	  	  (HA.11)	  was	  sourced	  rom	  Covance	  (Princeton,	  New	  Jersey).	  	  Monoclonal	  anti-­‐3-­‐phosphoglycerate	  kinase	  (PGK)	  was	  sourced	  from	  Invitrogen	  (Carslbad,	  California).	  	  Anti-CPY antibody was a gift from 
Reid Gilmore (University of Massachusetts, Worcester, MA). 
2.3.2 Pulse-chase analysis 
2.3.2.1 Metabolic labeling with S35 
Yeast cells were grown to log phase (~0.6-1.0 OD600) at 30°C (or 25°C for 
temperature sensitive trains) and pelleted by centrifugation at 2700rpm for 10 
minutes. 3 OD600 units of cells were resuspended in 0.9ml of SC selective media 
and incubated at 30°C in a waterbath (or 37°C for temperature sensitive strains) 
for 30 minutes. Pulse labeling was then initiated with the addition of 82.5 µCi of 
[35S]Met/Cys (EasyTagTM EXPRESS 35S, PerkinElmer) for 5 or 10 minutes 
depending on the labeling efficiency of the substrate of interest. Label was chased 
with the addition of excess cold methionine and cysteine to a concentration of 
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2mM. At the appropriate timepoints, pulse labeling/chase was terminated by the 
addition of 0.9ml of yeast cells to 100ul of 100% TCA for a final concentration of 
10% TCA. Cells were then homogenized by beadbeating for 30 seconds using a 
Mini-BeadBeater cell disrupter (Biospec Products) followed by a 5 minute 
incubation on ice, repeated 2 times. Homogenate was transferred to new 1.5ml 
screw tube and pooled with a subsequent wash of the beads with 0.6ml of 10% 
TCA. Homogenate was pelleted by centrifugation at 14000rpm at 4°C for 10 
minutes with the resulting supernatant decanted. The pellet was resuspended in 
TCA resuspension buffer (100 mM Tris-HCl pH 11.0, 3 % SDS, 1mM PMSF) by 
boiling for 15 minutes at 100°C and vigorous vortexing for 10 seconds every 5 
minutes. Cellular debris was pelleted by centrifugation at 140000rpm at 4°C for 
10 minutes and the cleared lysate was transferred to fresh 1.5ml screw-cap tubes.  
2.3.2.2 Immunoprecipitation 
The TCA-precipitable counts for each sample was measured using a scintillation 
counter (Beckman Coulter) and used to normalize the quantity of lysate used for 
immunoprecipitations of the various timepoints within each strain being analyzed. 
50ul of lysate for the timepoint with the lowest count was added to 707ul of IPS II 
buffer (50mM Tris pH 7.5, 150 mM NaCl, 1 % Triton X-100, 0.01 % NaN3, 
1mM PMSF, 0.3 µl protease inhibitor cocktail; Sigma-Aldrich) plus the 
appropriate antiserum. After a 1 hour incubation at 4°C, samples were centrifuged 
for 20 minutes at 14,000rpm and added to fresh 1.5 ml eppendorf tubes containing 
30ul of protein A-sepharose beads (50% PBS suspension).  After a 2 hour 
incubation at 4°C, beads were spun down at 10000rpm for 1 minute and washed 
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three times with IPS I buffer (0.2 % SDS, 1 % Triton X-100, 20 mM Tris-HCl, 
150 mM NaCl, 0.02 % NaN3, pH 7.4) followed by one wash with PBS. Proteins 
were eluted from the protein A-sepharose beads with the addition of protein 
loading buffer (PLB) and subsequent boiling at 100°C for 10 minutes. 
2.3.2.3 Phosphor screen exposure and quantification  
Immunoprecipitated samples were separated by SDS-PAGE.  Gels were vacuum-
dried for 50 minutes at 80°C and exposed to phosphor screens for time periods 
Exposed phosphor screens were scanned with a TyphoonTM phosphoimager and 
the visualized bands of interest quantified using ImageQuant TL software (GE 
Healthcare Life Sciences, Uppsala, Sweden).  Background signal from screen 
exposure was subtracted. All results presented are the means ± SD of at least three 
independent experiments. 
2.3.3 Trypsin sensitivity assay 
Yeast cells expressing the substrate of interest were grown to log phase (0.4-0.6 
OD) and resuspended in cytosol buffer (20 mM HEPES-KOH, pH 7.4, 14 % 
glycerol, 100 mM KOAc, and 2 mM MgOAc) at a concentration of 20 OD/mL.  
1mL of this resuspension was transferred to a 2ml screw-cap tube and 
homogenized by vortexing for 30 seconds in the presence of 1ml of 0.5mm 
diameter zirconium beads followed by a 1 minute incubation at 4°C.  This was 
performed for 5 cycles. The homogenate was transferred to 1.5ml eppendorf 
tubes. 0.6ml of fresh cytosol buffer was used to wash the beads and pooled with 
the original homogenate. Post-nuclear lysate was isolated by pelleting at 500xg 
for 5 minutes and transferring the supernatant to a fresh tube. The post-nuclear 
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lysate was incubated at 30°C for 5 minutes, followed by the addition of trypsin 
(stock solution: 1mg/ml in 1mM HCl, 2mCaCl2) to a working concentration of 
5µg/ml.  Samples were vortexed and incubated for 30°C, with 100ul aliquots 
taken at the indicated timepoints and mixed with 11.1ul of 100% TCA in fresh 
1.5ml eppendorf tubes. Aliquots were kept on ice for 5 minutes and pelleted at 
14000rpm for 20 minutes at 4°C.  Supernatant was discarded, sample pelleted 
again briefly, and supernatant again discarded.  The pellet was resuspended in 
10ul of TCA resuspension buffer (100 mM Tris-HCl pH 11.0, 3 % SDS, 1mM 
PMSF) by cycles of boiling at 100°C and vortexing. Samples were pelleted at 4°C 
to remove SDS and other insoluble particles, and the resultant supernatant 
transferred to a fresh tube.  10ul of 2x protein loading buffer (PLB) was added to 
10ul of supernatant for analysis by SDS-PAGE/Western Blotting using the 
appropriate antibodies. 
2.3.4 Immunoprecipitation of protein for sequencing 
Yeast cells expressing the protein of interest were grown to 1 OD/mL in selective 
media.  800OD of yeast cells were harvested at 3000xg for 15 minutes, washed 
once with 1x PBS, and pelleted again at 3000xg. Cells were washed in 
IP/NP40/PIC/DTT (50mM Tris-HCl, pH8 150mM NaCl, 0.1% NP-40, 0.1mM 
DTT), pelleted at 3000xg, and resuspended in IP/NP40/DTT containing protease 
inhibitors (complete, mini, EDTA-free protease inhibitor cocktail tablet, Roche) at 
a concentration of 50 OD/ml.  1 mL aliquots of the resuspension were transferred 
to a 2ml screw-cap tubes and homogenized by beadbeating for 30 seconds using a 
Mini-BeadBeater cell disrupter (Biospec Products) followed by a 5 minute a 
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minute incubation on ice; beadbeating and incubation on ice was repeated for 6 
cycles in the presence of 1ml of 0.5mm diameter zirconium beads. The 
homogenate was transferred to 1.5ml eppendorf tube. 0.6ml of fresh cytosol 
buffer was used to wash the beads and pooled with the original homogenate. 
Lysate was cleared by centrifugation at 14000 rpm and transferred to a fresh tube.  
Lysate was incubated with 65uL of Roche Anti-HA affinity matrix per 4mL of 
lysate for 2 hours or overnight at 4°C. Affinity matrix was spun down at 2700rpm 
for 1 minute and washed with ice cold IP/NP40/PIC/DTT three times, followed 
by one wash with cold IP buffer to remove residual NP40. Bound proteins were 
eluted from matrix through the addition of 2x protein loading buffer (PLB) and 
subsequent boiling at 100°C for 10 minutes. 
2.3.5 Edman degradation sequencing 
Immunoprecipitated proteins were resolved on 12% SDS-PAGE gels and 
transferred to a PVDF membrane (see Section 2.1.7 SDS-PAGE and Western 
Blotting).  Membrane was washed with dIH2O for 1 minute (3 x 1 minute, 
shaking at 70rpm) to eliminate traces of SDS, Tris, glycine, and other reagents 
that have the potential to interfere with Edman chemistry. The membrane was 
then stained with Coomassie Brilliant Blue (0.1% CBB, 5% acetic acid, 50% 
methanol) for 5 minutes by shaking at 70rpm.  Membrane was quickly destained 
with 50% methanol (3 x 1 minute, shaking at 70rpm).  Band containing the 
protein of interest was excised from the membrane and cut into smaller pieces to 
facilitate sample analysis.  Membrane fragments were loaded into an ABI Procise 
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494 Sequencer for sequencing using standard manufacturer recommended 
protocols. 
2.3.6 SDS-PAGE and Western blotting 
Protein samples were boiled for 10 minutes at 100°C and loaded into 10%, 12%, 
or 4-15% gradient polyacrylamide gels.  Gels were run at 120-150v.  Proteins 
were transferred to nitrocellulose or PVDF membranes using the Bio-Rad Trans-
Blot Turbo Transfer System at a constant I = 2.5A for 10 minutes. Membranes 
were blocked in 30ml of blot buffer (5% non-fat milk in PBST [pH 7.4, 0.1% 
Tween-20, 10 mM Na2HPO4, 2 mM KH2PO4,137 mM NaCl, 2.7 mM KCl]) for 
30 minutes at 37°C, shaken gently every 10 minutes. Blot buffer was discarded 
and another 30ml of blot buffer containing primary antibody at a 1:10000 dilution 
was added to the membrane. Membrane was then shaken at 70rpm for 45 minutes 
to 2 hours at room temperature.  Membrane was rinsed with dIH2O and washed 
twice with PBST for 13 minutes, or four times for 7 minutes if left at 4°C 
overnight after primary antibody incubation. The membrane was then incubated 
with a 1:10000 dilution of secondary antibody (α-mouse IgG HRP [horseradish 
peroxidase]) in PBST for 1 hour by shaking at 70rpm at room temperature. After 
incubation with secondary antibody, the membrane was washed with PBST three 
times for 8 minutes. Proteins were visualized by incubating the membrane with 
HRP substrate (SuperSignal West Pico, Pierce Biotechnology, Rockford, IL) for 5 
minutes and exposure to film. 
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2.4 Bioinformatic analysis 
2.4.1 Identification of yeast proteins harboring destabilizing P2-residues 
The raw data file containing protein translations for systematically-named ORFs 
was obtained from Saccharomyces Genome Database (SGD; 
http://downloads.yeastgenome.org/sequence/S288C_reference/orf_protein/; 
orf_trans.fasta.gz). The data file was modified to facilitate parsing with PHP, a 
server-side scripting language: quotation marks in protein descriptions were 
removed, and a termination character (“@”) was added to the end of the file. The 
PHP script (Figure 2.1, PHP Script #1) and data file were uploaded to a PHP 
enabled server. The script extracted from the data file the systematic name of each 
ORF, and the first 2 residues encoded by the respective ORF, and inserted the 
values into an SQL database. A second PHP script was written to produce a list of 
proteins with destabilizing P2 residues by screening the SQL database entries.  
ORFs with isoleucine, valine, leucine, lysine, valine, glycine, glutamine, arginine, 
and phenylalanine encoded at the P2 position were selected from SQL database 
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FIGURE 2.1 PHP Script #1. Creates mySQL database of yeast ORF systematic 
names and corresponding N-terminal sequences (first two residues) from SGD 






mysql_connect($mysql_host, $mysql_user, $mysql_password); 
     
@mysql_select_db($mysql_database) or die( "Unable to select 
database"); 
 








    $curr = fgetc($file); 
    if ($curr == "> " && $g==0) 
    { 
         $curr = fgetc($file); 
          while ($g !=1){ 
                if ($curr != " ")   { 
                   $gene = $gene.$curr; 
                   $curr = fgetc($file); 
                } 
                else{ 
                     echo "$gene,"; 
                     $g=1; 
                } 
          } 
    } 
 
         if($g==1){ 
           while($curr != '"'){ 
          $curr = fgetc($file); 
          } 
            $curr = fgetc($file); 
           while($curr != '"'){ 
           $curr = fgetc($file); 
           } 
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            $curr = fgetc($file); 
             $nsequence=$nsequence.$curr; 








while($curr != '*'){ 
$curr = fgetc($file); 
} 





}//end if g is 1 
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FIGURE 2.2 PHP Script #2. Retrieves list of systematic names of yeast ORFs 




   
 include("./dbinfo.inc.php"); 
 
 mysql_connect($mysql_host, $mysql_user, $mysql_password); 
     
@mysql_select_db($mysql_database) or die( "Unable to select    
database"); 
     
$query="SELECT * FROM ntermini WHERE (nsequence = 'MI' OR 
nsequence = 'ML' OR nsequence = 'MV' OR nsequence = 'MK' OR 
nsequence = 'MY' OR nsequence = 'MF' OR nsequence = 'MQ' OR 
nsequence = 'MG' OR OR nsequence = 'MR') ORDER BY nsequence"; 






while($i < $num){ 
 
    $gene = mysql_result($result,$i,"gene"); 
$nsequence = mysql_result($result,$i,"nsequence"); 
 
echo "$gene, $nsequence<br>"; 
$i++; 
} 
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2.4.2 Localization of destabilizing P2-residue harboring proteins 
Proteins with ORFs encoding destabilizing P2-residues (target proteins) were 
cross-referenced to data from a localization study of the yeast proteasome 
utilizing a GFP-fusion protein method (Huh et al. 2002): the list of systematic 
names of target proteins was appended to the Excel worksheet containing all 
successfully localized proteins.  A boolean flag was set to identify duplicated 
ORFs for which any localization is was listed (a duplicate indicated that the ORF 
was on the list of target proteins). Proteins with empty localization fields, or 
labeled as “ambiguous” were removed. Four main localization categories was 
defined: nuclear, mitochondrial, cytoplasmic, and secretory. 
 
The list of all proteins for each main protein category (nuclear, mitochondrial, 
cytoplasmic, or secretory) was selected based on the set of proteins with complete 
or partial localization to that category, as determined by the localization terms 
assigned to each protein’s ORF. Nuclear proteins included those assigned the 
following localization terms: nucleus, nucleolous, and nuclear periphery. 
Secretory proteins included those assigned the following terms: ER, Golgi, 
vacuole, endosome, and peroxisome. The list of proteins exclusively localized to 
each of the four main categories were selected based on whether the protein was 
localized to only one of the main categories in addition to any other localization 
classes used by the study. Proteins considered to have multiple localizations were 
those that exhibited localization to two or more of the four main protein 
categories.  Proteins listed in the “other” localization category were those that 
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were not assigned any localization terms associated with the four main categories. 
While some proteins in the “other” localization category were assigned 
localization terms such as “actin”, which could quite accurately be assumed to 
imply cytoplasmic localization, only those explicitly assigned to the main 
localization terms were considered to avoid any bias in classification.  
Furthermore, the small quantity of proteins falling into this category (79) is 
negligible relative to the total number of proteins being analyzed and would not 
impact the general results and conclusions of the analysis as performed. 
2.4.3 Classification of protein translocation fates 
Proteins exclusively assigned cytoplasmic localization out of the four main 
localization categories were classified as having a non-translocated fat.  Proteins 
exclusively assigned secretory, mitochondrial, or nuclear localization were 
classified as having a translocated fat.  Proteins assigned cytoplasmic localization 
in addition to one or more of the remaining three categories (nuclear, 
mitochondrial, or secretory) were classified as having a dual translocation-fate.  
Proteins not fulfilling any of these criteria were designated has having an 
“unknown” translocation fate.  The small quantity of proteins falling into this 
category (79) is negligible relative to the total number of proteins being analyzed 
and would not impact the general results and conclusions of the analysis as 
performed. 
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2.4.4 Determination of proportion of protein categories with exclusively 
localized destabilizing P2-residue harboring proteins 
For each of the main localization categories (nuclear, mitochondrial, cytoplasmic, 
and secretory), the number of proteins exclusively localized to the category and 
also carrying destabilizing P2-residues was divided by the total number of 
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CHAPTER 3 
Novel N-terminal determinants of Ubr1-mediated degradation 	  
3.1 Introduction 
Despite wide differences in cellular function and locale, all proteins share a 
common need to fold into their intended native conformations to function 
properly. However, due to the stochastic nature of protein folding and inherent 
error rates associated with replication, transcription, and translation processes, a 
high propensity exists for folding failures to occur (Hartl et al., 2011; Zaher and 
Green, 2009). Environmental stressors can further exacerbate the difficulties of 
protein maturation. Cells utilize several mechanisms to ameliorate the effects of 
wayward folding, one of which is the employment of folding chaperones that 
attempt to refold aberrantly structured proteins that have aggregated (Glover and 
Lindquist, 1998, Goloubinoff et al., 1999). An alternate mechanism is the 
sequestration of misfolded proteins into benign aggregates such as aggresomes, 
IPODS, and JUNQs, which limits their potential to disrupt basic cellular activities  
(Johnston et al., 1998; Kaganovich et al., 2008). On the other hand, terminally 
misfolded proteins that cannot be rescued or sequestered into benign inclusions 
may have the capacity to interfere with critical cellular pathways. Without 
effective clearance from the cell, these errant proteins have the potential to disrupt 
overall cellular homeostasis, leading to cellular toxicity. The disastrous effects of 
perturbations caused by the persistence of misfolded proteins are evident when 
taking into account the large numbers of protein misfolding-associated maladies 
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that have been identified, such as Alzheimer’s and Parkinson’s diseases (Dobson 
et al., 2004). 
 
In a eukaryotic cell, the site of folding for the majority of proteins is tightly 
coupled with the cellular destination and function of the protein upon maturation. 
Proteins of the secretory pathway fold in the endoplasmic reticulum, cytosolic 
proteins fold in the cytosol, and mitochondrial proteins fold in the mitochondria; 
nuclear proteins fold in the cytosol and are subsequently imported into the nucleus 
through the recognition of nuclear localization sequences within the protein. This 
complex scheme requires that the cell have separate and unique quality control 
machinery localized to the different folding compartments to prevent the 
accumulation of misfolded proteins in any part of the cell.  Folding that occurs in 
the ER is monitored by surveillance machinery known as ER-associated 
degradation (ERAD), which consists of luminal chaperones that facilitate the 
recognition of a misfolded protein by ER-membrane bound Hrd1 and Doa10 E3 
ligase complexes.  The eventual retrotranslocation of the aberrant protein back to 
the cytosol by the Hrd1 or Daoa10 complex allows the protein to be degraded in a 
26S proteasome-mediated manner (Hampton et al., 2002). Proteins that cannot 
successfully fold in the mitochondria are degraded by proteases as opposed to a 
UPS-mediated mechanism (Arnold and Langer, 2002; Luce et al., 2010). 
Cytosolic protein quality control (CytoQC) also involves a network E3 ligases, 
including San1p, Ubr1p, Ubr2p, Doa10p, and Hul5p (Prasad et al. 2010; Eisele 
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and Wolf, 2009; Trombetta and Parodi, 2003; McDonough and Patterson, 2003; 
Metzger et al., 2008).  
 
Central to the study of quality control pathways is the elucidation of mechanisms 
through which quality control factors are able to successfully identify proteins 
that are misfolded amongst the sea of proteins that are either fully folded or in 
intermediate stages of folding.  The latter presents a more pressing challenge, as 
proteins in the process of folding will likely have temporarily exposed 
hydrophobic residues that would eventually be directed to the inner hydrophobic 
core of the protein upon folding completely.  This transient exposure of 
hydrophobic amino acids to the environment is similar to the exposed 
hydrophobic residues that serve as degradation determinants for a terminally 
misfolded protein due to an inability to reach its lowest energy state in which 
hydrophobic residues are shielded. To resolve this problem, cells utilize additional 
determinants to differentiate between misfolded proteins and those that are in the 
intermediate stages of folding.  For example, glycosylated proteins that fail to fold 
in the ER are identified through a bi-partite signal comprising a misfolded region 
along with a N-linked glycan that has been processed further than normal, serving 
as a de facto timer that terminates the life of a protein if native conformation is 
not achieved in a timely fashion. More recently, O-mannosylation has been shown 
to serve as an additional indicator that a protein is not folding efficiently, thereby 
terminating futile folding cycles (Xu et al., 2013).  In the cytosol, additional 
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determinants of misfolded proteins recognized by quality control systems, aside 
from misfoldedness itself, have not yet been identified. 
 
The San1p and Ubr1p E3 ligases have been shown to function synergistically in 
the efficient degradation of a subset of cytosolically localized misfolded proteins, 
as demonstrated by experiments performed on several engineered model 
misfolded substrates. These aberrant proteins are first translocated into the 
nucleus in an Hsp70-, Hsp40-, and ATP-dependent manner, where they are 
subsequently ubiquitinated and degraded by the 26S proteasome within the 
nucleus (refer to Section 1.5 Cytosolic Quality Control).  Of particular interest are 
the determinants of misfolded proteins which are recognized by the San1p and 
Ubr1p, and if any, the differences between the two. 
 
Ubr1p is most widely known for its role as a mediator of the N-end rule pathway, 
which relates the N-terminal residue to the half-life of a protein (refer to Section 
1.6 The N-end Rule Pathway). Degradation determinants recognized by Ubr1p are 
referred to as N-degrons. In this chapter, we demonstrate the discovery of novel 
sequence-based N-terminal N-degrons that are required for the efficient 
recognition and degradation of misfolded proteins by Ubr1p, but which have a 
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3.2 Degradation of model cytosolic substrates Ste6*C and ∆2GFP is mediated 
by San1p and Ubr1p but with unique dependency levels 
3.2.1 Ste6*C and ∆2GFP are each efficiently degraded by a combination of 
the San1 and Ubr1 QC pathways 
We first sought to investigate the differences in substrate selectivity between the 
San1 and Ubr1 pathways, as well as the possible causes.  To do so, we utilized 
two model misfolded substrates, Ste6*C and ∆2GFP, which are efficiently 
degraded through a combination of the two pathways (Prasad et al., 2010, Prasad 
et al., 2012).  Ste6*C is a truncated form of Ste6p (plasma membrane ATP-
binding cassette transporter) containing only the cytosolic tail of the protein, and 
which harbors a deletion of residues 1249-1290 which induces misfolding and 
degradation. ∆2GFP is a derivative of wild-type GFP wherein residues 24-36 are 
deleted. Pulse-chase analysis confirmed that efficient degradation of each 
substrate requires both San1p and Ubr1p E3 ligases, as both substrates were 
partially stabilized in the single deletion mutants ∆san1+UBR1 and +SAN1∆ubr1, 
while the absence of both E3s in ∆san1∆ubr1 cells resulted in nearly full 
stabilization of the substrates (Figure 3.1).  The degradation of Ste6*C occurred 
more efficiently, requiring only half the time (30 minutes) to reach a similar level 
of substrate remaining when compared to ∆2GFP (~12.4% remaining after 60 
minutes). This could be attributed to the two substrates possessing unique 
structural formations, and as such, presenting different levels of recognizable 
misfoldedness by quality control factors. 
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Figure 3.1. Ste6*C and ∆2GFP are substrates synergistically degraded by the 
San1 and Ubr1 cytosolic quality control pathways with differing dependency 
levels. (A) and (B) Turnover of Ste6*C and ∆2GFP in wild-type, ∆san1+UBR1, 
+SAN1∆ubr1, and ∆san1∆ubr1 cells. Cells were grown to log phase and shifted 
to 30°C for 30 minutes followed by pulse-labeling with [35S]methionine/cysteine 
(5 min for Ste*6C and 10 min for ∆2GFP)  and chase at the times indicated. 
Substrates were HA-tagged C-terminally. Proteins were immunoprecipitated 
using anti-HA antibody and resolved by SDS-PAGE, then visualized by 
phosphoimager analysis. Data shown is the mean ±SD of three independent 
experiments. *p < 0.05, **p < 0.01, Student’s t test. 
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3.2.2 Degradation of Ste6*C is more reliant on Ubr1p, while degradation of 
∆2GFP is more reliant on San1p 
One notable difference we observed between the degradation of Ste6*C and 
∆2GFP is the contribution of San1p or Ubr1p to the total degradation efficiency 
achieved in wild-type cells. This was deduced by comparing the amount of 
degradation that occurs when only one of the E3s is present (∆san1+UBR1: only 
Ubr1p present; +SAN1∆ubr1: only San1p present) versus the case where both are 
present (+SAN1+UBR1; wild-type) (Figures 3.1; Ste6*C vs ∆2GFP). The 
degradation efficiency of Ste6*C by Ubr1p alone (∆san1+UBR1) is greater than 
by San1p alone (+SAN1∆ubr1), while the degradation efficiency of ∆2GFP by 
San1p alone is greater than by Ubr1p alone. Thus, while the wild-type 
degradation efficiencies of both Ste6*C and ∆2GFP rely on the combination of 
Ubr1 and San1 pathways, the degradation of Ste6*C is biased towards the Ubr1 
pathway, whereas the degradation of ∆2GFP is biased towards the San1 pathway. 
 
3.3 Mutation of a misfolded substrate’s P2 residue can enhance or inhibit 
degradation by Ubr1p but has a minimal effect on the San1-mediated 
degradation 
Ubr1p has long been recognized for its role in the N-end rule pathway.  The N-
end rule is conserved from bacteria and fungi to higher mammalian organisms, 
and relates the half-life of a protein to the identity of its N-terminal residue. There 
are two distinct branches of the N-end rule pathway: the Ac/N-end rule targets 
acetylated N-termini, while the Arg/N-end rule targets a subset of unacetylated 
	  76 	  
residues. Destabilizing N-terminal residues of the Arg/N-end rule are categorized 
as either Type-1 or Type-2, with the former consisting of bulky hydrophobic 
residues, and the latter, basic residues. N-recognins are E3 ligases that recognize 
proteins harboring destabilizing N-terminal residues and subsequently mark them 
for degradation by the ubiquitin proteasome system (UPS).  In yeast, the sole N-
recognin of the Arg/N-end rule pathway is Ubr1p  (refer to Section 1.6 The N-end 
Rule Pathway). 
 
Interestingly, Arg/N-end rule destabilizing residues are generally not present at 
the native N-termini of endogenous proteins.  This is due to the fact that Arg/N-
end rule destabilizing residues have side-chains with radii of gyration greater than 
1.29 Å, which precludes N-terminal methionine excision of proteins with such 
residues encoded in the 2nd position of the protein (P2 position) (Moerschell et 
al., 1990). The retention of the initiating methionine, which is not a destabilizing 
residue of the Arg/N-end rule, protects these proteins from degradation by Ubr1p 
through this pathway. Expectedly, almost all of the endogenous Arg/N-end rule 
substrates in mammalian and non-mammalian models identified thus far are 
generated as a result of either internal proteolytic cleavages of proteins that occur 
during specific physiological processes such as apoptosis, or N-terminal 
modification of full or proteolytically cleaved proteins in the form of N-terminal 
arginylation (Sriram et al., 2011; Tasaki et al., 2012; Piatkov et al., 2012).  
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Nevertheless, the well-established importance of N-termini for substrate 
recognition by Ubr1p in the Arg/N-end rule pathway suggested to us that the N-
terminus of a misfolded protein might play a pivotal role in its recognition by 
Ubr1p. If such a phenomenon were confirmed, it would provide an explanation 
for the differences we observed in degradation pathway dependencies from 
substrate to substrate (refer to Section 3.2). 
 
If the N-terminal sequence of a misfolded protein does indeed impact it’s 
recognition by the Ubr1 quality control pathway, we surmised that by altering the 
N-terminal sequences of Ste6*C and ∆2GFP, it would be possible to increase or 
decrease the amount of degradation which proceeds via a Ubr1-mediated 
mechanism.  To determine if such an effect exists, we generated N-terminal 
mutants of Ste6*C or ∆2GFP that mimicked the N-terminus of the other substrate 
and observed the impact on Ubr1-mediated degradation for each.  
 
Based on the previously discovered rules of N-terminal methionine excision, the 
P2 residue of a protein is the primary factor in determining whether its initiating 
methionine is removed (Moerschell et al., 1990). Therefore, we defined for each 
substrate, according to its P2 residue, the N-terminus to be “MX”, where X is the 
P2 residue and initiating methionine cleavage does not occur, or “-X”, where X is 
the P2 residue and methionine cleavage occurs (Table 3.1).  Furthermore, the 
suffix added to each substrate name identifies the substrate’s P2 mutation, if any. 
For example, Ste6*C–I2S indicates a mutant of Ste6*C in which the original P2 
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isoleucine was mutated to serine. Per these naming conventions and methionine 
cleavage rules, the N-terminus of Ste6*C-I2I (Ste6*C) is MI, while the N-
terminus of ∆2GFP-S2S (∆2GFP) is –S. 
 
 
Table 3.1 Substrate nomenclature and N-termini. Based on the Sherman Rule 
of N-terminal methionine excision (Moerschell et al., 1990). 
 
We modified the N-terminus of Ste6*C  (Ste6*C-I2I) to mimic that of ∆2GFP 
(∆2GFP-S2S) by substituting the P2 position isoleucine of Ste6*C with a serine 
residue, generating Ste6*C-I2S, which harbors a -S N-terminus. Interestingly, in 
contrast to Ste6*C-I2I, the presence of Ubr1p did not increase degradation rates 
of Ste6*C-I2S in either ∆san1 or +SAN1 backgrounds (∆san1∆ubr1 vs 
∆san1+UBR1; +SAN1∆ubr1 vs +SAN1+UBR1) (Figure 3.2A). Thus, by 
substituting the P2 isoleucine of Ste6*C with serine, Ubr1-mediated degradation 
of Ste6*C was effectively inhibited.  On the other hand, degradation of Ste6*C-
I2S in the presence of only San1p remained similar to Ste6*C-I2I (Figures 3.2A 
vs 3.1, Ste6*C, +SAN1∆ubr1). 
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The inverse experiment was performed with ∆2GFP (∆2GFP-S2S) by substituting 
the P2 serine with isoleucine, thus generating ∆2GFP-S2I, which carries an “MI” 
N-terminus.  Degradation of ∆2GFP-S2I was far more efficient in ∆san1+UBR1 
cells than ∆san1∆ubr1 cells, in contrast to ∆2GFP, for which the presence of 
Ubr1p (∆san1+UBR1) conferred only a minimal increase of degradation 
efficiency (Figures 3.2B vs 3.1, ∆2GFP, ∆san1+UBR1). As the case with Ste6*C-
I2S, degradation efficiency of ∆2GFP via the San1-mediated pathway remained 
relatively unaffected by the S2I substitution (Figures 3.2B vs 3.1, ∆2GFP, 
+SAN1∆ubr1). For both substrates, possessing a P2 isoleucine as opposed to a P2 
serine increases the overall degradation rate of the substrates in wild-type cells, 
suggesting that the enhancement of Ubr1-mediated degradation conferred by a P2 
isoleucine occurs under normal physiological conditions (Figure 3.2C). 
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Figure 3.2. Specific amino acid substitutions of the P2 residue of model 
misfolded substrates can enhance or inhibit degradation through the Ubr1 
pathway. (A) and (B) Turnover of Ste6*C-I2S and ∆2GFP-S2I in 
+SAN1+UBR1(wild-type), ∆san1+UBR1, +SAN1∆ubr1, and ∆san1∆ubr1 cells 
was examined by pulse-chase analysis as described in Figure 3.1. (C) Comparison 
of turnover of P2-serine substrates (Ste6*C-I2S, ∆2GFP-S2S) with P2-isoleucine 
substrates (Ste6*C-I2I, ∆2GFP-S2I) in wild-type cells by pulse-chase analysis as 
described in Figure 3.1.  Data shown is the mean ±SD of three independent 
experiments. *p < 0.05, **p < 0.01, Student’s t test.  Nonsignificant changes are 
denoted by “x” with p > 0.05. 
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3.4 Initiating methionine cleavage of a misfolded substrate is not necessary 
for degradation through the Ubr1p pathway 
We next addressed whether the initiating methionine of Ste6*C-I2I was being 
cleaved through an unidentified mechanism specific to the processing of 
misfolded proteins, presenting an exception to existing rules of N-terminal 
methionine excision (Moerschell et al., 1990).  In the Arg/N-end rule pathway, 
isoleucine is a Type-2 destabilizing residue (Varshavsky et al., 2011; Sriram et al., 
2011; Tasaki et al., 2012).  Cleavage of the N-terminal methionine of Ste6*C-I2I 
would expose the isoleucine residue at the P2 position, triggering its recognition 
by Ubr1p and subsequent degradation via the Arg/N-end rule pathway. 
 
In yeast, MetAP1 (Map1p) and MetAP2 (Map2p) catalyze the N-terminal 
methionine cleavage of nascent proteins. Yeast cells with MetAP1 or MetAP2 
deleted are viable, however the deletion of both MetAP1 and MetAP2 results in a 
synthetic lethal effect (Li and Chang, 1995).  Fumagillin is an anti-angiogenic 
drug that targets the methionine peptidase activity of MetAP2 (Sin et al., 1997). 
Preventing initiating methionine cleavage through the disabling of MetAP1 and 
MetAP2 activity should inhibit degradation of Ste6*C if it is indeed being 
recognized by Ubr1p through exposure of its P2 isoleucine upon methionine 
cleavage. To determine if this was the case, we observed the degradation of 
Ste6*C in ∆map1 cells exposed to a concentration of fumagillin (3uM) shown 
previously to effectively inhibit the methionine cleavage (Forte et al., 2011). The 
degradation of Ste6*C was largely unaffected in ∆map1 cells in the absence of 
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fumagillin, and was marginally inhibited with exposure to fumagillin (Figure 
3.3A). This suggested that initiating methionine cleavage might be occurring to 
Ste6*C, thus exposing the destabilizing P2 residue. However, in order to confirm 
this, the actual N-terminal sequence of Ste6*C was determined by performing 
Edman degradation protein sequencing on Ste6*C isolated from ∆san1∆ubr1 
cells.  This analysis showed the methionine was the first residue (Cycle 1), and 
isoleucine was the second residue (Cycle 2), indicating that the leading 
methionine is retained by Ste6*C as predicted (Figure 3.3B).  Since methionine is 
a stabilizing residue in the Arg/N-end rule pathway, the result suggests that 
Ste6*C is not recognized by Ubr1p via the Arg/N-end rule pathway, but by a 
distinct N-terminal-based recognition pathway, which we term the “misfolded 
protein/N-end rule”.  We therefore concluded that the slight inhibition observed 
when methionine aminopeptidase activity is disrupted must be due to an indirect 
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Figure 3.3. Methionine aminopeptidase activity is not required for the rapid 
turnover of Ste6*C. (A) Wild-type and ∆map1 cells were grown to log phase and 
incubated at 30° for 30 minutes in the presence or absence of 3uM fumagillin, 
followed by pulse-chase analysis as described in Figure 3.1. (B) Lysate was 
prepared from ∆san1∆ubr1 cells expressing Ste6*C-HA.  Protein was 
immunoprecipitated from lysate with anti-HA affinity matrix (Roche), resolved 
by SDS-PAGE, and transferred to PVDF membrane. Protein band carrying 
Ste6*C-HA was excised from the membrane and sequenced via Edman 
degradation. 
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3.5 N-terminal acetylation is not required to prevent Ubr1p recognition of 
misfolded proteins via the misfolded protein/N-end rule 
An acetylated N-terminus serves as a block against Ubr1p recognition in the 
Arg/N-end rule pathway, and we considered that such a modification to the N-
terminus of stable variants of Ste6*C such as Ste6*C-I2S may be a factor in 
preventing recognition by Ubr1p in the misfolded protein/N-end rule 
(Varshavsky, 2011; Sriram et al, 2011).  However, Ste6*C-I2S has proline 
encoded at the P3 position, which through proteome-wide analyses has been 
shown to inhibit N-terminal acetylation (Polevoda et al., 2003). Furthermore, 
successful N-terminal sequencing of Ste6*C-I2S confirmed that its N-terminus 
remains unblocked by modifications, and thus available for recognition (Figure 
3.4). Thus, specific N-terminal sequences are able to inhibit recognition by Ubr1p 
irrespective of N-terminal acetylation state. However, this does not yet rule out 
acetylation as a possible cause of the stabilization observed in other Ste6*C 
variants. 
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Figure 3.4. Edman degradation N-terminal sequencing of Ste6*C-HA-I2S. 
Lysate was prepared from ∆san1∆ubr1 cells expressing Ste6*C-HA-I2S. 
Immunoprecipitated protein was sequenced via Edman degradation as described 
in Figure 3.3B. 
 
3.6 P2-residue compability level with the Ubr1p degradation pathway varies 
widely and is residue specific 
We sought to determine which P2 position residues are compatible with Ubr1-
mediated degradation.  A systematic analysis was performed by substituting each 
of twenty amino acid residues into the P2 position of Ste6*C and analyzing the 
degradation rate of each variant when only Ubr1p is present (∆san1+UBR1), 
thereby eliminating degradation by the San1 pathway as a factor.  A large 
variation in degradation efficiencies was observed, with the percentage of 
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substrate remaining after 60 minutes ranging from 16%  (Ste6c-I2R) to 61% 
(Ste6c-I2N) (Figures 3.5 and 3.7) Therefore, N-terminal sequence compatibility 
with Ubr1 does not appear to be bimodal, but rather, there is a spectrum of 
compatibility levels with the Ubr1-mediated degradation pathway.  Strikingly, a 
number of residue substitutions resulted in a dramatic inhibition of Ubr1-mediated 
degradation, more than doubling the level of Ste6*C remaining at the 60 minute 
time-point in the ∆san1+UBR1 background (Figures 3.5 and 3.7; I2C, I2N, I2S, 
I2A, and I2E vs I2I).  Importantly, none of the substitutions had such an 
inhibitory effect on the degradation of Ste6*C in the case where only the San1-
mediated quality control pathway is available (+SAN1∆ubr1) (Figures 3.6 and 
3.7), suggesting that P2 residue compatibility of a misfolded substrate for 
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Figure 3.5. Efficient degradation of Ste6*C by the Ubr1p quality control 
pathway is highly dependent on P2 residue identity. Turnover rates of nineteen 
Ste6*C P2 amino acid residue mutants  (Ste6*C-I2X, where X = A[alanine], 
N[asparagine], S[serine], C[cysteine], E[glutamic acid], P[proline], D[aspartic 
acid], T[threonine], M[methionine], H[histidine], W[tryptophan], 
F[phenylalanine], Y[tyrosine], V[valine], Q[glutamine], G[glycine], K[lysine], 
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L[leucine], R[arginine]) was compared to the turnover rate of the original Ste6*C 
substrate (Ste6*C-I2I) in ∆san1+UBR1 background cells by pulse chase analysis 
as described in Figure 3.1. Data shown is the mean ±SD of three independent 







	  90 	  
 
 
Figure 3.6 Degradation of Ste6*C by the San1 quality control pathway is 
efficient, independent of P2 residue identity. Turnover rates of nineteen Ste6*C 
P2 amino acid residue mutants  (Ste6*C-I2X, where X = A[alanine], 
N[asparagine], S[serine], C[cysteine], E[glutamic acid], P[proline], D[aspartic 
acid], T[threonine], M[methionine], H[histidine], W[tryptophan], 
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F[phenylalanine], Y[tyrosine], V[valine], Q[glutamine], G[glycine], K[lysine], 
L[leucine], R[arginine]) was compared to the turnover rate of the original Ste6*C 
substrate (Ste6*C-I2I) in +SAN1∆ubr1 background cells by pulse chase analysis 
as described in Figure 3.1.  Data shown is the mean ±SD of three independent 




Figure 3.7 Heat-map reflecting the turnover rates of all Ste6*C-I2X 
substrates in ∆san1+UBR1 and +SAN1∆ubr1 cells as presented in Figures 3.5 
and 3.6. 
 
3.7 Methionine retention is not necessary for recognition by Ubr1p 
Since the majority of destabilizing P2 position residues were of the variety that 
prevents N-terminal methionine cleavage (see Section 3.3), we checked whether 
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methionine retention was critical for rapid degradation by Ubr1p.  Sequencing of 
Ste6*C-I2V, which is degraded rapidly by Ubr1p, confirmed its predicted mature 
N-terminus of -V, and verifies that methionine cleavage occurs for this variant 
(Figure 3.8).  Thus, leading methionine retention is not a prerequisite for a 
misfolded substrate’s compatibility with the Ubr1 degradation pathway. This 
result indicates that efficient Ubr1-mediated degradation of a misfolded protein 
depends on a compatible sequence being present at the N-terminus of the protein 




Figure 3.8. N-terminal sequencing of Ste6*C-HA-I2V. Lysate was prepared 
from ∆san1∆ubr1 cells expressing Ste6*C-HA-I2V. Immunoprecipitated protein 
was sequenced via Edman degradation as described in Figure 3.3B. 
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3.8 Degradation of misfolded substrate stGnd1 follows the misfolded 
protein/N-end rule 
To assess the general applicability of the misfolded protein/N-end rule under 
physiological conditions, we searched through the literature for previously 
identified endogenous cytosolic substrates of Ubr1 quality control. One such 
substrate is 3HA-stGnd1, a truncated form of Gnd1p (residues 1-150) that is 
truncated in the first folded domain of the protein (Figure 3.9A, Heck et al., 
2010). The results from Heck and colleagues demonstrated that 3HA-stGnd1 is 
degraded almost exclusively through the Ubr1p pathway. As hemagglutinin (HA) 
epitope tags are fused N-terminally to stGnd1 in this substrate, the result is an 
artificial N-terminal sequence with a destabilizing P2-residue, tyrosine. To 
determine if this artificial N-terminal sequence is the cause of recognition of the 
substrate by Ubr1p, we engineered a version of stGnd1 with the HA tag fused to 
the C-terminus instead, thereby allowing the substrate to possess the endogenous 
N-terminal sequence of Gnd1p and resulting in a substrate more representative of 
a C-terminally truncated form of Gnd1p that may occur physiologically. The P2 
residue is serine and therefore should have a stabilizing effect on the substrate per 
the misfolded protein/N-end rule.  Indeed, stGnd1-HA was no longer degraded in 
a Ubr1-dependent manner (Figure 3.9B). 
 
To determine if degradation of stGnd1-HA by Ubr1p could be re-induced through 
the misfolded protein/N-end rule, a destabilizing N-terminus similar to Ste6*C 
was engineered by replacing the 2nd position serine with an isoleucine, and the 3rd 
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position alanine with proline, producing stGnd1-HA-S2I,A3P. stGnd1-HA-
S2I,A3P was degraded efficiently in the presence of Ubr1p (+SAN1+UBR1 and 
∆san1+UBR1 cells), but stabilized in the absence of Ubr1p (+SAN1∆ubr1 and 
∆san1∆ubr1 cells) (Figure 3.9C). Other variants with destabilizing N-termini, 
stGnd1-HA-S2Y,A3P and stGnd1-HA-S2L,A3P were engineered to determine 
that the destabilization induced was not specific for a P2 isoleucine.  stGnd1-HA-
S2Y,A3P and stGnd1-HA-S2L,A3P was also degraded by Ubr1p to an equivalent 
extent (Figure 3.9D). 
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Figure 3.9. Ubr1-mediated degradation of misfolded substrate stGnd1 
follows the misfolded protein/N-end rule. (A) Crystal structure of full-length 
Gnd1. Black arrow indicates stGnd1 truncation point (Figure adapted from Heck 
et al., 2010) (B) C-terminally HA-tagged stGnd1 is not a substrate of San1 or 
Ubr1 quality control.  Turnover of stGnd1-HA was analyzed by pulse-chase 
analysis (5 min pulse) as described in Figure 3.1B. (C) stGnd1-HA-S2I, A3P, a 
mutant of stGnd1-HA with a destabilizing N-terminal sequence per the misfolded 
protein/N-end rule is degraded in a Ubr1-dependent manner, but not by San1. (D) 
Degradation of other stGnd1-HA mutants with destabilizing N-termini, stGnd1-
HA-S2Y,A3P and stGnd1-HA-S2L,A3P, is dependent on Ubr1p. All variants 
examined in B-D were expressed from a GND1 promoter. Where applicable, data 
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shown is the mean ±SD of three independent experiments. *p < 0.05, **p < 0.01, 
Student’s t test.  
 
3.9 Degradation of stGnd1-HA-S2I, A3P is partially dependent on cytosolic 
QC chaperones 
To determine if the degradation of the engineered misfolded N-end rule substrate, 
stGnd1-HA-S2I,A3P, requires the same chaperones required for the degradation 
of other model misfolded substrates examined thus far, we examined its 
degradation in ∆ydj1, ∆sse1, and ∆ssa1∆ssa2 cells.  Contrary to expectations, the 
deletion of Ydj1p, or Ssa1p and Ssa2p, did not significantly inhibit the 
degradation of stGnd1-HA-S2I,A3P (Figure 3.10A).  The absence of Sse1p, and 
Ssa1p and Ssa2p, slightly stabilized the substrate, but not to the extent seen with 
the deletion of Ubr1p (Figure 3.9A). This indicates that chaperone dependency in 
cytosolic quality control may differ from substrate to substrate. They may be due 
to several reasons. Since cytosolic misfolded proteins are generally trafficked to 
the nucleus, the disparity in chaperone dependency could result from a difference 
in the ability of a particular substrate to enter the nucleus, as this process was 
shown to be chaperone dependent.  Alternatively, stGnd1-HA-S2I,A3P may 
represent a unique class of misfolded proteins in the cytosol that does not require 
nuclear import for efficient degradation, but is eliminated through an alternate 
degradation mechanism that also requires the action of Ubr1 E3 ligase.  
 
To demonstrate that induction of Ubr1-mediated degradation is not restricted to 
specifically mimicking the N-terminal sequence of Ste6*C, stGnd1-HA-S2I,A3K 
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was created which reflects the N-terminus of ∆2GFP. Similar to stGnd1-HA-
S2I,A3P, stGnd1-HA-S2I,A3K was also degraded in a Ubr1-dependent manner 
but only partially dependent of the classical cytosolic quality control chaperones 
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Figure 3.10. stGnd1-S2I,A3P and stGnd1-S2I,A3K are degraded in a Ubr1-
dependent manner that is independent of Ydj1p and marginally dependent 
on Sse1p and Ssa1p/Ssa2p.  (A) and (B) Turnover of proteins in wild-type, 
∆ydj1, and ∆ssa1∆ssa2 cells as determined by pulse-chase analysis (5 min pulse) 
carried out as described in Figure 3.1B. (C) stGnd1-HA-S2I,A3K degradation 
dependency on Ubr1p and CytoQC chaperones is similar to that of stGnd1-HA-
S2I,A3P. Turnover of proteins in +SAN1∆ubr1 and ∆san1∆ubr1 was measured by 
pulse-chase analysis (5 min pulse), carried out as described in Figure 3.1B.  All 
variants examined in A-C were expressed from a GND1 promoter. Where 
applicable, data shown is the mean ±SD of three independent experiments. *p < 
0.05, **p < 0.01, Student’s t test. 
 
3.10 Discussion 
Since the discovery of San1p and Ubr1p as the primary E3s mediating cytosolic 
protein quality control, interest has been directed toward determining differences 
in the modes of recognition involved for their respective substrate specificities. It 
had previously been established that San1p, a nuclear-localized E3, guards against 
the deleterious effects of an accumulation of misfolded proteins in the nucleus by 
targeting them for degradation (Gardner et al., 2005). In this cellular context, 
exposed hydrophobicity of a substrate serves as a key determinant in recognition 
by San1p, which can be triggered by as few as five contiguous hydrophobic 
residues (Fredrickson et al., 2011).  Furthermore, San1p preferentially recognizes 
proteins with a degree of exposed hydrophobicity that results in a high 
predisposition towards protein insolubility and aggregation (Fredrickson et al., 
2013). Since cytosolic misfolded proteins first traffic to the nucleus before being 
ubiquitinated and degraded, it is possible that their detection by San1p is 
facilitated through similar determinants. 
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In contrast to San1p, the discovery of Ubr1p’s ability to target cytosolic misfolded 
proteins is the first time Ubr1p had been linked with a general role in protein 
quality control. Previously characterized substrates of the Arg/N-end rule in 
various model organisms may have provided clues to such a role.  However, in 
most cases, the degradation of such substrates were essential steps in specific 
cellular pathways that generate the substrates as byproducts, and thus represent 
cellular phenomena fundamentally distinct from the general clearance of aberrant 
or folding-incompetent proteins. 
 
For instance, one Ubr1p Arg/N-end rule substrate is a cleavage fragment of 
Scc1p, a subunit of the cohesin complex that facilitates the cohesion of sister 
chromatids during DNA replication. Upon sister chromatid separation, separase 
cleaves Scc1p at a junction which generates a C-terminal fragment possessing an 
N-terminal arginine, a destabilizing residue of the Arg/N-end rule. Consequently, 
the fragment is recognized and degraded by Ubr1p.  Efficient degradation of the 
Scc1p fragment through the N-end rule is required for fidelity of sister chromatid 
separation and chromosomal stability (Rao et al., 2001). Another example is 
Mgt1p, a DNA repair methyltransferase that is alkylated upon facilitating DNA 
repair, converting it into an inactive protein that is degraded by Ubr1p through 
recognition of an N-degron near its N-terminus (Hwang et al., 2008). Both the 
seperase-produced C-terminal fragment of Scc1p and inactive alkylated Mgt1p 
represent defunct proteinaceous entities that are of no functional use to the cell.  If 
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not eliminated, they can potentially have a negative effect on cellular health, as 
demonstrated for the separase-produced fragment of  Scc1p (Rao et al., 2001). 
 
While substrates of the Ubr1-mediated N-end rule pathway such as the C-terminal 
fragment of Scc1p and inactive Mgt1p are not a result of folding failures, the 
determinants by which they are recognized, that being N-terminally localized N-
degrons, provided useful insight leading to our discovery of the novel N-terminal 
N-degrons through which Ubr1p uniquely recognizes misfolded or otherwise 
aberrantly structured proteins. These N-terminal sequence-based N-degrons 
together constitute the “misfolded protein/N-end rule”, and represents a third 
branch of the N-end rule pathway, adding to the existing Arg/N-end rule and 
Ac/N-end rule pathways. 
 
Interestingly, there is a large overlap between the destabilizing residues of the 
Arg/N-end rule pathway and the misfolded protein/N-end rule, with the majority 
of both comprising residues carrying either basic or bulky hydrophobic side-
chains with the exception of glycine and valine, which are destabilizing in the 
misfolded protein/N-end rule but not the Arg/N-end rule (Figure 1.6 and 3.7).  
Furthermore, a major difference lies in the residue position at the N-terminus: 
Arg/N-end rule destabilizing residues are required at the N-terminal position, 
while misfolded protein/N-end rule destabilizing residues are at the P2 encoded 
position, independent of the final position after post-translational N-terminal 
processing (as the case for glycine and valine which generally reside at the N-
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terminal position after methionine cleavage). The apparent overlap of 
destabilizing residues in the two N-end rule pathways may indicate a convergence 
in the physical mechanisms for recognition. Ubr1p contains UBR box and ClpS 
homology domains, which are required for the recognition of Arg/N-end rule 
residues. In the next chapter, we look into the possibility that the two pathways 
may utilize the same Ubr1p recognition domains.  Understanding or ruling out 
such a possibility will aid in determining whether novel domains in Ubr1p exists 
for the binding to misfolded protein/N-end rule substrates, or if the substrate 
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CHAPTER 4 
A bi-partite signal for Ubr1-mediated cytosolic quality control 
4.1 Introduction 
One of the key challenges to effective protein quality control in a cell is 
distinguishing between terminally misfolded proteins from proteins that are on 
track to achieving native conformations but are in intermediate folding states. 
Both types of proteins will have greater amounts of hydrophobicity exposed to the 
cellular environment compared to a protein that is fully folded, as by then, 
hydrophobic residues will generally collapse into hydrophobic cores protected 
from the environment.  The burial of hydrophobic regions reduces the possibility 
of aberrant interactions with proteins or other components that could disrupt 
cellular signaling pathways or the folding of other nascent polypeptides. 
Molecular folding chaperones have the ability to bind and release hydrophobic 
regions of proteins during folding, which serves to facilitate efficient folding in 
addition to preventing abnormal interactions through different stages of the 
process.  
 
Since both misfolded and folding proteins exhibit heightened hydrophobic 
character relative to mature proteins, cells thus must have mechanisms for 
differentiating between the two in order to effectively eliminate aberrant proteins 
without disturbing the folding of normal proteins.  As discussed in Chapter 4, 
additional determinants signaling an aberrant protein for degradation exist in the 
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ER in the form of over-processed N-linked glycans.  Glycosylated proteins whose 
folding have been compromised will be subject to additional mannose-trimming 
of specific N-glycans, causing subsequent recognition by Yos9p. An 
appropriately modified N-glycan combined with structural aberrancy forms the 
bi-partite signal required for ERAD to identify proteins that are terminally 
misfolded and could not be rescued by chaperone binding cycles. 
 
In this series of experiments, we show that the novel N-terminal sequence based 
N-degrons characterized in Chapter 3 are necessary, but insufficient, to direct 
proteins for efficient degradation by Ubr1p.  An analysis of multiple substrates 
demonstrated that Ubr1p effectively targets misfolded proteins when they harbor 
N-degrons.  Targeting is much less efficient when the same misfolded protein is 
lacking an N-degron (Figure 3.1).  Interestingly, Ubr1p does not efficiently 
degrade the misfolded proteins’ fully folded counterparts despite possessing the 
same N-termimal destabilizing sequences. These results suggest that structural 
aberrancy, or misfoldedness, is a key factor in the recognition of misfolded 
protein/N-end rule N-degrons by Ubr1p – both are necessary.  Thus, a bi-partite 
signal that includes a destabilizing N-degron, and the characteristic of structural 
aberrancy, is required for recognition by the misfolded protein/N-end rule 
pathway. 
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4.2 Misfolded N-end rule substrates are recognized by Ubr1p through a bi-
partite signal  
As observed in Chapter 3, Ubr1p efficiently degrades the N-terminally 
destabilized mutant substrate, ∆2GFP-S2I, but is unable to efficiently degrade its 
parent substrate, ∆2GFP-S2S, which in contrast, carries a stabilizing N-terminus 
per the misfolded protein/N-end rule. This demonstrates that specific N-terminal 
sequences facilitate the degradation of misfolded proteins by Ubr1p.  To 
determine whether a destabilizing N-terminus of the misfolded protein/N-end rule 
is alone sufficient to direct a protein for Ubr1-mediated degradation, or if 
structural aberrancy is an essential co-prerequisite for recognition by Ubr1p 
through the destabilizing N-terminal sequences of the misfolded protein/N-end 
rule, we engineered at N-terminally destabilized, folded form of ∆2GFP-S2I by 
mutating the P2 residue of wild-type GFP from serine to isoleucine, generating 
GFP-S2I.  GFP-S2I bears the same N-terminal sequence that causes the rapid 
degradation of misfolded substrate ∆2GFP-S2I.  Interestingly GFP-S2I was 
significantly more stable compared to ∆2GFP-S2I, and furthermore, only slightly 
susceptible to degradation by Ubr1p (Figure 4.1A).   GFP-S2I was largely 
resistant to trypsin digestion compared to ∆2GFP-S2I, an indication of its 
relatively stable, folded structural conformation (Figure 4.1B).  Together, these 
data suggest that structural abnormality is required for efficient degradation of a 
protein through the misfolded N-end rule.  Thus, the recognition and degradation 
of a substrate through this pathway requires that the substrate present a bi-partite 
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Figure 4.1. Recognition of misfolded substrates by Ubr1p is mediated 
through a bi-partite degradation signal comprising a destabilizing N-
terminus and structural aberrancy. (A) GFP-S2I is not efficiently recognized 
by Ubr1-mediated quality control.  Turnover of GFP-S2I and ∆2GFP-S2I was 
compared by pulse-chase analysis in ∆san1∆ubr and ∆san1+UBR1 cells as 
described in Figure 3.1B. (B) Trypsin sensitivity assay demonstrates the structural 
stability of GFP-S2I relative to ∆2GFP-S2I.  Postnuclear lysates were prepared 
from ∆san1∆ubr cells and treated with 5.0µg/ml trypsin for the durations 
indicated.  Protein was analyzed by immunoblotting with monoclonal anti-HA 
antibody.  Endogenously expressed phosphoglycerate kinase (PGK) was assayed 
to serve as a folded protein control. Data shown is the mean ±SD of three 
independent experiments. *p < 0.05, **p < 0.01, Student’s t test.  Nonsignificant 
changes are denoted by “x” with p > 0.05. 
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4.3 Ste6C is structurally semi-stable and partially recognized by Ubr1p  
To establish that the bi-partite signal of the misfolded N-end rule characterized in 
Section 4.2 applies as a general rule to diverse aberrant proteins, we constructed a 
“folded” version of Ste6*C, Ste6C-F, which is the full cytosolic tail of Ste6p 
(residues 1249-1290) without the C-terminal deletion contained in Ste6*C.  
Ste6C-F exhibited slight susceptibility to degradation by Ubr1p, but significantly 
more stable relative to Ste6*C (Figure 4.2A). Ste6C-F was only partially resistant 
to degradation by trypsin digestion, resulting in the formation of two smaller 
proteolytic products that persisted over the course of the digestion (Figure 4.2B).  
This may be attributed to that fact that while Ste6C-F does not carry the deletion 
that induces misfolding in Ste6p/Ste6*C, it is removed from its native state as an 
ER-membrane tethered domain, which may include interactions that are disrupted 
when detached from the ER membrane and cause the exposure of regions of the 
structure susceptible to trypsin activity. Hence, this structural abnormality may 
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Figure 4.2. Ste6*C is efficiently recognized by Ubr1 quality control through a 
bi-partite signal. (A) Turnover rate of Ste6-F (Ste6*C without C-terminal 
deletion), was compared with Ste6*C in in WT, ∆ubr1, and ∆san1 cells by pulse-
chase analysis as described in Figure 3.1B. (B) Ste6-F is conformationally semi-
stable.  Trypsin sensitivity assay was performed on Ste6-F as described in Figure 
4.1B. 
 
4.4 Gnd1p-S2I,A3P with an engineered destabilizing N-terminus is an 
endogenous protein-based cytosolic substrate protected from Ubr1 quality 
control by virtue of being folded  
Gnd1p, the native, folded counterpart of stGnd1 was also examined for resistance 
to the misfolded protein/N-end rule pathway. Natively, Gnd1p bears a stabilizing 
N-terminus with a serine residue at the P2 position, and is stable as expected.  A 
version of Gnd1p carrying the same mutations that caused the destabilization of 
stGnd1-HA was engineered by substituting the P2 position serine with an 
isoleucine and P3 position alanine with a proline, generating the substrate Gnd1-
HA-S2I, A3P.  Gnd1-HA-S2I,A3P was completely stable in both wild-type and 
∆ubr1 cells over the same time period in which stGnd1-HA-S2I, A3P was 
degraded rapidly by Ubr1p (Figure 4.3 vs Figure 3.9C)  While folded GFP and 
Ste6C are not native cytosolic proteins in yeast, Gnd1-HA-S2I,A3P represents an 
endogenous cytosolic protein in yeast that is representative of the subset of 
proteins that would not be subject to recognition by Ubr1 despite being localized 
to the cytosol and carrying a destabilizing N-terminal sequence. However, 
stGnd1-HA-S2I,A3P, an aberrant form of Gnd1p-HA-S2I-A3P, is degraded 
efficiently by Ubr1p. Thus, the misfolded protein/N-end rule is applicable to 
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misfolded forms of endogenous proteins with the necessary destabilizing N-
termini, but not their folded counterparts. 
Figure 4.3. Gnd1-HA-S2I,A3P is stable in vivo despite possessing a 
destabilizing N-terminal sequence. Turnover of Gnd1-HA-S2I,A3P expressed 
from its endogenous promoter in wild-type and ∆ubr1 cells was determined by 
pulse-chase analysis as described in Figure 3.1. Protein was expressed from a 
GND1 promoter 
 
4.5 Ubr1p overexpression leads to partially promiscuous, N-degron 
independent degradation of substrates 
In the ER, glycosylated substrates with luminal lesions are recognized by ERAD 
through a bi-partite signal consisting of an Htm1 processed N-linked glycan and 
aberrant conformational structure.  This leads to the substrate’s retro-translocation 
by the Hrd1 E3 ligase complex and degradation in the cytosol by the 26S 
proteasome.  A complex consisting of Hrd3p, Yos9p, and Kar2p serves as the 
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luminal surveillance system that selectively recognizes proteins bearing both 
components of the bi-partite signal (Carvalho et al., 2006; Denic et al., 2006).  
However, Hrd3 overexpression was shown to result in the degradation of 
misfolded CPY* lacking the proper N-linked glycan determinant. This results 
indicates that glycosylated misfolded proteins in the ER can still recognized when 
missing the sugar-based determinant. A corollary to this finding is that the levels 
of quality control factors in the ER are precisely regulated for the most efficient 
and accurate screening of proteins for degradation.  Without this moderation, the 
ERAD system would inadvertently target proteins that are merely in the process 
of folding and decrease cellular efficiency, with the possible consequence of 
effecting fitness. 
 
Ubr1p is endogenously expressed at relatively low levels.  To assess whether this 
limited level of expression of Ubr1p is required for the proper specificity for 
substrates by Ubr1 mediated cytosolic quality control, we compared the 
degradation rates of Ste6*C-I2S, a substrate lacking a destabilizing N-degron, in 
in the presence of Ubr1p expressed under control of either its endogenous 
promoter, or an ADH1 high-expression promoter. As previously observed, 
Ste6*C-I2I, but not Ste6*C-I2S, was efficiently degraded in the presence of 
Ubr1p under the control of its endogenous promoter in ∆san1∆ubr cells (Figure 
4.4) However, overexpression of Ubr1p expressed from a high expression ADH1 
promoter resulted in increased destabilization of both Ste6*C-I2I and Ste6*C-I2S 
when compared to the stability of the substrates when co-expressed with Ubr1p 
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under control of its low-expression endogenous promoter.  This result suggests 
that the endogenous levels of Ubr1p are limited in order to maintain the proper 





Figure 4.4. Overexpression of Ubr1p results in the promiscuous degradation 
of misfolded susbtrates that do not possess destabilizing N-termini 
recognized by Ubr1p via the misfolded protein/N-end rule. Turnover of 
proteins in ∆san1∆ubr1 cells expressing Ste6*C-I2I or Ste6*C-I2S and co-
expressing Ubr1p either under control of a UBR1 promoter or an ADH1 




A role for bi-partite signaling in protein quality control has been demonstrated in 
the ERAD (Xie et al. 2009).  For glycoproteins, this signaling mechanism requires 
N-linked glycosylation, which occurs in the ER, and involves the addition of a 
branched oligosaccharide unit consisting of three glucoses, nine mannoses, and 
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two N-aceytl-glucosamines (Man9Glc3GlcNAc2) (Spiro RG, 2000). Transfer of 
this lipid-bound core glycan precursor to N-X-S/T consensus motifs of nascent 
polypeptides entering the ER is carried out by an oligosaccharyltransferase. While 
mature N-linked glycans have multiple functions, including targeting, they also 
serve as a critical determinant in the evaluation of a proteins for misfolding during 
early stages of protein maturation in the ER (Vagin et al., 2000; Helenius and 
Aebi, 2004).  First, Man9Glc3GlcNAc2 undergoes mannose trimming by ER 
mannosidase 1 (Mns1p), converting the N-glycan to a Man9Glc3GlcNAc2 
structure. When a glycoprotein does not fold efficiently, a sign that terminal 
misfoldedness may occur, a timer mechanism is invoked; if a protein does not 
complete folding within a certain window of opportunity, specific N-linked 
glycans becomes further modified. This involves the processing of 
Man8Glc3GlcNAc2 to Man7Glc3GlcNAc2 by ER-degradation-enhancing α-
mannosidase–like protein (EDEM), or Htm1p in yeast (Clerc et al. 2009; Gauss et 
al., 2011).  The Man7Glc3GlcNAc2 structure is then recognized by luminally 
localized Yos9p (Yeast OS-9 homolog), which acts in concert with Kar2p 
(KARyogamy) and Hrd3p (HMG-coA Reductase Degradation) as a luminal 
surveillance complex that identifies and facilitates transfer of misfolded proteins 
to the ER-bound Hrd1 E3 ligase complex (Denic et al, 2006). As a chaperone, 
Kar2p selectively binds to proteins that are unfolded, either to facilitate the 
completion of folding, or to maintain protein solubility for degradation 
(Nishikawa et al., 2001). Thus, protein misfoldedness, combined with an N-linked 
Man7Glc3GlcNAc2 oligosaccharide, constitutes the bi-partite signal required for 
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recognition by ER quality control: Kar2p preferentially recognizes and binds to 
proteins displaying characteristics of unfoldedness, while lectin-receptor Yos9p 
binds to the Htm1p-processed N-glycan. 
 
In this study, we have characterized a bi-partite signal recognized in the cytosol 
that serves as determinant for efficient targeting of misfolded proteins to 
degradation.  For a subset of substrates, interaction with chaperones serve the dual 
role of facilitating the selection of misfolded proteins for import into the nucleus, 
the primary site of misfolded protein degradation, along with maintaining the 
import-competence of misfolded proteins (Heck et al., 2010; Prasad et al., 2010; 
Park et al., 2013). The deletion of San1p and Ubr1p was shown to result in the 
accumulation of misfolded substrates in the nucleus (Prasad et al., 2010).  These 
previous findings, together with the results presented here, suggest that Ubr1p 
scans substrates in the nucleus for destabilizing N-degrons present at the N-
termini per the misfolded protein/N-end rule, and if detected, marks the substrate 
for degradation. 
 
Overexpression of Ubr1p resulted in an increased the destabilization of Ste6*C 
possessing either a destabilizing or stabilizing N-terminus, suggesting that while a 
destabilizing N-terminus is required for efficient degradation by the Ubr1 
pathway, the misfolded component of the bi-partite degradation signal is able to 
independently act as a determinant to a limited extent.  Enhanced degradation 
through overexpression of Ubr1p suggests that the lower endogenous expression 
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level of Ubr1p is rate-limiting towards the recognition of misfolded protein. The 
physiological purpose for moderating the Ubr1 pathway’s affinity for misfolded 
substrates independent of N-termini may be a result of those substrates bearing 
stabilizing N-termini to be within a particular set of proteins that should not be 
degraded. This may be due to a few possibilities. One is that destabilizing N-
termini may serve as an indicator of whether a substrate is actually aberrant, or if 
it is intrinsically disordered.  Alternatively, given the role of N-terminal 
sequences in protein localization, destabilizing N-termini may also relate to 
Ubr1p the inappropriateness of a particular protein in a specific location, and 
together with misfoldedness, provides a strengthened signal for a cell to eliminate 
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CHAPTER 5 	  
Mis-translocated mitochondria and secretory pathway proteins are 
candidate substrates of Ubr1-mediated quality control 
5.1 Introduction 
While a consensus has been established on Ubr1p’s role as a factor in cytosolic 
protein quality control, the majority of substrates that have been identified as 
being degraded through the Ubr1-mediated quality control pathway are not 
expressed endogenously in yeast, are grossly mutated forms of endogenous 
proteins, and/or are modified in order to artificially induce cytosolic localization. 
The first of such substrates to be confirmed was ∆ssCL*myc, which is a signal 
sequence deleted form of vacuolar carboxypeptidase Y with a mutation (G255R) 
that causes its misfolding and degradation through ER quality control pathways 
(ERAD) when the signal sequence is still intact (Finger et al., 2003; Hiller et al., 
1996; Eisele and Wolf, 2008). Next, a study utilizing a genetic screen for 
substrates identified truncated cytosolic proteins tFas1, tYor296w, tGnd1, and 
stGnd1 as substrates, with stGnd1 being the most Ubr1-dependent (Heck et al., 
2010).  However, as demonstrated in the previous chapter, we disproved the 
validity of stGnd1 as an endogenous substrate by showing that the N-terminally 
fused hemagglutinin (HA) tag used in the original study was artificially inducing 
the observed Ubr1-dependent degradation of stGnd1.  Once the substrate was re-
engineered to carry the HA-tag C-terminally instead, Ubr1-mediated degradation 
was abolished.  Based on the HA-tag relocation experiments with stGnd1, the 
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validity of the remaining substrates identified in the study, such as tGnd1, and 
those identified in other published studies, is placed into question. ∆ssCPY*, a 
mistranslocated and misfolded form of carboxypeptidase Y, and ∆2GFP, a 
derivative of green fluorescent protein, endogenous to Aequorea victoria but not 
yeast, were both shown to primarily rely on San1p for degradation and only 
secondarily on Ubr1p (Prasad et al., 2010).  
 
Nillegoda and colleagues identified several endogenous cytosolic proteins by 
subjecting cells to geldanamycin (GA) treatment (2010).  GA is an Hsp90 
inhibitor that hinders the folding of protein kinases and other clients of Hsp90, 
leading to their rapid degradation (Whitesell and Lindquist, 2005; Caplan et al., 
2007b). They show that the degradation Tpk2p is partially stabilized by the 
deletion of Ubr1 in the presence of GA, exhibiting the highest degree of 
stabilization among the protein kinases that were analyzed. Interestingly, most of 
the experiments involving Tpk2 were performed on N-terminally HA-tagged 
Tpk2, again bringing into question whether the novel engineered N-terminal 
sequence had artificially enhanced its degradation by Ubr1p via the misfolded 
protein/N-end rule. Nevertheless, they show inconclusively, as the experiment 
was performed only once, that a C-terminally TAP tagged version of Tpk2 also 
exhibits Ubr1 dependency at a slightly lower level. Additional substrates found 
through this method include C-terminally TAP tagged Cdc28, Rim11, and Kss1, 
all of which were not stabilized as significantly as HA-Tpk2 by the deletion of 
Ubr1p. Natively, these protein kinases, along with Tpk2p, do not possess 
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destabilizing P2 residues of the misfolded protein/N-end rule. Therefore, they are 
recognized by Ubr1p to a certain extent without an N-degron, in contrast to the 
substrates we have analyzed in this thesis which require a bi-partite signal 
involving an N-degron.  It is possible that the disruption of Hsp90 chaperone 
activity by geldanamycin treatment interferes with the standard Ubr1p recognition 
mechanism for misfolded substrates.  Alternatively, an overall greater level of 
misfoldedness in a substrate may possibly reduce the requirement for an N-degron 
by enhancing interactions with Ubr1p. 
 
Other recently substrates discovered include Rpo41T920-L1217, an internal fragment 
of the mitochondrial RNA polymerase, and slGFP, a short-lived chimeric GFP 
fusion with a disordered N-terminal domain, were both determined to be 
substrates of Ubr1 quality control with a dependency on the Hsp40 chaperones 
Fes1p and Sis1p, respectively, for effective degradation (Gowda et al., 2013; 
Summers et al., 2013). 
 
All of the aforementioned Ubr1 QC substrates are grossly mutated proteins with 
truncations or deletions, not endogenously expressed, or do not possess an N-
degron as part of a bi-partite signal involving the misfolded protein/N-end rule. 
While the discovery of these substrates suggests that the misfolded protein/N-end 
rule is not the only pathway through which Ubr1p recognizes misfolded proteins, 
our experiments with N-terminally modified misfolded substrates (see Chapter 3 
and 4) indicated that a large set of endogenously expressed proteins carrying 
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misfolded protein/N-end rule N-degrons could make up a large number of bona 
fide endogenous Ubr1 quality control substrates that are degraded efficiently 
through recognition of a bi-partite signal comprising an N-degron and structural 
aberrancy. 
 
In this final chapter, we apply the discoveries of novel N-degrons (Chapter 3) and 
the requirement of a bi-partite signal for efficient recognition and degradation by 
the Ubr1 pathway (see Chapter 4) to a bioinformatics analysis of the entire yeast 
proteome.  Through this approach, we identify large numbers of mistranslocated, 
cytosolically localized mitochondrial and secretory pathway proteins as 
endogenous candidate substrates of Ubr1 quality control due to a bias for these 
categories of proteins having encoded specific destabilizing N-terminal sequences 
as well as the increased likelihood of protein misfolding in a non-native folding 
environment, the cytosol. Futhermore, we biochemically confirm for 
representative mistranslocated substrates of both protein classes the dependency 
on Ubr1p for effective degradation. 
 
5.2 Candidate endogenous proteins of the misfolded protein/N-end rule 
To discover endogenous candidate substrates of the misfolded protein/N-end rule, 
we conducted a bioinformatically driven proteome-wide search for proteins 
encoding P2 residues, that when substituted into the P2 position of Ste6*C, had 
resulted in its most efficient degradation by Ubr1p (more than 67% degraded after 
60 minutes in ∆san1+UBR1 cells; I2L, I2K, I2I, I2V, I2Y, I2F, I2R, I2G, I2Q) 
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(Figures 3.5 and 3.7).  The Ubr1-dependent degradation of these variants was 
confirmed, as all of them were significantly stabilized in ∆san1∆ubr1 cells (Figure 
5.1A and 5.1B). This search yielded 2085 nuclear-encoded proteins (Refer to 
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Figure 5.1. Ste6*C-I2X mutants bearing destabilizing P2 residues are 
stabilized in ∆san1∆ubr1 cells. (A) Turnover rates of N-terminally destabilized 
Ste6*C-I2X mutants in ∆san1∆ubr1 cells were assessed by pulse-chase analysis 
as described in Figure 1B.  Degradation of Ste6*C-I2I in ∆san1+UBR1 cells was 
also examined as a control. (B) Heat map reflecting turnover rates of Ste6*C-I2X 
substrates presented in A. Data shown is the mean ±SD of three independent 
experiments. *p < 0.05, **p < 0.01, Student’s t test. 
 
5.3 Localizations of candidate endogenous proteins 
The current understanding of Ubr1 quality control is that it functions on misfolded 
proteins in the cytosol.  This prompted us to determine the localizations of the 
2085 candidate substrates. Cross-referencing the candidate substrates to a 
genome-wide GFP-based localization study by Huh and colleagues, 1322 
candidates with destabilizing P2 residues were successfully localized (Huh et al., 
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2003) (See Appendix A, Table A1). We classified these localizations into four 
main categories: cytoplasmic, nuclear, mitochondrial, and secretory proteins. 
Among these proteins, 267 (20.2%) were localized to the cytoplasm, 292 (22.1%) 
to the mitochondria, 162 (12.3%) to the nucleus, and 262 (19.8%) to secretory 
pathway components, 260 (19.7%) exhibited localization in more than one of the 
four localization categories, and 79 (6%) were not localized to any of the four 
categories (Figure 5.2A and Appendix A, Table A1). Interestingly, proteins that 
were not localized to the cytoplasm (translocated fate), made up the majority of 
proteins (55%) with destabilizing P2 residues, while a much smaller proportion 
(20%) were localized exclusively to the cytoplasm (non-translocated fate) (Figure 
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Figure 5.2 Bioinformatic analysis of proteins with destabilizing P2-residues. 
(A) Percentages of total localized proteins in four main localization categories: 
mitochondrial, secretory, nuclear, cytoplasmic. Based on GFP-fusion localization 
data from Huh et al. (2003), proteins in the mitochondrial, secretory, nuclear, or 
cytoplasmic categories are explicitly localized to the respective categories but 
may exhibit localizations to other locations not explicitly linked to one of the 
other three categories.  Proteins in the “multiple” localization category are 
explicitly localized to two or more of the four main categories.  Proteins in the 
“other” category are not explicitly localized to any of the four main categories. 
(B) The majority of proteins encoded with destabilizing P2-residues have a 
translocated fate. Mitochondrial, secretory, and nuclear localized proteins from 
Table A1 were classified as translocated. Cytoplasmic proteins were classified as 
non-translocated. Proteins with cytoplasmic localization in addition to localization 
to one or more of the remaining three categories were classified in the dual 
translocation fate category (translocated and non-translocated). Proteins without 
explicit localization to one of the four main protein categories were classified as 
having an “unknown” translocation fate. 
 
5.4 Mitochondrial and secretory pathway proteins have the highest 
percentage of destabilizing P2-residue harboring proteins 
To determine which category of proteins would be most subject to Ubr1 quality 
control, we determined the proportion of each localization category containing 
proteins exclusively localized to that category and carrying destabilizing P2 
residues (Figure 5.3 and Appendix A, Table A1). Surprisingly, secretory pathway 
and mitochondrially-localized proteins exhibited the highest proportion of 
exclusively localized, destabilizing P2 residue-harboring proteins, suggesting that 
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Figure 5.3 Mitochondrial and secretory proteins have the highest proportion 
of destabilizing P2-residue encoded proteins. The percentages of all proteins 
localized to each cellular compartment encoded with destabilizing P2-residues 
and are exclusively localized to the respective category were calculated by 
dividing the number of destabilizing P2-residue encoded proteins with exclusive 
localization to each category by the total number of proteins with both exclusive 
and non-exclusive localization to the category as determined by GFP-fusion 
screening by Huh et al. (2003). 
 
5.5 Mistranslocated forms of Atp2 are degraded by Ubr1p/CytoQC 
As secretory and mitochondrial proteins are generally restricted from the cytosol, 
away from the scope of Ubr1 quality control surveillance, how would they be 
targeted by Ubr1p?  This led us to formulate a simple model in which proteins of 
the secretory and mitochondrial pathways are subject to Ubr1-mediated 
degradation when they fail to successfully translocate into their respective 
compartments. The plausibility of this model is buoyed by studies demonstrating 
the importance of compartment-specific chaperones and enzymes in the native 
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folding processes of secretory and mitochondrial proteins (Hartl and Hartl, 2011; 
Haynes and Ron, 2010; Stevens and Argon, 1999). Spontaneous folding by 
mitochondrial proteins in the cytosol has been shown to occur, thereby preventing 
import, in which unfolded import-competent states are required (Strobel et al., 
2002). However, the lack of cognate folding factors and binding partners would 
likely hinder the success rate of folding for the majority of mislocalized proteins. 
In addition, various cytosolic chaperones are designed to maintain pre-
translocated proteins in partially-folded, import-competent states, while the 
folding efficiency of signal-sequence carrying precursor proteins has been to 
shown to be significantly lower than for that of their mature, signal-sequence 
cleaved counterparts (Neupert, 1997; Laminet and Pluckthun, 1989). All these 
factors pose barriers to a mislocalized protein’s attempts at folding in the cytosol 
and increase the chances of its detection by quality control systems. Thus, a 
translocation failure of mitochondrial and secretory proteins potentially generates 
the bi-partite signal required for recognition by Ubr1p: lack of signal sequence 
cleavage causes a destabilizing P2 residue-harboring protein to retain its N-
degron, while proper folding is prevented or significantly retarded. 	  
To test this model, we examined ATP2Δ1,2,3, a translocation-defective mutant of 
Atp2p, beta subunit of the mitochondrial F1F0 ATP synthase.  ATP2Δ1,2,3 was 
previously found to be import-deficient and degraded in the cytosol (Bedwell et 
al., 1987). Per the misfolded protein/N-end rule, ATP2Δ1,2,3 carries a 
destabilizing P2 residue. Pulse-chase analysis showed that degradation is 
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dependent on a combination of San1 and Ubr1 pathways, and that degradation by 
Ubr1 (Δsan1+UBR1) is efficient (Figure 5.4A).  We then mutated the 
destabilizing N-terminus (-V) of ATP2Δ1,2,3 to a stabilizing sequencing (-SP) 
and observed an inhibition of Ubr1-mediated degradation (Figure 5.4B). 
Degradation of ATP2Δ1,2,3 was dependent on Sse1, Ydj1, and Ssa1 and Ssa2 
chaperones (Figure 5.4C), another hallmark of misfolded proteins. Furthermore, 
degradation of wild-type Atp2p in a temperature sensitive mitochondrial-import 
mutant, tom40-2, was partially dependent on Ubr1 (Krimmer et al.,. 2001) (Figure 
5.4D).  Together, these results confirm that translocation-deficient Atp2p is an 
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Figure 5.4 Mistranslocated forms of mitochondrial protein Atp2p are 
substrates of cytosolic quality control and the misfolded protein/N-end rule. 
(A) ATP2∆1,2,3, an import-deficient mutant of Atp2p, is degraded by a 
combination of the San1 and Ubr1 quality control pathways.  Turnover of 
ATP2∆1,2,3 in +SAN1+UBR1(wild-type), ∆san1+UBR1, +SAN1∆ubr1, and 
∆san1∆ubr1 cells were determined by pulse-chase analysis as described in Figure 
1B. (B) Mutation of the destabilizing N-terminal sequence of ATP2∆1,2,3 to a 
stabilizing N-terminal sequencing  (based on misfolded protein/N-end rules) 
inhibits degradation through the Ubr1 pathway. Turnover rates of proteins were 
compared in ∆san1+UBR1 and ∆san1∆ubr1 cells by pulse-chase analysis as 
described in Figure 1B. (C) Wild-type Atp2p is degraded by Ubr1p in 
mitochondrial import mutant strain tom40-2. HA-tagged wild-type ATP2 protein 
expressed in TOM40 (wild-type), tom40-2, and tom40-2∆ubr1 cells was analyzed 
by pulse-chase analysis as described in Figure 3.1. (D) ATP2∆1,2,3 degradation is 
dependent on CytoQC chaperones.  Stability of ATP2∆1,2,3 in wild-type, ∆ydj1, 
∆sse1, and ∆ssa1∆ssa2 cells were analyzed by pulse-chase analysis as described 
in Figure 3.1. Data shown is the mean ±SD of three independent experiments. *p 
< 0.05, **p < 0.01, Student’s t test. 	  
 
5.6 Mistranslocated CPY is degraded by Ubr1p 
To determine if translocation-defective secretory pathway proteins are also 
subject to Ubr1 quality control in the cytosol, we generated an import-impaired 
mutant of vacuolar carboxypeptidase Y (CPY), CPY-12iE.  CPY-12iE contains a 
glutamic acid residue positioned centrally (residue 12) within the hydrophobic 
core of CPY’s signal sequence, thereby disrupting its structure and inhibiting ER 
translocation (Ng et al., 1996). However, previous studies have demonstrated that 
even when CPY is devoid of its signal-sequence, translocation-competence is 
partially retained, with the successfully translocated fraction processed into a 
mature vacuolar form (Dyson and Stevens, 1987). The presence of any mature, 
vacuole-processed CPY-12iE may prevent accurate analysis of its pre-form levels. 
To resolve this, we utilized the fact that C-terminal processing of CPY-HA results 
in HA tag removal upon maturation within the vacuole, as CPY-HA expressed in 
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Δprc1, a strain deficient of endogenous CPY, was detectable by anti-CPY 
antibody but not anti-HA. Deletion of PEP4, a vacuolar protease, prevented C-
terminal cleavage and consequent HA-tag removal (Figure 5.5A).  Thus, analyses 
were performed on HA-tagged PRC1-12iE to ensure an accurate quantification of 
pre-form levels. Degradation of pre-CPY-12iE was reduced significantly by the 
absence of Ubr1p (Figure 5.5B, Δsan1+UBR1 vs Δsan1Δubr1). These results 
indicate that the Ubr1 quality control pathway also degrades secretory pathway 
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Figure 5.5 Mistranslocated CPY is degraded in a Ubr1-dependent manner. 
(A) C-terminal HA-tag is removed from HA-tagged CPY in the vacuole.  Pulse-
chase analysis was performed in ∆prc1, ∆pep4, ∆san1+UBR1, and ∆san1∆ubr1 
cells as described in Figure 3.1. CPY was probed with anti-CPY and anti-HA 
antibodies in ∆prc1 cells, and anti-HA in ∆pep4 cells. (B) CPY-12iE-HA, a 
translocation-impaired CPY mutant is degraded efficiently in ∆san1+UBR1 cells 
and stabilized in ∆san1∆ubr1 cells. Turnover of CPY-12iE-HA was measured by 
pule-chase analysis as described in Figure 3.1.  Samples from ∆san1∆ubr1 
timepoints were exposed to a phosphor screen for an extended period (5 days vs 3 
days for ∆san1+UBR1 cells) for imaging and quantitative analysis due to a lower 
overall detection level of the expressed substrate compared to ∆san1+UBR1 cells. 
Data shown is the mean ±SD of three independent experiments. *p < 0.05, **p < 
0.01, Student’s t test.  
 
5.7 Misfolded N-end rule substrates are not recognized by UBR1 Type-1 and 
Type-2 domains 
Ubr1p recognizes Arg/N-end rule substrates through its Type-1 (ClpS) and Type-
2 (UBR Box) recognition domains (Varshavsky, 2011; Sriram et al., 2011; Tasaki 
et al., 2012).  To determine whether these domains are involved in the recognition 
of misfolded protein/N-end rule pathway substrates, Ubr1 point mutants defective 
in the recognition of either Type-1 (D176E-1) or Type-2 (P406S-2) substrates 
were employed (Xia et al., 2008). The degradation rate of Ste6*C-I2I in the 
presence of UBR1 Type-1 or Type-2 mutant was equivalent to degradation seen 
in the presence wild-type UBR1 (Figure 6). Thus, Ubr1-mediated degradation of 
misfolded substrates does not require the Ubr1 Type-1 or Type-2 recognition 
domains, suggesting that there exists an alternate mode of recognition for the N-
termini of misfolded proteins through a yet to be characterized domain. 
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Figure 6. Degradation of misfolded/N-end rule substrate Ste6*C occurs 
independently of the Ubr1 Type-1 and Type-2 recognition domains.  Turnover 
of Ste6*C in ∆ubr1 cells expressing Ste6*C, and also expressing wild-type 
UBR1, UBR1 D176E-1 (Type-1 domain mutant), UBR1 P406S-2 (Type-2 
domain mutant), or carrying an empty vector (control), was measured by pulse-
chase analysis as described in Figure 3.1. Data shown is the mean ±SD of three 
independent experiments. *p < 0.05, **p < 0.01, Student’s t test. 
 
5.8 Discussion 
The discovery that Ubr1p targets precursor mitochondrial and secretory pathway 
proteins unable to translocate efficiently into their respective compartments places 
it in a unique role as a regulator of protein translocation fidelity in addition to a 
more general role as mediator of cytosolic protein quality control. The importance 
of N-termini for the efficient recognition of substrates by Ubr1p reveals that N-
terminal sequences not only facilitate the proper targeting of proteins, as in the 
case of signal sequences, but also provide an elaborate signaling system that 
describes to cognate detectors whether the presence of a protein in the cytosol is 
likely to be abnormal. In line with this model, a comprehensive analysis 
comparing secretory proteins with cytosolic proteins demonstrated that a 
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significant majority of signal-sequence bearing proteins carry destabilizing P2 
residues, while those in the cytosol are much more likely to possess stabilizing P2 
residues (Stirling et al., 2011).   The combination of these destabilizing N-
terminal signals with misfolded determinants provides a double confirmation to 
the cytosolic surveillance system as to which proteins pose the greatest threat to 
homeostasis and should be most quickly eliminated. Further studies may help to 
determine whether the variation in destabilization caused by different N-termini 
may reflect differing levels of necessity for the degradation of particular sets of 
mistranslocated proteins, and whether this may be related to a mechanism of 
evaluating the most economical usage of cellular resources under circumstances 
where levels of degradation machinery are rate-limiting. Finally, the requirement 
of the bi-partite signal for recognition by Ubr1p may result from the need to 
differentiate cytosolic proteins that are in intermediate stages of folding from 
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CHAPTER 6 
 
Conclusions and future directions 
 
The eukaryotic cell is the basic biological unit that enables the existence and 
livelihood of advanced organisms. This special characteristic is a result of the 
complexity of single eukaryotic cells themselves, which contain multiple 
specialized compartments, numerous protein types, and diverse signaling 
pathways that facilitate the necessary intra- and inter-cellular functions that allow 
them to grow, propagate, and interact with the environment and other cells. 
Cellular proteins are the primary mediators in the majority of these activities, and 
as such, their folding into fully functional native conformations is critical. 
 
The eukaryotic cytosolic compartment houses the molecular machinery that 
synthesizes the majority of a cell’s proteins, which includes cytosolic proteins and 
organelle proteins, such as those of the secretory pathway, mitochondria, and the 
nucleus. Subsequent protein folding of secretory and mitochondrial proteins occur 
after translocation into the ER and mitochondria, while nuclear proteins may be 
imported in a folded state.  Naturally, cytosolic proteins fold in the cytosol. 
Systems for the detection of protein misfolding specific and localized to several of 
these cellular compartments including the cytosol have been characterized. 
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Evidence indicates that the San1, Ubr1, and Hul5 E3 ligases serve as the primary 
ubiquitin ligases involved in the UPS-mediated degradation of misfolded proteins 
in the cytosol, a key pathway of quality control in this site. Hul5p is thought to act 
as an E4 in the process, facilitating the elongation of ubiquitination chains 
conjugated to misfolded proteins previously identified by CytoQC. Thus, while 
the specificity and identification of misfolded substrates had been readily 
attributed to San1p and Ubr1p based on several studies, differences in their modes 
of target recognition and selection have been elusive. 
 
In this thesis work, we took into account Ubr1’s previously characterized role in 
the Arg/N-end rule pathway and its preference for substrates with specific N-
terminal residues to reveal novel N-terminal sequence degradation determinants, 
or N-degrons, that makeup a new branch of the N-end rule: the misfolded 
protein/N-end rule.  The difference between the misfolded protein/N-end rule and 
the Arg/N-end rule lies in the fact that destabilizing N-terminal sequences of the 
misfolded protein/N-end rule are specific for aberrantly structured proteins, as the 
name suggests. Thus, N-degrons of the misfolded/N-end rule are not sufficient for 
targeting a protein for degradation by Ubr1p – they must be accompanied by 
sufficient conformational abnormality in the candidate substrate to trigger 
recognition by Ubr1p. The N-terminal sequence and structural requirements are 
components of a bi-partite degradation signal necessary for the efficient 
degradation by Ubr1-mediated quality control.  On the other hand, such a bi-
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partite signal was not critical for degradation through the San1p pathway, which 
only requires misfoldedness as a recognition determinant. 
 
Identifying the nature of the misfolded protein/N-end rule allowed us to conduct 
rigorous bioinformatic analysis of the yeast proteome to determine the most likely 
endogenous substrates within a eukaryotic cell based on the requirements for the 
bi-partite degradation signal.  These candidates turned out to be a largely proteins 
of the secretory and mitochondrial pathways for two reasons: 1) based on ORF 
sequences, these categories of proteins have the highest percentage with 
destabilizing N-termini encoded into their sequence, and 2) when mis-
translocated, misfolding or lack of folding for these proteins is likely to occur.  
Furthermore, retention of the signal sequences will leave the destabilizing N-
termini intact and available for recognition by Ubr1p. This mechanism seems to 
suggest that cells encode the N-termini of proteins in such a way that serves to 
ensure that proteins that do not belong in the cytosol are efficiently eliminated by 
Ubr1p. 
 
From the work presented in this thesis, several interesting topics arise. First, 
varying levels of compatibility with Ubr1-mediated degradation were observed 
between misfolded substrates possessing different destabilizing N-terminal 
sequences. Whether this phenomenon is by chance, or a sign of an even more 
precise system for governing protein stability through N-terminal sequences 
remains to be investigated.  In addition, the knowledge acquired in this study 
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regarding the client ranges of San1 and Ubr1 allows for a more informed 
investigation of the underlying dynamics between the San1 and Ubr1 pathways of 
cytosolic quality control: while the role of Ubr1p is specific for the elimination of 
certain sets of proteins, San1p appears to play a more general role -- does the 
presence of Ubr1p help to buffer the load on San1p in times of stress which may 
hinder protein translocation efficiency? Another important study would address 
whether San1p’s demonstrated sensitivity to smaller regions of hydrophobicity is 
absent from Ubr1p, thus also serving as a supplement for the otherwise limited 
scope of Ubr1p quality control.  A clearer understanding of these issues will aid in 
determining the importance of each pathway to achieving overall cellular 
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APPENDIX A 
 	  
Table A1. Localizations of proteins of 1322 gene ORFS encoding 
destabilizing P2 residues.  A list of the 2085 nuclear-encoded gene ORFS 
encoding destabilizing P2-residues was cross-referenced to the list of successfully 




Name	  (if	  any)	  
Localization(s)	  
YNL106C	   INP52	   actin	  
YNR035C	   ARC35	   actin	  
YOR181W	   LAS17	   actin	  
YLR313C	   SPH1	   ambiguous,bud	  neck,bud	  
YBR102C	   EXO84	   ambiguous,bud	  neck,cell	  periphery,bud	  
YBR200W	   BEM1	   ambiguous,bud	  neck,cell	  periphery,bud	  
YLR353W	   BUD8	   ambiguous,bud	  neck,cell	  periphery,bud	  
YOL112W	   MSB4	   ambiguous,bud	  neck,cell	  periphery,bud	  
YAL053W	   	   ambiguous,bud	  neck,cell	  periphery,punctate	  
composite,late	  Golgi,bud	  
YNL166C	   BNI5	   ambiguous,bud	  neck,cytoplasm,bud	  
YDL146W	   	  	   ambiguous,bud	  neck,cytoplasm,cell	  
periphery,bud	  
YKR090W	   PXL1	   ambiguous,bud	  neck,cytoplasm,cell	  
periphery,bud	  
YLR187W	   	  	   ambiguous,bud	  neck,cytoplasm,cell	  
periphery,bud	  
YOR008C	   SLG1	   ambiguous,bud	  neck,cytoplasm,vacuole,bud	  
YGR238C	   KEL2	   ambiguous,cell	  periphery,bud	  
YFR016C	   	  	   ambiguous,cytoplasm,bud	  
YLR414C	   	  	   ambiguous,cytoplasm,cell	  periphery,bud	  
YDR181C	   SAS4	   ambiguous,cytoplasm,nucleus	  
YJR104C	   SOD1	   ambiguous,cytoplasm,nucleus	  
YDR313C	   PIB1	   ambiguous,endosome	  
YPL100W	   MAI1	   ambiguous,endosome	  
YER005W	   YND1	   ambiguous,Golgi,early	  Golgi	  
YDR204W	   COQ4	   ambiguous,mitochondrion	  
YJL066C	   MPM1	   ambiguous,mitochondrion	  
YJR051W	   OSM1	   ambiguous,mitochondrion	  
YMR207C	   HFA1	   ambiguous,mitochondrion	  
YDL089W	   	  	   ambiguous,nuclear	  periphery	  
YER124C	   DSE1	   bud	  neck	  




Name	  (if	  any)	  
Localization(s)	  
YPL158C	   	  	   bud	  neck	  
YLR084C	   RAX2	   bud	  neck,cell	  periphery	  
YOL062C	   APM4	   bud	  neck,cell	  periphery	  
YER008C	   SEC3	   bud	  neck,cell	  periphery,bud	  
YPL221W	   BOP1	   bud	  neck,cell	  periphery,vacuole	  
YER155C	   BEM2	   bud	  neck,cytoplasm	  
YGR092W	   DBF2	   bud	  neck,cytoplasm	  
YNL161W	   CBK1	   bud	  neck,cytoplasm	  
YNL271C	   BNI1	   bud	  neck,cytoplasm	  
YDL240W	   LRG1	   bud	  neck,cytoplasm,cell	  periphery	  
YFL047W	   RGD2	   bud	  neck,cytoplasm,cell	  periphery	  
YLR319C	   BUD6	   bud	  neck,cytoplasm,cell	  periphery	  
YHR149C	   	  	   bud	  neck,cytoplasm,cell	  periphery,bud	  
YNL278W	   CAF120	   bud	  neck,cytoplasm,cell	  periphery,bud	  
YFR024C-­‐A	   LSB3	   bud	  neck,cytoplasm,mitochondrion,cell	  
periphery	  
YBR043C	   AQR2	   cell	  periphery	  
YDR034W-­‐
B	  
	  	   cell	  periphery	  
YDR040C	   ENA1	   cell	  periphery	  
YDR090C	   	  	   cell	  periphery	  
YER020W	   GPA2	   cell	  periphery	  
YGL108C	   	  	   cell	  periphery	  
YGL139W	   	  	   cell	  periphery	  
YHR005C	   GPA1	   cell	  periphery	  
YIL147C	   SLN1	   cell	  periphery	  
YKL051W	   SFK1	   cell	  periphery	  
YKR003W	   OSH6	   cell	  periphery	  
YLL010C	   PSR1	   cell	  periphery	  
YLR219W	   MSC3	   cell	  periphery	  
YLR332W	   MID2	   cell	  periphery	  
YMR086W	   	  	   cell	  periphery	  
YMR212C	   EFR3	   cell	  periphery	  
YOR094W	   ARF3	   cell	  periphery	  
YBR008C	   FLR1	   cell	  periphery,vacuole	  
YBR068C	   BAP2	   cell	  periphery,vacuole	  
YDR497C	   ITR1	   cell	  periphery,vacuole	  
YEL017C-­‐A	   PMP2	   cell	  periphery,vacuole	  
YKR093W	   PTR2	   cell	  periphery,vacuole	  




Name	  (if	  any)	  
Localization(s)	  
YML116W	   ATR1	   cell	  periphery,vacuole	  
YMR319C	   FET4	   cell	  periphery,vacuole	  
YNL268W	   LYP1	   cell	  periphery,vacuole	  
YOL019W	   TOS7	   cell	  periphery,vacuole	  
YPL265W	   DIP5	   cell	  periphery,vacuole	  
YAL031C	   FUN21	   cytoplasm	  
YAL060W	   BDH1	   cytoplasm	  
YBL039C	   URA7	   cytoplasm	  
YBL072C	   RPS8A	   cytoplasm	  
YBL104C	   	  	   cytoplasm	  
YBL107C	   	  	   cytoplasm	  
YBR028C	   	  	   cytoplasm	  
YBR056W	   	  	   cytoplasm	  
YBR061C	   TRM7	   cytoplasm	  
YBR071W	   	  	   cytoplasm	  
YBR094W	   	  	   cytoplasm	  
YBR118W	   TEF2	   cytoplasm	  
YBR125C	   PTC4	   cytoplasm	  
YBR129C	   OPY1	   cytoplasm	  
YBR137W	   	  	   cytoplasm	  
YBR166C	   TYR1	   cytoplasm	  
YBR172C	   SMY2	   cytoplasm	  
YBR181C	   RPS6B	   cytoplasm	  
YBR191W	   RPL21A	   cytoplasm	  
YBR271W	   	  	   cytoplasm	  
YCL030C	   HIS4	   cytoplasm	  
YCL057W	   PRD1	   cytoplasm	  
YCR093W	   CDC39	   cytoplasm	  
YCR095C	   	  	   cytoplasm	  
YDL001W	   RMD1	   cytoplasm	  
YDL045C	   FAD1	   cytoplasm	  
YDL055C	   PSA1	   cytoplasm	  
YDL090C	   RAM1	   cytoplasm	  
YDL112W	   TRM3	   cytoplasm	  
YDL133C-­‐A	   RPL41B	   cytoplasm	  
YDL159W	   STE7	   cytoplasm	  
YDL160C	   DHH1	   cytoplasm	  
YDL184C	   RPL41A	   cytoplasm	  
YDL215C	   GDH2	   Cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YDL219W	   DTD1	   cytoplasm	  
YDR023W	   SES1	   cytoplasm	  
YDR066C	   	  	   cytoplasm	  
YDR108W	   GSG1	   cytoplasm	  
YDR127W	   ARO1	   cytoplasm	  
YDR139C	   RUB1	   cytoplasm	  
YDR147W	   EKI1	   cytoplasm	  
YDR179C	   CSN9	   cytoplasm	  
YDR200C	   VPS64	   cytoplasm	  
YDR214W	   AHA1	   cytoplasm	  
YDR236C	   FMN1	   cytoplasm	  
YDR239C	   	  	   cytoplasm	  
YDR300C	   PRO1	   cytoplasm	  
YDR371W	   CTS2	   cytoplasm	  
YDR382W	   RPP2B	   cytoplasm	  
YDR385W	   EFT2	   cytoplasm	  
YDR422C	   SIP1	   cytoplasm	  
YDR447C	   RPS17B	   cytoplasm	  
YDR453C	   TSA2	   cytoplasm	  
YDR500C	   RPL37B	   cytoplasm	  
YDR539W	   	  	   cytoplasm	  
YER007C-­‐A	   	  	   cytoplasm	  
YER033C	   ZRG8	   cytoplasm	  
YER075C	   PTP3	   cytoplasm	  
YER091C	   MET6	   cytoplasm	  
YER098W	   UBP9	   cytoplasm	  
YER102W	   RPS8B	   cytoplasm	  
YER168C	   CCA1	   cytoplasm	  
YFL029C	   CAK1	   cytoplasm	  
YFL033C	   RIM15	   cytoplasm	  
YFR031C-­‐A	   RPL2A	   cytoplasm	  
YFR033C	   QCR6	   cytoplasm	  
YFR053C	   HXK1	   cytoplasm	  
YGL031C	   RPL24A	   cytoplasm	  
YGL036W	   MTC2	   cytoplasm	  
YGL060W	   YBP2	   cytoplasm	  
YGL110C	   CUE3	   cytoplasm	  
YGL115W	   SNF4	   cytoplasm	  
YGL147C	   RPL9A	   cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YGL169W	   SUA5	   cytoplasm	  
YGL173C	   KEM1	   cytoplasm	  
YGL178W	   MPT5	   cytoplasm	  
YGL234W	   ADE5,7	   cytoplasm	  
YGL253W	   HXK2	   cytoplasm	  
YGR118W	   RPS23A	   cytoplasm	  
YGR122W	   	  	   cytoplasm	  
YGR142W	   BTN2	   cytoplasm	  
YGR148C	   RPL24B	   cytoplasm	  
YGR173W	   GIR1	   cytoplasm	  
YGR189C	   CRH1	   cytoplasm	  
YGR194C	   XKS1	   cytoplasm	  
YGR200C	   ELP2	   cytoplasm	  
YGR217W	   CCH1	   cytoplasm	  
YGR234W	   YHB1	   cytoplasm	  
YGR240C	   PFK1	   cytoplasm	  
YGR277C	   	  	   cytoplasm	  
YGR285C	   ZUO1	   cytoplasm	  
YHL027W	   RIM101	   cytoplasm	  
YHL039W	   	  	   cytoplasm	  
YHR021C	   RPS27B	   cytoplasm	  
YHR053C	   CUP1-­‐1	   cytoplasm	  
YHR112C	   	  	   cytoplasm	  
YHR113W	   	  	   cytoplasm	  
YHR141C	   RPL42B	   cytoplasm	  
YHR144C	   DCD1	   cytoplasm	  
YHR192W	   	  	   cytoplasm	  
YHR204W	   MNL1	   cytoplasm	  
YIL002C	   INP51	   cytoplasm	  
YIL064W	   	  	   cytoplasm	  
YIL066C	   RNR3	   cytoplasm	  
YIL071C	   PCI8	   cytoplasm	  
YIL107C	   PFK26	   cytoplasm	  
YIL108W	   	  	   cytoplasm	  
YIL116W	   HIS5	   cytoplasm	  
YIL154C	   IMP2'	   cytoplasm	  
YIL156W	   UBP7	   cytoplasm	  
YIR035C	   	  	   cytoplasm	  
YIR036C	   	  	   cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YJL016W	   	  	   cytoplasm	  
YJL068C	   	  	   cytoplasm	  
YJL070C	   	  	   cytoplasm	  
YJL101C	   GSH1	   cytoplasm	  
YJL144W	   	  	   cytoplasm	  
YJL145W	   SFH5	   cytoplasm	  
YJL155C	   FBP26	   cytoplasm	  
YJL180C	   ATP12	   cytoplasm	  
YJL201W	   ECM25	   cytoplasm	  
YJL217W	   	  	   cytoplasm	  
YJR014W	   	  	   cytoplasm	  
YJR032W	   CPR7	   cytoplasm	  
YJR074W	   MOG1	   cytoplasm	  
YJR103W	   URA8	   cytoplasm	  
YJR149W	   	  	   cytoplasm	  
YKL018C-­‐A	   	  	   cytoplasm	  
YKL056C	   	  	   cytoplasm	  
YKL060C	   FBA1	   cytoplasm	  
YKL126W	   YPK1	   cytoplasm	  
YKL151C	   	  	   cytoplasm	  
YKL156W	   RPS27A	   cytoplasm	  
YKL168C	   KKQ8	   cytoplasm	  
YKL181W	   PRS1	   cytoplasm	  
YKL190W	   CNB1	   cytoplasm	  
YKL215C	   	  	   cytoplasm	  
YKR021W	   	  	   cytoplasm	  
YKR094C	   RPL40B	   cytoplasm	  
YLL007C	   	  	   cytoplasm	  
YLL062C	   MHT1	   cytoplasm	  
YLR006C	   SSK1	   cytoplasm	  
YLR028C	   ADE16	   cytoplasm	  
YLR063W	   	  	   cytoplasm	  
YLR133W	   CKI1	   cytoplasm	  
YLR143W	   	  	   cytoplasm	  
YLR146C	   SPE4	   cytoplasm	  
YLR172C	   DPH5	   cytoplasm	  
YLR185W	   RPL37A	   cytoplasm	  
YLR199C	   	  	   cytoplasm	  
YLR248W	   RCK2	   cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YLR257W	   	  	   cytoplasm	  
YLR309C	   IMH1	   cytoplasm	  
YLR384C	   IKI3	   cytoplasm	  
YLR427W	   MAG2	   cytoplasm	  
YLR436C	   ECM30	   cytoplasm	  
YLR452C	   SST2	   cytoplasm	  
YML006C	   GIS4	   cytoplasm	  
YML017W	   PSP2	   cytoplasm	  
YML024W	   RPS17A	   cytoplasm	  
YML109W	   ZDS2	   cytoplasm	  
YML131W	   	  	   cytoplasm	  
YMR132C	   	  	   cytoplasm	  
YMR138W	   CIN4	   cytoplasm	  
YMR140W	   SIP5	   cytoplasm	  
YMR162C	   DNF3	   cytoplasm	  
YMR165C	   SMP2	   cytoplasm	  
YMR173W	   DDR48	   cytoplasm	  
YMR216C	   SKY1	   cytoplasm	  
YMR230W	   RPS10B	   cytoplasm	  
YMR232W	   FUS2	   cytoplasm	  
YMR250W	   GAD1	   cytoplasm	  
YMR260C	   TIF11	   cytoplasm	  
YMR281W	   GPI12	   cytoplasm	  
YMR283C	   RIT1	   cytoplasm	  
YNL001W	   DOM34	   cytoplasm	  
YNL032W	   SIW14	   cytoplasm	  
YNL053W	   MSG5	   cytoplasm	  
YNL056W	   	  	   cytoplasm	  
YNL067W	   RPL9B	   cytoplasm	  
YNL116W	   	  	   cytoplasm	  
YNL162W	   RPL42A	   cytoplasm	  
YNL197C	   WHI3	   cytoplasm	  
YNL207W	   RIO2	   cytoplasm	  
YNL220W	   ADE12	   cytoplasm	  
YNL227C	   	  	   cytoplasm	  
YNL264C	   PDR17	   cytoplasm	  
YNL288W	   CAF40	   cytoplasm	  
YNL301C	   RPL18B	   cytoplasm	  
YNL311C	   	  	   cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YNR007C	   AUT1	   cytoplasm	  
YNR033W	   ABZ1	   cytoplasm	  
YNR034W-­‐
A	  
	  	   cytoplasm	  
YNR050C	   LYS9	   cytoplasm	  
YNR051C	   BRE5	   cytoplasm	  
YOL039W	   RPP2A	   cytoplasm	  
YOL098C	   	  	   cytoplasm	  
YOL100W	   PKH2	   cytoplasm	  
YOL102C	   TPT1	   cytoplasm	  
YOL124C	   	  	   cytoplasm	  
YOL141W	   PPM2	   cytoplasm	  
YOL159C-­‐A	   	  	   cytoplasm	  
YOR018W	   ROD1	   cytoplasm	  
YOR118W	   	  	   cytoplasm	  
YOR129C	   	  	   cytoplasm	  
YOR133W	   EFT1	   cytoplasm	  
YOR164C	   	  	   cytoplasm	  
YOR173W	   DCS2	   cytoplasm	  
YOR232W	   MGE1	   cytoplasm	  
YOR239W	   ABP140	   cytoplasm	  
YOR253W	   NAT5	   cytoplasm	  
YOR276W	   CAF20	   cytoplasm	  
YOR281C	   PLP2	   cytoplasm	  
YOR353C	   SOG2	   cytoplasm	  
YOR359W	   VTS1	   cytoplasm	  
YOR361C	   PRT1	   cytoplasm	  
YOR385W	   	  	   cytoplasm	  
YPL009C	   	  	   cytoplasm	  
YPL017C	   	  	   cytoplasm	  
YPL026C	   SKS1	   cytoplasm	  
YPL067C	   	  	   cytoplasm	  
YPL079W	   RPL21B	   cytoplasm	  
YPL090C	   RPS6A	   cytoplasm	  
YPL096W	   PNG1	   cytoplasm	  
YPL108W	   	  	   cytoplasm	  
YPL110C	   	  	   cytoplasm	  
YPL144W	   	  	   cytoplasm	  
YPL152W	   RRD2	   cytoplasm	  




Name	  (if	  any)	  
Localization(s)	  
YPL179W	   PPQ1	   cytoplasm	  
YPL183C	   	  	   cytoplasm	  
YPL184C	   	  	   cytoplasm	  
YPL199C	   	  	   cytoplasm	  
YPL231W	   FAS2	   cytoplasm	  
YPL239W	   YAR1	   cytoplasm	  
YPL243W	   SRP68	   cytoplasm	  
YPR008W	   HAA1	   cytoplasm	  
YPR033C	   HTS1	   cytoplasm	  
YPR080W	   TEF1	   cytoplasm	  
YPR111W	   DBF20	   cytoplasm	  
YPR132W	   RPS23B	   cytoplasm	  
YPR185W	   APG13	   cytoplasm	  
YGL181W	   GTS1	   cytoplasm,actin	  
YML016C	   PPZ1	   cytoplasm,cell	  periphery	  
YPR032W	   SRO7	   cytoplasm,cell	  periphery,bud	  
YLL040C	   VPS13	   cytoplasm,endosome	  
YPL084W	   BRO1	   cytoplasm,endosome	  
YBR001C	   NTH2	   cytoplasm,mitochondrion	  
YBR238C	   	  	   cytoplasm,mitochondrion	  
YFR011C	   	  	   cytoplasm,mitochondrion	  
YJL060W	   BNA3	   cytoplasm,mitochondrion	  
YNL104C	   LEU4	   cytoplasm,mitochondrion	  
YNR052C	   POP2	   cytoplasm,mitochondrion	  
YPL262W	   FUM1	   cytoplasm,mitochondrion	  
YPR002W	   PDH1	   cytoplasm,mitochondrion	  
YDL048C	   STP4	   cytoplasm,mitochondrion,nucleus	  
YDR305C	   HNT2	   cytoplasm,mitochondrion,nucleus	  
YPL091W	   GLR1	   cytoplasm,mitochondrion,nucleus	  
YCL059C	   KRR1	   cytoplasm,nucleolus	  
YLL008W	   DRS1	   cytoplasm,nucleolus,nucleus	  
YLR196W	   PWP1	   cytoplasm,nucleolus,nucleus	  
YAL001C	   TFC3	   cytoplasm,nucleus	  
YAL015C	   NTG1	   cytoplasm,nucleus	  
YAL033W	   POP5	   cytoplasm,nucleus	  
YAL061W	   	  	   cytoplasm,nucleus	  
YBL005W	   PDR3	   cytoplasm,nucleus	  
YBL008W	   HIR1	   cytoplasm,nucleus	  
YBL026W	   LSM2	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YBL056W	   PTC3	   cytoplasm,nucleus	  
YBR046C	   ZTA1	   cytoplasm,nucleus	  
YBR060C	   ORC2	   cytoplasm,nucleus	  
YBR090C	   	  	   cytoplasm,nucleus	  
YBR105C	   VID24	   cytoplasm,nucleus	  
YBR111C	   YSA1	   cytoplasm,nucleus	  
YBR114W	   RAD16	   cytoplasm,nucleus	  
YBR135W	   CKS1	   cytoplasm,nucleus	  
YBR158W	   AMN1	   cytoplasm,nucleus	  
YBR170C	   NPL4	   cytoplasm,nucleus	  
YBR175W	   SWD3	   cytoplasm,nucleus	  
YBR197C	   	  	   cytoplasm,nucleus	  
YBR281C	   	  	   cytoplasm,nucleus	  
YCL034W	   LSB5	   cytoplasm,nucleus	  
YCL035C	   GRX1	   cytoplasm,nucleus	  
YCR018C	   SRD1	   cytoplasm,nucleus	  
YCR036W	   RBK1	   cytoplasm,nucleus	  
YCR082W	   	  	   cytoplasm,nucleus	  
YDL003W	   MCD1	   cytoplasm,nucleus	  
YDL036C	   	  	   cytoplasm,nucleus	  
YDL047W	   SIT4	   cytoplasm,nucleus	  
YDL063C	   	  	   cytoplasm,nucleus	  
YDL078C	   MDH3	   cytoplasm,nucleus	  
YDL126C	   CDC48	   cytoplasm,nucleus	  
YDL139C	   SCM3	   cytoplasm,nucleus	  
YDL205C	   HEM3	   cytoplasm,nucleus	  
YDL233W	   	  	   cytoplasm,nucleus	  
YDR005C	   MAF1	   cytoplasm,nucleus	  
YDR034C	   LYS14	   cytoplasm,nucleus	  
YDR035W	   ARO3	   cytoplasm,nucleus	  
YDR043C	   NRG1	   cytoplasm,nucleus	  
YDR047W	   HEM12	   cytoplasm,nucleus	  
YDR052C	   DBF4	   cytoplasm,nucleus	  
YDR140W	   FYV9	   cytoplasm,nucleus	  
YDR191W	   HST4	   cytoplasm,nucleus	  
YDR272W	   GLO2	   cytoplasm,nucleus	  
YDR328C	   SKP1	   cytoplasm,nucleus	  
YDR346C	   SGI1	   cytoplasm,nucleus	  
YDR353W	   TRR1	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YDR361C	   BCP1	   cytoplasm,nucleus	  
YDR364C	   CDC40	   cytoplasm,nucleus	  
YDR395W	   SXM1	   cytoplasm,nucleus	  
YDR409W	   SIZ1	   cytoplasm,nucleus	  
YDR423C	   CAD1	   cytoplasm,nucleus	  
YDR440W	   DOT1	   cytoplasm,nucleus	  
YDR461W	   MFA1	   cytoplasm,nucleus	  
YDR487C	   RIB3	   cytoplasm,nucleus	  
YDR499W	   LCD1	   cytoplasm,nucleus	  
YDR530C	   APA2	   cytoplasm,nucleus	  
YDR540C	   	  	   cytoplasm,nucleus	  
YEL037C	   RAD23	   cytoplasm,nucleus	  
YEL038W	   UTR4	   cytoplasm,nucleus	  
YEL050C	   RML2	   cytoplasm,nucleus	  
YEL058W	   PCM1	   cytoplasm,nucleus	  
YEL066W	   HPA3	   cytoplasm,nucleus	  
YER035W	   EDC2	   cytoplasm,nucleus	  
YER038C	   KRE29	   cytoplasm,nucleus	  
YER040W	   GLN3	   cytoplasm,nucleus	  
YER062C	   HOR2	   cytoplasm,nucleus	  
YER089C	   PTC2	   cytoplasm,nucleus	  
YER104W	   RTT105	   cytoplasm,nucleus	  
YER112W	   LSM4	   cytoplasm,nucleus	  
YER142C	   MAG1	   cytoplasm,nucleus	  
YER152C	   	  	   cytoplasm,nucleus	  
YER171W	   RAD3	   cytoplasm,nucleus	  
YFL008W	   SMC1	   cytoplasm,nucleus	  
YFL028C	   CAF16	   cytoplasm,nucleus	  
YFL044C	   	  	   cytoplasm,nucleus	  
YFR027W	   ECO1	   cytoplasm,nucleus	  
YFR031C	   SMC2	   cytoplasm,nucleus	  
YFR034C	   PHO4	   cytoplasm,nucleus	  
YGL009C	   LEU1	   cytoplasm,nucleus	  
YGL035C	   MIG1	   cytoplasm,nucleus	  
YGL125W	   MET13	   cytoplasm,nucleus	  
YGL130W	   CEG1	   cytoplasm,nucleus	  
YGL141W	   HUL5	   cytoplasm,nucleus	  
YGL166W	   CUP2	   cytoplasm,nucleus	  
YGL175C	   SAE2	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YGL232W	   	  	   cytoplasm,nucleus	  
YGR003W	   CUL3	   cytoplasm,nucleus	  
YGR013W	   SNU71	   cytoplasm,nucleus	  
YGR037C	   ACB1	   cytoplasm,nucleus	  
YGR042W	   	  	   cytoplasm,nucleus	  
YGR048W	   UFD1	   cytoplasm,nucleus	  
YGR052W	   	  	   cytoplasm,nucleus	  
YGR135W	   PRE9	   cytoplasm,nucleus	  
YGR152C	   RSR1	   cytoplasm,nucleus	  
YGR161C	   RTS3	   cytoplasm,nucleus	  
YGR178C	   PBP1	   cytoplasm,nucleus	  
YGR192C	   TDH3	   cytoplasm,nucleus	  
YGR209C	   TRX2	   cytoplasm,nucleus	  
YGR233C	   PHO81	   cytoplasm,nucleus	  
YGR248W	   SOL4	   cytoplasm,nucleus	  
YGR253C	   PUP2	   cytoplasm,nucleus	  
YGR258C	   RAD2	   cytoplasm,nucleus	  
YHR009C	   	  	   cytoplasm,nucleus	  
YHR027C	   RPN1	   cytoplasm,nucleus	  
YHR031C	   RRM3	   cytoplasm,nucleus	  
YHR041C	   SRB2	   cytoplasm,nucleus	  
YHR055C	   CUP1-­‐2	   cytoplasm,nucleus	  
YHR070W	   TRM5	   cytoplasm,nucleus	  
YHR163W	   SOL3	   cytoplasm,nucleus	  
YHR200W	   RPN10	   cytoplasm,nucleus	  
YIL008W	   URM1	   cytoplasm,nucleus	  
YIL033C	   BCY1	   cytoplasm,nucleus	  
YIL035C	   CKA1	   cytoplasm,nucleus	  
YIL046W	   MET30	   cytoplasm,nucleus	  
YIL092W	   	  	   cytoplasm,nucleus	  
YIL119C	   RPI1	   cytoplasm,nucleus	  
YIL145C	   PAN6	   cytoplasm,nucleus	  
YIL148W	   RPL40A	   cytoplasm,nucleus	  
YIR009W	   MSL1	   cytoplasm,nucleus	  
YJL013C	   MAD3	   cytoplasm,nucleus	  
YJL035C	   TAD2	   cytoplasm,nucleus	  
YJL047C	   RTT101	   cytoplasm,nucleus	  
YJL052W	   TDH1	   cytoplasm,nucleus	  
YJL082W	   IML2	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YJL090C	   DPB11	   cytoplasm,nucleus	  
YJL121C	   RPE1	   cytoplasm,nucleus	  
YJL127C	   SPT10	   cytoplasm,nucleus	  
YJL197W	   UBP12	   cytoplasm,nucleus	  
YJR009C	   TDH2	   cytoplasm,nucleus	  
YJR025C	   BNA1	   cytoplasm,nucleus	  
YJR049C	   UTR1	   cytoplasm,nucleus	  
YJR052W	   RAD7	   cytoplasm,nucleus	  
YJR055W	   HIT1	   cytoplasm,nucleus	  
YJR096W	   	  	   cytoplasm,nucleus	  
YJR130C	   STR2	   cytoplasm,nucleus	  
YKL015W	   PUT3	   cytoplasm,nucleus	  
YKL053C-­‐A	   MDM35	   cytoplasm,nucleus	  
YKL069W	   	  	   cytoplasm,nucleus	  
YKL164C	   PIR1	   cytoplasm,nucleus	  
YKL166C	   TPK3	   cytoplasm,nucleus	  
YKL189W	   HYM1	   cytoplasm,nucleus	  
YKL213C	   DOA1	   cytoplasm,nucleus	  
YKR014C	   YPT52	   cytoplasm,nucleus	  
YKR018C	   	  	   cytoplasm,nucleus	  
YKR038C	   KAE1	   cytoplasm,nucleus	  
YKR064W	   	  	   cytoplasm,nucleus	  
YKR077W	   	  	   cytoplasm,nucleus	  
YKR079C	   	  	   cytoplasm,nucleus	  
YKR086W	   PRP16	   cytoplasm,nucleus	  
YKR103W	   	  	   cytoplasm,nucleus	  
YLL039C	   UBI4	   cytoplasm,nucleus	  
YLR011W	   LOT6	   cytoplasm,nucleus	  
YLR016C	   	  	   cytoplasm,nucleus	  
YLR043C	   TRX1	   cytoplasm,nucleus	  
YLR094C	   GIS3	   cytoplasm,nucleus	  
YLR107W	   REX3	   cytoplasm,nucleus	  
YLR129W	   DIP2	   cytoplasm,nucleus	  
YLR186W	   EMG1	   cytoplasm,nucleus	  
YLR218C	   	  	   cytoplasm,nucleus	  
YLR234W	   TOP3	   cytoplasm,nucleus	  
YLR245C	   CDD1	   cytoplasm,nucleus	  
YLR254C	   	  	   cytoplasm,nucleus	  
YLR316C	   TAD3	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YLR383W	   RHC18	   cytoplasm,nucleus	  
YLR420W	   URA4	   cytoplasm,nucleus	  
YML053C	   	  	   cytoplasm,nucleus	  
YML058W	   SML1	   cytoplasm,nucleus	  
YML082W	   	  	   cytoplasm,nucleus	  
YML099C	   ARG81	   cytoplasm,nucleus	  
YMR009W	   	  	   cytoplasm,nucleus	  
YMR021C	   MAC1	   cytoplasm,nucleus	  
YMR030W	   	  	   cytoplasm,nucleus	  
YMR047C	   NUP116	   cytoplasm,nucleus	  
YMR069W	   NAT4	   cytoplasm,nucleus	  
YMR078C	   CTF18	   cytoplasm,nucleus	  
YMR079W	   SEC14	   cytoplasm,nucleus	  
YMR178W	   	  	   cytoplasm,nucleus	  
YMR190C	   SGS1	   cytoplasm,nucleus	  
YMR244C-­‐
A	  
	  	   cytoplasm,nucleus	  
YMR278W	   	  	   cytoplasm,nucleus	  
YMR284W	   YKU70	   cytoplasm,nucleus	  
YMR311C	   GLC8	   cytoplasm,nucleus	  
YMR314W	   PRE5	   cytoplasm,nucleus	  
YNL007C	   SIS1	   cytoplasm,nucleus	  
YNL010W	   	  	   cytoplasm,nucleus	  
YNL045W	   	  	   cytoplasm,nucleus	  
YNL064C	   YDJ1	   cytoplasm,nucleus	  
YNL072W	   RNH35	   cytoplasm,nucleus	  
YNL077W	   APJ1	   cytoplasm,nucleus	  
YNL141W	   AAH1	   cytoplasm,nucleus	  
YNL180C	   RHO5	   cytoplasm,nucleus	  
YNL223W	   AUT2	   cytoplasm,nucleus	  
YNL254C	   	  	   cytoplasm,nucleus	  
YNL281W	   HCH1	   cytoplasm,nucleus	  
YNL330C	   RPD3	   cytoplasm,nucleus	  
YNR015W	   SMM1	   cytoplasm,nucleus	  
YNR046W	   	  	   cytoplasm,nucleus	  
YOL032W	   	  	   cytoplasm,nucleus	  
YOL059W	   GPD2	   cytoplasm,nucleus	  
YOL125W	   	  	   cytoplasm,nucleus	  
YOL136C	   PFK27	   cytoplasm,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YOR006C	   	  	   cytoplasm,nucleus	  
YOR026W	   BUB3	   cytoplasm,nucleus	  
YOR028C	   CIN5	   cytoplasm,nucleus	  
YOR039W	   CKB2	   cytoplasm,nucleus	  
YOR101W	   RAS1	   cytoplasm,nucleus	  
YOR110W	   TFC7	   cytoplasm,nucleus	  
YOR144C	   ELG1	   cytoplasm,nucleus	  
YOR162C	   YRR1	   cytoplasm,nucleus	  
YOR163W	   DDP1	   cytoplasm,nucleus	  
YOR197W	   MCA1	   cytoplasm,nucleus	  
YOR274W	   MOD5	   cytoplasm,nucleus	  
YOR302W	   	  	   cytoplasm,nucleus	  
YOR346W	   REV1	   cytoplasm,nucleus	  
YOR363C	   PIP2	   cytoplasm,nucleus	  
YOR370C	   MRS6	   cytoplasm,nucleus	  
YOR386W	   PHR1	   cytoplasm,nucleus	  
YPL014W	   	  	   cytoplasm,nucleus	  
YPL038W	   MET31	   cytoplasm,nucleus	  
YPL075W	   GCR1	   cytoplasm,nucleus	  
YPL089C	   RLM1	   cytoplasm,nucleus	  
YPL260W	   	  	   cytoplasm,nucleus	  
YPR062W	   FCY1	   cytoplasm,nucleus	  
YPR103W	   PRE2	   cytoplasm,nucleus	  
YPR175W	   DPB2	   cytoplasm,nucleus	  
YPR186C	   PZF1	   cytoplasm,nucleus	  
YEL011W	   GLC3	   cytoplasm,nucleus,punctate	  composite	  
YPL166W	   	  	   cytoplasm,nucleus,punctate	  composite	  
YML124C	   TUB3	   cytoplasm,nucleus,spindle	  pole	  
YCR004C	   YCP4	   cytoplasm,punctate	  composite	  
YEL060C	   PRB1	   cytoplasm,punctate	  composite	  
YER054C	   GIP2	   cytoplasm,punctate	  composite	  
YML028W	   TSA1	   cytoplasm,punctate	  composite	  
YMR080C	   NAM7	   cytoplasm,punctate	  composite	  
YOR070C	   GYP1	   cytoplasm,punctate	  composite	  
YPL214C	   THI6	   cytoplasm,punctate	  composite	  
YML085C	   TUB1	   cytoplasm,punctate	  composite,spindle	  
pole,microtubule	  
YDR003W	   	  	   cytoplasm,vacuole	  
YOL052C-­‐A	   DDR2	   cytoplasm,vacuole	  




Name	  (if	  any)	  
Localization(s)	  
YOR247W	   SRL1	   cytoplasm,vacuole	  
YDR137W	   RGP1	   early	  Golgi	  
YJL004C	   SYS1	   early	  Golgi	  
YPL051W	   ARL3	   early	  Golgi	  
YDL137W	   ARF2	   early	  Golgi,late	  Golgi	  
YBR097W	   VPS15	   endosome	  
YBR131W	   CCZ1	   endosome	  
YDR456W	   NHX1	   endosome	  
YGL079W	   	  	   endosome	  
YKL061W	   	  	   endosome	  
YLR073C	   	  	   endosome	  
YLR148W	   PEP3	   endosome	  
YLR360W	   VPS38	   endosome	  
YLR408C	   	  	   endosome	  
YPR079W	   MRL1	   endosome	  
YAL007C	   ERP2	   ER	  
YAL058W	   CNE1	   ER	  
YBR096W	   	  	   ER	  
YBR110W	   ALG1	   ER	  
YBR265W	   TSC10	   ER	  
YBR273C	   	  	   ER	  
YBR287W	   	  	   ER	  
YCL045C	   	  	   ER	  
YCL052C	   PBN1	   ER	  
YCR011C	   ADP1	   ER	  
YCR017C	   CWH43	   ER	  
YCR044C	   PER1	   ER	  
YDL212W	   SHR3	   ER	  
YDL232W	   OST4	   ER	  
YDR055W	   PST1	   ER	  
YDR056C	   	  	   ER	  
YDR077W	   SED1	   ER	  
YDR196C	   	  	   ER	  
YDR221W	   	  	   ER	  
YDR307W	   	  	   ER	  
YDR331W	   GPI8	   ER	  
YDR437W	   	  	   ER	  
YDR498C	   SEC20	   ER	  
YEL001C	   	  	   ER	  




Name	  (if	  any)	  
Localization(s)	  
YEL002C	   WBP1	   ER	  
YER044C	   ERG28	   ER	  
YER053C-­‐A	   	  	   ER	  
YFL004W	   VTC2	   ER	  
YFL025C	   BST1	   ER	  
YGL010W	   	  	   ER	  
YGL022W	   STT3	   ER	  
YGL047W	   	  	   ER	  
YGL065C	   ALG2	   ER	  
YHR079C	   IRE1	   ER	  
YHR101C	   BIG1	   ER	  
YHR110W	   ERP5	   ER	  
YHR181W	   SVP26	   ER	  
YHR190W	   ERG9	   ER	  
YIL039W	   	  	   ER	  
YIR004W	   DJP1	   ER	  
YJL002C	   OST1	   ER	  
YJL078C	   PRY3	   ER	  
YJL171C	   	  	   ER	  
YJL192C	   SOP4	   ER	  
YJL196C	   ELO1	   ER	  
YJL198W	   PHO90	   ER	  
YJR088C	   	  	   ER	  
YJR117W	   STE24	   ER	  
YJR131W	   MNS1	   ER	  
YKL096W	   CWP1	   ER	  
YKL096W-­‐A	   CWP2	   ER	  
YKL119C	   VPH2	   ER	  
YKL154W	   SRP102	   ER	  
YLR034C	   SMF3	   ER	  
YLR042C	   	  	   ER	  
YLR050C	   	  	   ER	  
YLR066W	   SPC3	   ER	  
YLR110C	   CCW12	   ER	  
YLR120C	   YPS1	   ER	  
YLR130C	   ZRT2	   ER	  
YLR194C	   	  	   ER	  
YLR292C	   SEC72	   ER	  
YLR350W	   ORM2	   ER	  




Name	  (if	  any)	  
Localization(s)	  
YLR390W-­‐A	   CCW14	   ER	  
YLR440C	   	  	   ER	  
YML012W	   ERV25	   ER	  
YML059C	   	  	   ER	  
YML128C	   MSC1	   ER	  
YMR149W	   SWP1	   ER	  
YMR238W	   DFG5	   ER	  
YMR251W-­‐
A	  
HOR7	   ER	  
YNL048W	   ALG11	   ER	  
YNL095C	   	  	   ER	  
YNL280C	   ERG24	   ER	  
YNL300W	   TOS6	   ER	  
YNL323W	   LEM3	   ER	  
YNR013C	   PHO91	   ER	  
YNR026C	   SEC12	   ER	  
YNR030W	   ECM39	   ER	  
YNR075W	   COS10	   ER	  
YOL013C	   HRD1	   ER	  
YOL101C	   	  	   ER	  
YOR016C	   ERP4	   ER	  
YOR044W	   	  	   ER	  
YOR175C	   	  	   ER	  
YOR214C	   	  	   ER	  
YOR307C	   SLY41	   ER	  
YOR311C	   HSD1	   ER	  
YOR317W	   FAA1	   ER	  
YPL227C	   ALG5	   ER	  
YPR071W	   	  	   ER	  
YDL195W	   SEC31	   ER	  to	  Golgi	  
YLR208W	   SEC13	   ER	  to	  Golgi	  
YKL046C	   DCW1	   ER,ambiguous,bud	  
YNL190W	   	  	   ER,cell	  periphery	  
YMR215W	   GAS3	   ER,cytoplasm	  
YOR087W	   YVC1	   ER,cytoplasm	  
YPL137C	   	  	   ER,cytoplasm	  
YMR307W	   GAS1	   ER,mitochondrion,nuclear	  periphery	  
YLR074C	   BUD20	   ER,nucleus	  
YOL030W	   GAS5	   ER,nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YGL054C	   ERV14	   ER,vacuole	  
YJR073C	   OPI3	   ER,vacuole	  
YBR015C	   MNN2	   Golgi	  
YCR043C	   	  	   Golgi	  
YDR503C	   LPP1	   Golgi	  
YEL036C	   ANP1	   Golgi	  
YGL005C	   COG7	   Golgi	  
YKL063C	   	  	   Golgi	  
YLR039C	   RIC1	   Golgi	  
YLR268W	   SEC22	   Golgi	  
YBR080C	   SEC18	   Golgi,early	  Golgi	  
YDL145C	   COP1	   Golgi,early	  Golgi	  
YDR264C	   AKR1	   Golgi,early	  Golgi	  
YER113C	   	  	   Golgi,early	  Golgi	  
YFR051C	   RET2	   Golgi,early	  Golgi	  
YGL137W	   SEC27	   Golgi,early	  Golgi	  
YOL107W	   	  	   Golgi,early	  Golgi	  
YCR094W	   CDC50	   late	  Golgi	  
YJL044C	   GYP6	   late	  Golgi	  
YKR068C	   BET3	   late	  Golgi	  
YMR237W	   	  	   late	  Golgi	  
YOR299W	   BUD7	   late	  Golgi	  
YBR042C	   	  	   lipid	  particle	  
YCL005W	   	  	   lipid	  particle	  
YDR275W	   BSC2	   lipid	  particle	  
YLL012W	   	  	   lipid	  particle	  
YMR148W	   	  	   lipid	  particle	  
YNL231C	   PDR16	   lipid	  particle	  
YOL048C	   	  	   lipid	  particle	  
YOR246C	   	  	   lipid	  particle	  
YMR168C	   CEP3	   microtubule	  
YPL209C	   IPL1	   microtubule	  
YAL010C	   MDM10	   mitochondrion	  
YAL039C	   CYC3	   mitochondrion	  
YAL044C	   GCV3	   mitochondrion	  
YBL013W	   FMT1	   mitochondrion	  
YBL022C	   PIM1	   mitochondrion	  
YBL038W	   MRPL16	   mitochondrion	  
YBL045C	   COR1	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YBL059W	   	  	   mitochondrion	  
YBL064C	   PRX1	   mitochondrion	  
YBL080C	   PET112	   mitochondrion	  
YBL090W	   MRP21	   mitochondrion	  
YBL099W	   ATP1	   mitochondrion	  
YBR003W	   COQ1	   mitochondrion	  
YBR026C	   ETR1	   mitochondrion	  
YBR037C	   SCO1	   mitochondrion	  
YBR039W	   ATP3	   mitochondrion	  
YBR047W	   	  	   mitochondrion	  
YBR084W	   MIS1	   mitochondrion	  
YBR122C	   MRPL36	   mitochondrion	  
YBR163W	   DEM1	   mitochondrion	  
YBR221C	   PDB1	   mitochondrion	  
YBR227C	   MCX1	   mitochondrion	  
YBR251W	   MRPS5	   mitochondrion	  
YBR263W	   SHM1	   mitochondrion	  
YBR268W	   MRPL37	   mitochondrion	  
YBR269C	   	  	   mitochondrion	  
YBR282W	   MRPL27	   mitochondrion	  
YCL009C	   ILV6	   mitochondrion	  
YCL017C	   NFS1	   mitochondrion	  
YCR024C	   PMP1	   mitochondrion	  
YCR028C-­‐A	   RIM1	   mitochondrion	  
YCR071C	   IMG2	   mitochondrion	  
YCR079W	   	  	   mitochondrion	  
YCR083W	   TRX3	   mitochondrion	  
YDL027C	   	  	   mitochondrion	  
YDL033C	   	  	   mitochondrion	  
YDL044C	   MTF2	   mitochondrion	  
YDL104C	   QRI7	   mitochondrion	  
YDL107W	   MSS2	   mitochondrion	  
YDL120W	   YFH1	   mitochondrion	  
YDL130W-­‐
A	  
STF1	   mitochondrion	  
YDL142C	   CRD1	   mitochondrion	  
YDL174C	   DLD1	   mitochondrion	  
YDL178W	   DLD2	   mitochondrion	  
YDL181W	   INH1	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YDL202W	   MRPL11	   mitochondrion	  
YDR036C	   EHD3	   mitochondrion	  
YDR041W	   RSM10	   mitochondrion	  
YDR070C	   	  	   mitochondrion	  
YDR079W	   PET100	   mitochondrion	  
YDR116C	   MRPL1	   mitochondrion	  
YDR125C	   ECM18	   mitochondrion	  
YDR148C	   KGD2	   mitochondrion	  
YDR175C	   RSM24	   mitochondrion	  
YDR185C	   	  	   mitochondrion	  
YDR194C	   MSS116	   mitochondrion	  
YDR231C	   COX20	   mitochondrion	  
YDR232W	   HEM1	   mitochondrion	  
YDR234W	   LYS4	   mitochondrion	  
YDR258C	   HSP78	   mitochondrion	  
YDR296W	   MHR1	   mitochondrion	  
YDR298C	   ATP5	   mitochondrion	  
YDR316W	   	  	   mitochondrion	  
YDR322W	   MRPL35	   mitochondrion	  
YDR347W	   MRP1	   mitochondrion	  
YDR377W	   ATP17	   mitochondrion	  
YDR430C	   CYM1	   mitochondrion	  
YDR462W	   MRPL28	   mitochondrion	  
YDR538W	   PAD1	   mitochondrion	  
YEL024W	   RIP1	   mitochondrion	  
YEL052W	   AFG1	   mitochondrion	  
YER014W	   HEM14	   mitochondrion	  
YER073W	   ALD5	   mitochondrion	  
YER077C	   	  	   mitochondrion	  
YER078C	   	  	   mitochondrion	  
YER080W	   	  	   mitochondrion	  
YER141W	   COX15	   mitochondrion	  
YER153C	   PET122	   mitochondrion	  
YER154W	   OXA1	   mitochondrion	  
YER170W	   ADK2	   mitochondrion	  
YER178W	   PDA1	   mitochondrion	  
YER182W	   	  	   mitochondrion	  
YFL018C	   LPD1	   mitochondrion	  
YFL046W	   	  	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YFR049W	   YMR31	   mitochondrion	  
YGL018C	   JAC1	   mitochondrion	  
YGL057C	   	  	   mitochondrion	  
YGL085W	   	  	   mitochondrion	  
YGL119W	   ABC1	   mitochondrion	  
YGL129C	   RSM23	   mitochondrion	  
YGL187C	   COX4	   mitochondrion	  
YGR021W	   	  	   mitochondrion	  
YGR046W	   	  	   mitochondrion	  
YGR049W	   SCM4	   mitochondrion	  
YGR062C	   COX18	   mitochondrion	  
YGR084C	   MRP13	   mitochondrion	  
YGR096W	   TPC1	   mitochondrion	  
YGR102C	   	  	   mitochondrion	  
YGR150C	   	  	   mitochondrion	  
YGR171C	   MSM1	   mitochondrion	  
YGR174C	   CBP4	   mitochondrion	  
YGR193C	   PDX1	   mitochondrion	  
YGR222W	   PET54	   mitochondrion	  
YGR244C	   LSC2	   mitochondrion	  
YHL004W	   MRP4	   mitochondrion	  
YHL021C	   	  	   mitochondrion	  
YHL038C	   CBP2	   mitochondrion	  
YHR008C	   SOD2	   mitochondrion	  
YHR024C	   MAS2	   mitochondrion	  
YHR037W	   PUT2	   mitochondrion	  
YHR038W	   RRF1	   mitochondrion	  
YHR051W	   COX6	   mitochondrion	  
YHR059W	   FYV4	   mitochondrion	  
YHR067W	   RMD12	   mitochondrion	  
YHR083W	   	  	   mitochondrion	  
YHR106W	   TRR2	   mitochondrion	  
YHR120W	   MSH1	   mitochondrion	  
YHR199C	   	  	   mitochondrion	  
YIL051C	   MMF1	   mitochondrion	  
YIL070C	   MAM33	   mitochondrion	  
YIL077C	   	  	   mitochondrion	  
YIL093C	   RSM25	   mitochondrion	  
YIL094C	   LYS12	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YIL111W	   COX5B	   mitochondrion	  
YIL125W	   KGD1	   mitochondrion	  
YIL155C	   GUT2	   mitochondrion	  
YIR024C	   GIF1	   mitochondrion	  
YJL043W	   	  	   mitochondrion	  
YJL062W-­‐A	   	  	   mitochondrion	  
YJL096W	   MRPL49	   mitochondrion	  
YJL131C	   	  	   mitochondrion	  
YJL133W	   MRS3	   mitochondrion	  
YJL147C	   	  	   mitochondrion	  
YJL161W	   	  	   mitochondrion	  
YJL166W	   QCR8	   mitochondrion	  
YJL200C	   	  	   mitochondrion	  
YJL209W	   CBP1	   mitochondrion	  
YJR003C	   	  	   mitochondrion	  
YJR016C	   ILV3	   mitochondrion	  
YJR062C	   NTA1	   mitochondrion	  
YJR080C	   	  	   mitochondrion	  
YJR101W	   RSM26	   mitochondrion	  
YJR113C	   RSM7	   mitochondrion	  
YJR121W	   ATP2	   mitochondrion	  
YJR122W	   CAF17	   mitochondrion	  
YKL003C	   MRP17	   mitochondrion	  
YKL027W	   	  	   mitochondrion	  
YKL029C	   MAE1	   mitochondrion	  
YKL040C	   NFU1	   mitochondrion	  
YKL085W	   MDH1	   mitochondrion	  
YKL106W	   AAT1	   mitochondrion	  
YKL134C	   	   mitochondrion	  
YKL138C	   MRPL31	   mitochondrion	  
YKL150W	   MCR1	   mitochondrion	  
YKL170W	   MRPL38	   mitochondrion	  
YKL192C	   ACP1	   mitochondrion	  
YKL194C	   MST1	   mitochondrion	  
YKL195W	   	  	   mitochondrion	  
YKL208W	   CBT1	   mitochondrion	  
YKR036C	   CAF4	   mitochondrion	  
YKR065C	   	  	   mitochondrion	  
YKR070W	   	  	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YKR085C	   MRPL20	   mitochondrion	  
YKR087C	   	  	   mitochondrion	  
YLL027W	   ISA1	   mitochondrion	  
YLL041C	   SDH2	   mitochondrion	  
YLR121C	   YPS3	   mitochondrion	  
YLR142W	   PUT1	   mitochondrion	  
YLR163C	   MAS1	   mitochondrion	  
YLR168C	   MSF1'	   mitochondrion	  
YLR188W	   MDL1	   mitochondrion	  
YLR193C	   	  	   mitochondrion	  
YLR201C	   	  	   mitochondrion	  
YLR204W	   QRI5	   mitochondrion	  
YLR259C	   HSP60	   mitochondrion	  
YLR289W	   GUF1	   mitochondrion	  
YLR290C	   	  	   mitochondrion	  
YLR295C	   ATP14	   mitochondrion	  
YLR346C	   	  	   mitochondrion	  
YLR369W	   SSQ1	   mitochondrion	  
YLR382C	   NAM2	   mitochondrion	  
YLR393W	   ATP10	   mitochondrion	  
YLR395C	   COX8	   mitochondrion	  
YML007C-­‐A	   	  	   mitochondrion	  
YML009C	   MRPL39	   mitochondrion	  
YML078W	   CPR3	   mitochondrion	  
YML081C-­‐A	   ATP18	   mitochondrion	  
YML110C	   COQ5	   mitochondrion	  
YML120C	   NDI1	   mitochondrion	  
YMR024W	   MRPL3	   mitochondrion	  
YMR060C	   TOM37	   mitochondrion	  
YMR062C	   ECM40	   mitochondrion	  
YMR064W	   AEP1	   mitochondrion	  
YMR066W	   SOV1	   mitochondrion	  
YMR083W	   ADH3	   mitochondrion	  
YMR089C	   YTA12	   mitochondrion	  
YMR108W	   ILV2	   mitochondrion	  
YMR115W	   	  	   mitochondrion	  
YMR145C	   NDE1	   mitochondrion	  
YMR157C	   	  	   mitochondrion	  
YMR177W	   MMT1	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YMR189W	   GCV2	   mitochondrion	  
YMR225C	   MRPL44	   mitochondrion	  
YMR252C	   	  	   mitochondrion	  
YMR257C	   PET111	   mitochondrion	  
YMR286W	   MRPL33	   mitochondrion	  
YMR287C	   MSU1	   mitochondrion	  
YMR301C	   ATM1	   mitochondrion	  
YMR302C	   PRP12	   mitochondrion	  
YNL037C	   IDH1	   mitochondrion	  
YNL052W	   COX5A	   mitochondrion	  
YNL081C	   SWS2	   mitochondrion	  
YNL083W	   	  	   mitochondrion	  
YNL100W	   	  	   mitochondrion	  
YNL121C	   TOM70	   mitochondrion	  
YNL122C	   	  	   mitochondrion	  
YNL252C	   MRPL17	   mitochondrion	  
YNL284C	   MRPL10	   mitochondrion	  
YNL306W	   MRPS18	   mitochondrion	  
YNL310C	   	  	   mitochondrion	  
YNL328C	   MDJ2	   mitochondrion	  
YNR018W	   	  	   mitochondrion	  
YNR022C	   MRPL50	   mitochondrion	  
YNR041C	   COQ2	   mitochondrion	  
YOL023W	   IFM1	   mitochondrion	  
YOL027C	   MDM38	   mitochondrion	  
YOL033W	   MSE1	   mitochondrion	  
YOL042W	   NGL1	   mitochondrion	  
YOL043C	   NTG2	   mitochondrion	  
YOL077W-­‐
A	  
ATP19	   mitochondrion	  
YOL096C	   COQ3	   mitochondrion	  
YOL140W	   ARG8	   mitochondrion	  
YOR004W	   	  	   mitochondrion	  
YOR017W	   PET127	   mitochondrion	  
YOR022C	   	  	   mitochondrion	  
YOR037W	   CYC2	   mitochondrion	  
YOR040W	   GLO4	   mitochondrion	  
YOR065W	   CYT1	   mitochondrion	  
YOR108W	   LEU9	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YOR136W	   IDH2	   mitochondrion	  
YOR142W	   LSC1	   mitochondrion	  
YOR147W	   MDM32	   mitochondrion	  
YOR158W	   PET123	   mitochondrion	  
YOR176W	   HEM15	   mitochondrion	  
YOR196C	   LIP5	   mitochondrion	  
YOR205C	   	  	   mitochondrion	  
YOR215C	   	  	   mitochondrion	  
YOR221C	   MCT1	   mitochondrion	  
YOR226C	   ISU2	   mitochondrion	  
YOR228C	   	  	   mitochondrion	  
YOR286W	   	  	   mitochondrion	  
YOR297C	   TIM18	   mitochondrion	  
YOR305W	   	  	   mitochondrion	  
YOR350C	   MNE1	   mitochondrion	  
YOR354C	   MSC6	   mitochondrion	  
YOR356W	   	  	   mitochondrion	  
YOR374W	   ALD4	   mitochondrion	  
YPL040C	   ISM1	   mitochondrion	  
YPL059W	   GRX5	   mitochondrion	  
YPL060W	   LPE10	   mitochondrion	  
YPL063W	   TIM50	   mitochondrion	  
YPL083C	   SEN54	   mitochondrion	  
YPL097W	   MSY1	   mitochondrion	  
YPL104W	   MSD1	   mitochondrion	  
YPL107W	   	  	   mitochondrion	  
YPL135W	   ISU1	   mitochondrion	  
YPL183W-­‐A	   GON5	   mitochondrion	  
YPL188W	   POS5	   mitochondrion	  
YPL222W	   	  	   mitochondrion	  
YPL252C	   YAH1	   mitochondrion	  
YPL270W	   MDL2	   mitochondrion	  
YPR001W	   CIT3	   mitochondrion	  
YPR004C	   	  	   mitochondrion	  
YPR006C	   ICL2	   mitochondrion	  
YPR020W	   ATP20	   mitochondrion	  
YPR047W	   MSF1	   mitochondrion	  
YPR061C	   	  	   mitochondrion	  
YPR067W	   ISA2	   mitochondrion	  




Name	  (if	  any)	  
Localization(s)	  
YPR100W	   MRPL51	   mitochondrion	  
YPR116W	   	  	   mitochondrion	  
YPR125W	   	  	   mitochondrion	  
YPR134W	   MSS18	   mitochondrion	  
YPR155C	   NCA2	   mitochondrion	  
YPR191W	   QCR2	   mitochondrion	  
YDL164C	   CDC9	   mitochondrion,nucleus	  
YLR059C	   REX2	   mitochondrion,nucleus	  
YGR255C	   COQ6	   mitochondrion,punctate	  composite	  
YHL032C	   GUT1	   mitochondrion,punctate	  composite	  
YHR011W	   DIA4	   mitochondrion,punctate	  composite	  
YLR067C	   PET309	   mitochondrion,punctate	  composite	  
YBL079W	   NUP170	   nuclear	  periphery	  
YDL088C	   ASM4	   nuclear	  periphery	  
YDL207W	   GLE1	   nuclear	  periphery	  
YER105C	   NUP157	   nuclear	  periphery	  
YFR002W	   NIC96	   nuclear	  periphery	  
YGL092W	   NUP145	   nuclear	  periphery	  
YGL172W	   NUP49	   nuclear	  periphery	  
YGR119C	   NUP57	   nuclear	  periphery	  
YHR133C	   YIG1	   nuclear	  periphery	  
YJL039C	   NUP192	   nuclear	  periphery	  
YJL048C	   	  	   nuclear	  periphery	  
YKL068W	   NUP100	   nuclear	  periphery	  
YKL205W	   LOS1	   nuclear	  periphery	  
YLR018C	   POM34	   nuclear	  periphery	  
YML031W	   NDC1	   nuclear	  periphery	  
YNL158W	   	  	   nuclear	  periphery	  
YPR174C	   	  	   nuclear	  periphery	  
YCR057C	   PWP2	   nucleolus	  
YCR087C-­‐A	   	  	   nucleolus	  
YDL208W	   NHP2	   nucleolus	  
YDL213C	   NOP6	   nucleolus	  
YFR028C	   CDC14	   nucleolus	  
YGL120C	   PRP43	   nucleolus	  
YGR280C	   PXR1	   nucleolus	  
YHR196W	   UTP9	   nucleolus	  
YJL076W	   NET1	   nucleolus	  
YJR041C	   	  	   nucleolus	  




Name	  (if	  any)	  
Localization(s)	  
YKR010C	   TOF2	   nucleolus	  
YLL011W	   SOF1	   nucleolus	  
YLR336C	   SGD1	   nucleolus	  
YMR128W	   ECM16	   nucleolus	  
YMR193W	   MRPL24	   nucleolus	  
YMR229C	   RRP5	   nucleolus	  
YNR004W	   	  	   nucleolus	  
YPL157W	   TGS1	   nucleolus	  
YML043C	   RRN11	   nucleolus,microtubule	  
YBR142W	   MAK5	   nucleolus,nucleus	  
YCL031C	   RRP7	   nucleolus,nucleus	  
YDR325W	   YCG1	   nucleolus,nucleus	  
YDR457W	   TOM1	   nucleolus,nucleus	  
YER006W	   NUG1	   nucleolus,nucleus	  
YGL111W	   NSA1	   nucleolus,nucleus	  
YGR081C	   	  	   nucleolus,nucleus	  
YGR103W	   NOP7	   nucleolus,nucleus	  
YJL010C	   	  	   nucleolus,nucleus	  
YKL021C	   MAK11	   nucleolus,nucleus	  
YKR060W	   UTP30	   nucleolus,nucleus	  
YKR081C	   RPF2	   nucleolus,nucleus	  
YLL034C	   	  	   nucleolus,nucleus	  
YLR068W	   FYV7	   nucleolus,nucleus	  
YMR121C	   RPL15B	   nucleolus,nucleus	  
YMR239C	   RNT1	   nucleolus,nucleus	  
YNL061W	   NOP2	   nucleolus,nucleus	  
YNL110C	   NOP15	   nucleolus,nucleus	  
YNR038W	   DBP6	   nucleolus,nucleus	  
YOR206W	   NOC2	   nucleolus,nucleus	  
YOR210W	   RPB10	   nucleolus,nucleus	  
YOR293W	   RPS10A	   nucleolus,nucleus	  
YPL211W	   NIP7	   nucleolus,nucleus	  
YPR143W	   	  	   nucleolus,nucleus	  
YAL032C	   PRP45	   nucleus	  
YBL018C	   POP8	   nucleus	  
YBR088C	   POL30	   nucleus	  
YCR033W	   SNT1	   nucleus	  
YDL005C	   MED2	   nucleus	  
YDL108W	   KIN28	   nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YDL140C	   RPO21	   nucleus	  
YDL201W	   TRM8	   nucleus	  
YDL227C	   HO	   nucleus	  
YDR014W	   RAD61	   nucleus	  
YDR081C	   PDC2	   nucleus	  
YDR123C	   INO2	   nucleus	  
YDR190C	   RVB1	   nucleus	  
YDR207C	   UME6	   nucleus	  
YDR240C	   SNU56	   nucleus	  
YDR404C	   RPB7	   nucleus	  
YDR427W	   RPN9	   nucleus	  
YDR460W	   TFB3	   nucleus	  
YER049W	   	  	   nucleus	  
YER064C	   	  	   nucleus	  
YFL013C	   IES1	   nucleus	  
YFL017W-­‐A	   SMX2	   nucleus	  
YFL049W	   	  	   nucleus	  
YFR036W	   CDC26	   nucleus	  
YGL013C	   PDR1	   nucleus	  
YGL029W	   CGR1	   nucleus	  
YGL066W	   SGF73	   nucleus	  
YGL097W	   SRM1	   nucleus	  
YGL133W	   ITC1	   nucleus	  
YGL246C	   RAI1	   nucleus	  
YGR030C	   POP6	   nucleus	  
YGR074W	   SMD1	   nucleus	  
YGR104C	   SRB5	   nucleus	  
YGR252W	   GCN5	   nucleus	  
YGR274C	   TAF1	   nucleus	  
YHL025W	   SNF6	   nucleus	  
YHR062C	   RPP1	   nucleus	  
YHR084W	   STE12	   nucleus	  
YHR156C	   LIN1	   nucleus	  
YIL010W	   DOT5	   nucleus	  
YIL036W	   CST6	   nucleus	  
YIL101C	   XBP1	   nucleus	  
YIL104C	   SHQ1	   nucleus	  
YIL122W	   POG1	   nucleus	  
YIL126W	   STH1	   nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YIR015W	   RPR2	   nucleus	  
YJL011C	   RPC17	   nucleus	  
YJL074C	   SMC3	   nucleus	  
YJL157C	   FAR1	   nucleus	  
YJR068W	   RFC2	   nucleus	  
YKL022C	   CDC16	   nucleus	  
YKL043W	   PHD1	   nucleus	  
YKL108W	   SLD2	   nucleus	  
YKL113C	   RAD27	   nucleus	  
YKL160W	   ELF1	   nucleus	  
YKR008W	   RSC4	   nucleus	  
YKR063C	   LAS1	   nucleus	  
YLL022C	   HIF1	   nucleus	  
YLL036C	   PRP19	   nucleus	  
YLR015W	   BRE2	   nucleus	  
YLR052W	   IES3	   nucleus	  
YLR095C	   IOC2	   nucleus	  
YLR103C	   CDC45	   nucleus	  
YLR176C	   RFX1	   nucleus	  
YLR278C	   	  	   nucleus	  
YLR323C	   CWC24	   nucleus	  
YLR373C	   VID22	   nucleus	  
YML041C	   VPS71	   nucleus	  
YML126C	   ERG13	   nucleus	  
YMR112C	   MED11	   nucleus	  
YMR125W	   STO1	   nucleus	  
YMR182C	   RGM1	   nucleus	  
YNL103W	   MET4	   nucleus	  
YNL136W	   	  	   nucleus	  
YNL230C	   ELA1	   nucleus	  
YNL245C	   CWC25	   nucleus	  
YNL251C	   NRD1	   nucleus	  
YNR053C	   NOG2	   nucleus	  
YOL028C	   YAP7	   nucleus	  
YOL054W	   PSH1	   nucleus	  
YOL115W	   TRF4	   nucleus	  
YOR033C	   EXO1	   nucleus	  
YOR038C	   HIR2	   nucleus	  
YOR048C	   RAT1	   nucleus	  




Name	  (if	  any)	  
Localization(s)	  
YOR116C	   RPO31	   nucleus	  
YOR207C	   RET1	   nucleus	  
YOR217W	   RFC1	   nucleus	  
YPL007C	   TFC8	   nucleus	  
YPL093W	   NOG1	   nucleus	  
YPL129W	   TAF14	   nucleus	  
YPL213W	   LEA1	   nucleus	  
YPR023C	   EAF3	   nucleus	  
YPR045C	   	  	   nucleus	  
YPR052C	   NHP6A	   nucleus	  
YPR057W	   BRR1	   nucleus	  
YPR070W	   MED1	   nucleus	  
YPR108W	   RPN7	   nucleus	  
YPR135W	   CTF4	   nucleus	  
YPR144C	   NOC4	   nucleus	  
YPR152C	   	  	   nucleus	  
YGR140W	   CBF2	   nucleus,spindle	  pole,microtubule	  
YDR265W	   PEX10	   peroxisome	  
YGL037C	   PNC1	   peroxisome	  
YMR204C	   	  	   peroxisome	  
YNL329C	   PEX6	   peroxisome	  
YOL147C	   PEX11	   peroxisome	  
YPR128C	   ANT1	   peroxisome	  
YCL056C	   	  	   punctate	  composite	  
YCR061W	   	  	   punctate	  composite	  
YDL222C	   	  	   punctate	  composite	  
YDR222W	   	  	   punctate	  composite	  
YDR270W	   CCC2	   punctate	  composite	  
YDR357C	   	  	   punctate	  composite	  
YDR373W	   FRQ1	   punctate	  composite	  
YDR495C	   VPS3	   punctate	  composite	  
YDR517W	   GRH1	   punctate	  composite	  
YEL005C	   VAB2	   punctate	  composite	  
YFL036W	   RPO41	   punctate	  composite	  
YGL180W	   APG1	   punctate	  composite	  
YGL203C	   KEX1	   punctate	  composite	  
YGR130C	   	  	   punctate	  composite	  
YHR136C	   SPL2	   punctate	  composite	  
YIR006C	   PAN1	   punctate	  composite	  




Name	  (if	  any)	  
Localization(s)	  
YJL178C	   ETF1	   punctate	  composite	  
YJL186W	   MNN5	   punctate	  composite	  
YKL140W	   TGL1	   punctate	  composite	  
YLR035C-­‐A	   	  	   punctate	  composite	  
YML052W	   SUR7	   punctate	  composite	  
YNL130C	   CPT1	   punctate	  composite	  
YNL173C	   MDG1	   punctate	  composite	  
YOR109W	   INP53	   punctate	  composite	  
YOR284W	   HUA2	   punctate	  composite	  
YPL065W	   VPS28	   punctate	  composite	  
YPL206C	   	  	   punctate	  composite	  
YPR029C	   APL4	   punctate	  composite	  
YPR149W	   NCE102	   punctate	  composite	  
YBR164C	   ARL1	   punctate	  composite,early	  Golgi	  
YBR288C	   APM3	   punctate	  composite,early	  Golgi	  
YJL024C	   APS3	   punctate	  composite,early	  Golgi	  
YJL029C	   VPS53	   punctate	  composite,early	  Golgi	  
YNL238W	   KEX2	   punctate	  composite,early	  Golgi	  
YDL192W	   ARF1	   punctate	  composite,early	  Golgi,late	  Golgi	  
YBL017C	   PEP1	   punctate	  composite,endosome	  
YHR123W	   EPT1	   punctate	  composite,Golgi	  
YOR216C	   RUD3	   punctate	  composite,Golgi	  
YDR367W	   	  	   punctate	  composite,Golgi,early	  Golgi	  
YGR261C	   APL6	   punctate	  composite,Golgi,early	  Golgi	  
YLR250W	   SSP120	   punctate	  composite,Golgi,early	  Golgi	  
YMR313C	   TGL3	   punctate	  composite,lipid	  particle	  
YAL047C	   SPC72	   spindle	  pole	  
YIL144W	   TID3	   spindle	  pole	  
YJR112W	   NNF1	   spindle	  pole	  
YKR037C	   SPC34	   spindle	  pole	  
YLL003W	   SFI1	   spindle	  pole	  
YLR212C	   TUB4	   spindle	  pole	  
YLR457C	   NBP1	   spindle	  pole	  
YPL155C	   KIP2	   spindle	  pole,microtubule	  
YAR002C-­‐A	   ERP1	   vacuolar	  membrane	  
YBR077C	   	  	   vacuolar	  membrane	  
YBR127C	   VMA2	   vacuolar	  membrane	  
YDL008W	   APC11	   vacuolar	  membrane	  
YDR105C	   TMS1	   vacuolar	  membrane	  




Name	  (if	  any)	  
Localization(s)	  
YDR119W	   	  	   vacuolar	  membrane	  
YEL013W	   VAC8	   vacuolar	  membrane	  
YFL041W	   FET5	   vacuolar	  membrane	  
YGR106C	   	  	   vacuolar	  membrane	  
YIL047C	   SYG1	   vacuolar	  membrane	  
YJR138W	   IML1	   vacuolar	  membrane	  
YKR007W	   	  	   vacuolar	  membrane	  
YML018C	   	  	   vacuolar	  membrane	  
YMR243C	   ZRC1	   vacuolar	  membrane	  
YOL092W	   	  	   vacuolar	  membrane	  
YOR316C	   COT1	   vacuolar	  membrane	  
YPL045W	   VPS16	   vacuolar	  membrane	  
YPL162C	   	  	   vacuolar	  membrane	  
YPL180W	   BIT89	   vacuolar	  membrane	  
YPL236C	   	  	   vacuolar	  membrane	  
YPR036W	   VMA13	   vacuolar	  membrane	  
YMR077C	   VPS20	   vacuolar	  membrane,endosome	  
YAR071W	   PHO11	   vacuole	  
YBR092C	   PHO3	   vacuole	  
YBR093C	   PHO5	   vacuole	  
YBR139W	   	  	   vacuole	  
YBR161W	   	  	   vacuole	  
YBR162C	   TOS1	   vacuole	  
YBR187W	   	  	   vacuole	  
YBR199W	   KTR4	   vacuole	  
YBR302C	   COS2	   vacuole	  
YCL027W	   FUS1	   vacuole	  
YCL043C	   PDI1	   vacuole	  
YDL010W	   	  	   vacuole	  
YDL180W	   	  	   vacuole	  
YDL211C	   	  	   vacuole	  
YDR131C	   	  	   vacuole	  
YDR144C	   MKC7	   vacuole	  
YDR262W	   	  	   vacuole	  
YDR304C	   CPR5	   vacuole	  
YDR452W	   PPN1	   vacuole	  
YER001W	   MNN1	   vacuole	  
YER056C	   FCY2	   vacuole	  
YER150W	   SPI1	   vacuole	  




Name	  (if	  any)	  
Localization(s)	  
YFL062W	   COS4	   vacuole	  
YGL032C	   AGA2	   vacuole	  
YGR014W	   MSB2	   vacuole	  
YGR125W	   	  	   vacuole	  
YGR279C	   SCW4	   vacuole	  
YGR282C	   BGL2	   vacuole	  
YGR295C	   COS6	   vacuole	  
YHL008C	   	  	   vacuole	  
YHL028W	   WSC4	   vacuole	  
YHR132C	   ECM14	   vacuole	  
YHR202W	   	  	   vacuole	  
YHR215W	   PHO12	   vacuole	  
YIL005W	   EPS1	   vacuole	  
YIL067C	   	  	   vacuole	  
YIL123W	   SIM1	   vacuole	  
YIL158W	   	  	   vacuole	  
YIR014W	   	  	   vacuole	  
YJL079C	   PRY1	   vacuole	  
YJL158C	   CIS3	   vacuole	  
YJR054W	   	  	   vacuole	  
YJR161C	   COS5	   vacuole	  
YKL073W	   LHS1	   vacuole	  
YKL077W	   	  	   vacuole	  
YKR013W	   PRY2	   vacuole	  
YKR042W	   UTH1	   vacuole	  
YLR083C	   EMP70	   vacuole	  
YLR093C	   NYV1	   vacuole	  
YLR297W	   	  	   vacuole	  
YLR300W	   EXG1	   vacuole	  
YML132W	   COS3	   vacuole	  
YMR297W	   PRC1	   vacuole	  
YMR305C	   SCW10	   vacuole	  
YNL058C	   	  	   vacuole	  
YNL066W	   SUN4	   vacuole	  
YNL115C	   	  	   vacuole	  
YNL336W	   COS1	   vacuole	  
YNR028W	   CPR8	   vacuole	  
YNR061C	   	  	   vacuole	  
YNR067C	   DSE4	   vacuole	  




Name	  (if	  any)	  
Localization(s)	  
YOL007C	   CSI2	   vacuole	  
YOL011W	   PLB3	   vacuole	  
YOL088C	   MPD2	   vacuole	  
YOL154W	   ZPS1	   vacuole	  
YOR288C	   MPD1	   vacuole	  
YOR320C	   GNT1	   vacuole	  
YOR336W	   KRE5	   vacuole	  
YPL019C	   VTC3	   vacuole	  
YPL057C	   SUR1	   vacuole	  
YPL087W	   YDC1	   vacuole	  
YPL120W	   VPS30	   vacuole	  
YPL154C	   PEP4	   vacuole	  
YPL163C	   SVS1	   vacuole	  
YPR037C	   ERV2	   vacuole	  
YML115C	   VAN1	   vacuole,Golgi	  
 
